




Identifying mechanisms underlying the 
pathogenesis of age-associated periventricular 




Motaz Mohammed Fadul 
 
Submitted for the degree of Doctor of Philosophy (PhD) 
 
Sheffield Institute for Translational Neuroscience  











There are so many people whom I would like to thank. First and foremost, I would 
like to acknowledge my father, Mohammed, and mother, Nadia, for their continuous 
help and unconditional support. Thank you for believing in me which made me 
achieve this goal and they have always encouraged me to the best I can be.  
 
Thank you, Sara, my wonderful wife and my best friend, I am so blessed to have your 
love and support behind all my endeavours. She has been extremely supportive even 
when she was also busy doing her PhD. We have been through this together. Thank 
you to my son Mohammed (Hamoodi), who witnessed all this journey since he was 
one and a half year old, you have been my comfort zone and I would like to say sorry 
for being grumpy whilst I wrote this thesis. 
 
Thank you to my supervisors, Dr Julie Simpson and Prof Stephen Wharton for their 
guidance and support throughout my PhD. 
 
I would like to express my sincere gratitude to Dr Julie Simpson, as she always 
believed in me and for her continuous encouragement, help, guidance and 
reassurance throughout this adventure.  
 
I would like to thank Dr Paul Heath, with his RNA analysis expertise. I gained 






would also like to thank Dr Jonathan Cooper-Knock for his help in computational 
deconvolution analysis. 
 
Thank you to the Neuropathology research group and all SITraN staff for their 
support and help. Thank you to Dr Rachel Waller, Dr Irina Vázquez-Villaseñor, Dr 
Hemant Mistry, Catherine Gelsthorpe, Lynne Baxter and Daniel Fillingham.  
 
To King Abdulaziz University in Saudi Arabia for funding this project, and for 
sponsoring my postgraduate studies.  
 
Thank you to all donors and their families for considering donating their tissue to 








Fadul, M.M.; Heath, P.R.; Cooper-Knock, J.; Kurz, J.M.; Al-Azzawi, H.A.; Ali, Z.; Smith, 
T.; Matthews, F.E.; Brayne, C.; Wharton, S.B.; Simpson, J.E., on behalf of the Cognitive 
Function and Ageing Neuropathology Study Group; Transcriptomic Analysis of Age-
Associated Periventricular Lesions Reveals Dysregulation of the Immune 




Fadul, M.M., Brayne, C, Matthews, F.E., Ince, P., Wharton, S.B., Simpson, J.E. 
Characterising the microglial profile of age-associated confluent white matter 
lesions. Alzheimer’s Research United Kingdom, March 2018, London.  
 
Fadul, M.M., Heath, P., Cooper-Knock, J., Wharton, S.B., Simpson, J.E. The role of 
microglia in the pathogenesis of age-associated white matter lesions. Dementia 
Futures, July 2018, Sheffield. 
 
Fadul, M.M., Heath, P., Cooper-Knock, J., Brayne, C., Matthews, F.E., Wharton, S.B., 
Simpson, J.E. A microarray analysis approach to identify mechanisms underlying the 
pathogenesis of age-associated periventricular white matter lesions. XIV European 









Age-associated white matter lesions (WML) appear as hyperintense signals on T2-
weighted magnetic resonance imaging (MRI) scans and are associated with 
dementia and cognitive decline. Based on their anatomical location, WML are 
classified into deep subcortical lesions (DSCL), which are associated with high levels 
of CD68+ amoeboid microglia; periventricular lesions (PVL), which are 
characterised by increased levels of MHC II+ immune activated microglia; and 
confluent lesions which encompass both periventricular and deep subcortical regions. 
 
As the microglial phenotype is significantly different in PVL compared to DSCL, the 
profile of CD68+ and MHC-II+ microglia in confluent lesions was 
immunohistologically assessed to test the hypothesis that confluent lesions arise as 
a result of combined PVL and DSCL spread.  The immunoreactive profile of microglia 
within confluent lesions was classified into four lesion subtypes with distinct 
staining patterns: MHC II+ and CD68+ microglia primarily associated with the 
periventricular region and deep subcortical region, respectively; MHC II+ microglia 
predominantly throughout all regions; CD68+ microglia predominantly throughout 
all regions; a mix of both CD68+ and MHC II+ microglia present throughout the 
confluent lesions. The current study demonstrates a range of confluent lesion 
subtypes which may reflect a spread of DSCL pathology, PVL lesion pathology or 
both, suggesting that a variety of mechanisms may be associated with the 







While transcriptomic profiling of DSCL has previously been performed to identify 
the underlying mechanisms associated with the formation of these lesions, the 
current study is the first in the field to employ this approach to identify gene 
expression changes which may underlie the formation of PVL. Interestingly, 
histological characterisation of radiologically control white matter identified a 
subgroup of control cases which displayed intact myelin, but also high levels of 
MHC-II+ microglia and were subsequently reclassified as “pre-lesional”.  The current 
study characterised the gene expression profile of age-associated periventricular 
white matter using two independent approaches, namely microarray analysis and 
Nanostring.  The research presented in this thesis suggests that established PVL are 
part of a continuous spectrum of white matter injury.  Bioinformatic analysis of the 
datasets revealed both “pre-lesions” and established PVL are associated with the 
significant down-regulation of an immune response. Furthermore, increased 
signalling pathways in “pre-lesions”, including calcium and glutamate signalling, 
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Age-associated white matter lesions (WML) appear as hyperintensities on T2-
weighted magnetic resonance imaging (MRI) scans (Prins & Scheltens, 2015). 
Different terminologies have been used in the literature to describe these 
hyperintensities, including white matter changes (WMC) and white matter 
hyperintensities (WMH). In 1986, Hachinski and colleagues used Leukoaraiosis 
(from the greek “leuko” meaning “white” and “araiosis” meaning “rarefaction”) as a 
descriptive term for the intensities found on computed tomography (CT) (Hachinski 
et al., 1986). The current study will refer to these hyperintensities as WML. 
 
There are few truly ageing population-representative neuropathology cohorts 
worldwide. In the UK, the Cognitive Function and Ageing Study (CFAS) is a large-
scale study of the ageing population that also has a population-representative brain 
donor cohort (Ince, 2001; Wharton et al., 2011). Population-representative studies, 
such as CFAS and others, have shown that while WMLs are commonly observed in 
healthy elderly people aged 65 and older, they are also associated with neurological 
diseases, such as Alzheimer’s disease (AD) (Lee et al., 2016), and vascular dementia 
(Hu et al., 2021). Age-associated WMLs, clinically manifest as cognitive impairment 
(Prins et al., 2005), dementia (Fernando & Ince, 2004; Matthews et al., 2009; Debette 
& Markus, 2010), depression (O’Brien et al., 1996; Lee et al., 2015), gait dysfunction 
(De Laat et al., 2011; Rosario et al., 2016) and/or balance disturbance (Baezner et 
al., 2008; Veselý et al., 2016). Increasing age is the most common risk factor for WML 
formation (Basile et al., 2006; Zhuang et al., 2018; Garnier-Crussard et al., 2020). 




hyperintensities have been found, including hypertension and cardiovascular 
disease (de Leeuw et al., 2002; Verhaaren et al., 2013; Zhao et al., 2019), while 
smoking and increased age are the most predictive factors for the progression of 
WML (Van Dijk et al., 2008; Garnier-Crussard et al., 2020). 
 
1.2 The brain vasculature 
The major arteries responsible for supplying blood to the brain are the internal 
carotid arteries, and the vertebral arteries. The basilar artery arises from the distal 
union of the two vertebral arteries, forming the vertebrobasilar arterial system. 
Vertebrobasilar stroke, arising from occlusion of large vessels in this system, usually 
leads to major disability or death. However, many vertebrobasilar lesions arise from 
small vessel disease.  The basilar artery and internal carotid arteries connect to the 
Circle of Willis, which forms an anastomotic ring enabling perfusion of the cerebral 
hemispheres via three major arteries: the anterior, middle and posterior cerebral 
arteries (Cipolla, 2009).  
 
Cerebral white matter is primarily supplied by the medullary artery which is a 
branch of the vertebral arteries and distributes in the cerebral parenchyma, 
subdividing into superficial cerebral and basal perforating arteries (Akashi et al., 
2017).  White matter in the periventricular white matter mainly receives its blood 
supply through the long perforating branches of the cerebral pial and 
ventriculofugal blood vessels. Ventriculofugal vessels arise from the striatal 
arteries' terminal branches or the choroidal artery (Rowbotham & Little, 1965; Van 




a blood supply watershed, making the periventricular white matter vulnerable to 
ischaemia. In contrast, the subcortical white matter primarily receives its blood 
supply via the long perforating branches of the medullary arteries, which arise from 
the cortical branches of the middle cerebral artery, which often have a long and 
tortuous course. These characteristics also make the subcortical white matter 
vulnerable to hypoxic-ischemic damage (Rowbotham & Little, 1965; Pantoni & 
Garcia, 1997; Akashi et al., 2017) (Figure 1.1). 
 
1.2.1 Brain barriers 
In the brain, two major barriers protect the CNS, namely, the blood-brain barrier 
(BBB), and the blood-cerebrospinal fluid barrier (BCSFB). These barriers regulate 
the exchange between the circulation and the CNS (Saunders et al., 2013), and 
function to maintain brain homeostasis (Segarra et al., 2021). The BBB is mainly 
composed of cerebral endothelial cells which express tight junction proteins, 
smooth muscle cells, pericytes and astrocytes (Graves & Baker, 2020; Kadry et al., 
2020), and plays a major role in inhibiting the passage of blood-borne molecules 
into the CNS. 
 
In contrast, the blood-cerebrospinal fluid barrier is composed of choroid plexus 
epithelial cells in the ventricles which, similar to the BBB endothelial cells, express 
tight junction proteins, and inhibit the paracellular movement of water soluble 
molecules across the barrier (Engelhardt & Sorokin, 2009; Saunders et al., 2016; 





Figure 1.1 Periventricular and deep subcortical white matter arterial supply 
The periventricular white matter is supplied by the pial arterioles which originate 
from the cortical arteries (1) and the ventriculofugal vessels (2), arising either from 
the subependymal arteries (3), which branch from the choroidal artery, or from the 
striatal arteries' terminal branches. The deep subcortical region is supplied by long 
perforating branches of the medullary arteries which arises from the cortical 
branches of the middle cerebral artery. Adapted from (Medrano Martorell et al., 




1.3  White matter lesions (WML) 
1.3.1 Classification 
Many studies classify white matter hyperintensities into two major categories based 
on their anatomical location (Figure 1.2): periventricular white matter lesions 
which are located adjacent to the ventricular system (PVL) and deep subcortical 
lesions, which are located in the deep white matter (DSCL), distant from the 
ventricles (De Groot et al., 2002; Kim et al., 2008; Wharton et al., 2011). Numerous 
visual rating scales used in clinical settings are based on this distinction (Fazekas et 
al., 1987; Scheltens et al., 1993; Ylikoski et al., 1993). Population-based studies have  
shown that around 90% of the ageing population have PVL, while DSCL are found in 
around 60% of the over 65s (de Leeuw, 2001). Lesions tend to extend to become 
more confluent (Figure 1.2. B) (Barkhof & Scheltens, 2006), but whether these 







Figure 1.2 MRI detection of age-associated WML 
Depending on their anatomical location, age-associated WML are classified as (A) 
periventricular lesions (PVL, red arrow) or deep subcortical lesions (DSCL). Extensive WML 







1.3.2 Clinical manifestation 
1.3.2.1 WML and cognition: 
Cognitive dysfunction is a common clinical feature in people with WML and is 
thought to be associated with cerebral small vessel disease (SVD) (Prins & Scheltens, 
2015). In the ageing brain, vascular pathologies have been reported in 71% of non-
demented individuals compared to 84% of patients with dementia. PVL are common 
in demented (95%) ageing population compared to non-demented (87%), while 
DSCL are less common (60% in non-demented compared to 73% in demented) 
(Matthews et al., 2009). While these WML are a common feature of the ageing brain, 
they have been identified as a significant independent risk factor for dementia  
(Fernando & Ince, 2004; Matthews et al., 2009).  
 
Increased WML volumes are associated with the increasing risk of cognitive 
impairment and dementia (Prins & Scheltens, 2015).  However, it should be 
acknowledged that there are conflicting reports regarding the association between 
WML subtypes and cognitive impairment. Several studies indicate that PVL, but not 
DSCL, are directly related to deterioration in cognition and are associated with an 
increased risk of dementia (De Groot et al., 2002; Prins et al., 2004; van den Heuvel 
et al., 2006). Conversely, other studies have shown that both PVL and DSCL have a 
similar impact on cognitive decline (Burns et al., 2005).  
 
1.3.2.2 Depression 
Assessment of the presence and severity of PVL and DSCL in a large population-
based study of 1077 elderly people revealed that cerebral white matter changes, in 




Furthermore, increases in the volume of DSCL have been shown to increase the risk 
of late-life depression (Chen et al., 2006). 
 
1.3.3 Pathological correlates of WML 
Both PVL and DSCL share some similar histopathological features, including myelin 
attenuation, axonal damage, astrogliosis and microglial activation (Gouw et al., 
2011; Schmidt et al., 2011; Wharton et al., 2015); however, it should be noted that 
each WML subtype also has distinct features.  
 
PVL are characterised histologically by ventricular ependymal denudation and 
subependymal dense astrogliosis (Fernando et al., 2006). This disruption in the 
ependymal lining may lead to abnormal leakage of cerebrospinal fluid (CSF) into the 
periventricular white matter area, and initiate or exacerbate lesional pathology 
(Scheltens et al., 1995; Simpson et al., 2007a). While numbers of remyelinating 
oligodendrocyte progenitor cells (OPC) are significantly increased at the border of 
PVL, it has been suggested that the dense astrogliosis associated with these lesions 
may prevent remyelination (Simpson et al., 2007a). Microglia in PVL have a ramified 
morphology and an immune-activated phenotype, associated with the significant 
increase in major histocompatibility complex-II (MHC II) expression (Simpson et al., 
2007b).  
 
In striking contrast to PVL, the microglia in DSCL are large, round and amoeboid in 




al., 2006). These differences in microglial morphologies suggest microglia play 
different roles in the pathogenesis of DSCL and PVL (as discussed below). 
 
1.3.4 Proposed Mechanisms of WML formation  
While the precise mechanism(s) underlying the pathogenesis of WML remains 
unknown; however, several hypotheses have been suggested. These include (i) 
chronic cerebral hypoperfusion leading to a hypoxic environment (Tomimoto et al., 
2003; Duncombe et al., 2017), (ii) blood-brain barrier dysfunction resulting in the 
extravasation and accumulation of plasma proteins which stimulate a 
neuroinflammatory response (Simpson et al., 2007a), (iii) cortical pathology 
preceding and underlying WML formation (Leys et al., 1991; Huang et al., 2007; 
McAleese et al., 2017). 
 
1.3.4.1 Hypoperfusion/Hypoxia  
The prevalence of WML in the ageing population is increased by vascular risk factors 
such as hypertension (Dufouil et al., 2001; Van Dijk et al., 2004), hyperlipidaemia 
and a previous history of stroke (Sonohara et al., 2008). The resulting reduction in 
cerebral blood flow leads to tissue damage and is associated with the formation of 
WML (Marstrand et al., 2002; Makedonov et al., 2013; Wong et al., 2019).  
 
Cerebral hypoperfusion results in a hypoxic environment, a feature of both PVL and 
DSCL, evidenced by the increased expression and nuclear translocation of hypoxia-
inducible transcription factors, and the increased expression of several hypoxia-




While detected in both PVL and DSCL, these findings are predominantly associated 
with DSCL (Fernando et al., 2006). Differences in the vascular supply of both lesion 
types could contribute to these differences. The WM is supplied by arteries that do 
not anastomose, which increases the susceptibility to ischemia (Auriel et al., 2012). 
The periventricular white matter is supplied by long, penetrating arterioles, forming 
a watershed area that makes it vulnerable to ischemic injury (Prins & Scheltens, 
2015).  
 
In contrast, the deep subcortical white matter is supplied by small arteries which 
are more prone to arteriolosclerotic vascular changes and are highly susceptible to 
hypoxic damage (Rowbotham & Little, 1965; Pantoni & Garcia, 1995; Simpson et al., 
2009; Xiong & Mok, 2011). The majority of studies have mainly focused on the 
impact of arterial alterations on the formation of WML, with less attention to the 
role venous pathology plays. Those studies investigating venules in the 
periventricular white matter have shown an association between severe 
periventricular vascular collagenosis and WML (Moody et al., 1995; Black et al., 
2009; Keith et al., 2017). 
 
The rat model of cerebral hypoperfusion is a widely used and robust experimental 
model, where the common carotid arteries of rats are bilaterally occluded (Washida 
et al., 2019).  This model exhibits cognitive impairment in addition to white matter 
pathology resembling cerebral WML (Farkas et al., 2004). These studies support the 
hypoxia/hypoperfusion hypothesis, strongly suggesting that a reduction in cerebral 




plays a major role in the development and pathogenesis of age-associated WML 
(Fernando et al., 2006; Schmidt et al., 2011). 
 
1.3.4.2 Blood Brain Barrier (BBB) dysfunction 
The BBB is highly selective in its ability to regulate the movement of molecules from 
the blood to the CNS, and vice versa (Stevenson et al., 1986; Furuse et al., 1993; Zhao 
et al., 2015). Disruption of the BBB is a common feature of normal ageing (Montagne 
et al., 2015) and neurodegenerative diseases, including Alzheimer’s disease 
(Halliday et al., 2016). While the expression of tight junction proteins (TJP), 
including zona occludens-1 (ZO-1), claudin-5 and occludin are not significantly 
different in WML compared to radiologically normal WM, BBB dysfunction is a 
prominent feature of age-associated WM pathology (Simpson et al., 2010; 
Hainsworth et al., 2017). Post-mortem studies suggest that BBB dysfunction plays a 
role in the pathogenesis of WML, showing that the accumulation of plasma proteins, 
such as albumin, thrombin, and fibrinogen is a prominent feature of WML (Simpson 
et al., 2007a; Winkler et al., 2014; Hainsworth et al., 2017). Under normal conditions, 
serum proteins are excluded from the CNS. However, BBB dysfunction and the 
leakage of these proteins, some of which are neurotoxic, induces inflammatory 
processes and/or causes oedema that consequently leads to hypoperfusion 
(Winkler et al., 2014).  
 
The presence of clasmatodendritic astrocytes is considered as a marker of BBB 
dysfunction.  These astrocytes are characterised by large rounded cell bodies with 
beaded processes, resembling the morphology of amoeboid microglia, and have 




particular, clasmatodendritic astrocytes are a prominent feature of age-associated 
PVL (Simpson et al., 2007a) and frontal white matter of post-stroke dementia 
patients (Chen et al., 2016a; Freeze et al., 2020), suggesting a correlation between 
BBB dysfunction and cognitive impairment.  
 
In addition to post-mortem studies, the rat model of chronic cerebral hypoperfusion 
supports the hypothesis that dysfunction of the BBB contributes to white matter 
pathology (Ueno et al., 2002; Lee et al., 2017). However, while the majority of the 
literature supports a role for BBB dysfunction in WM pathology, it should be noted 
that an MRI study suggests that BBB dysfunction is not related to the pathogenesis 
of WML (Wahlund & Bronge, 2000). 
 
1.3.4.3 Cortical Pathology 
Cortical pathologies such as AD have been suggested to contribute to the 
development of WML (McAleese et al., 2017). AD is neuropathologically 
characterised by the presence of neurofibrillary tangles (NFT) of 
hyperphosphorylated tau that may lead to axonal damage and myelin loss as part of 
the neurodegenerative process (Huang et al., 2007; McAleese et al., 2015).  
 
CAA is associated with the abnormal deposition of β-amyloid (Aβ) within vascular 
walls, including the leptomeningeal blood vessels that supply the cortex. It has been 
suggested that CAA affects the vascular supply to the WM and causes ischaemia 
which leads to the formation of WML (Vinters et al., 2000; Weller et al., 2015). 
Recently, a study revealed that periventricular white matter hyperintensities are 




predictor for the formation of periventricular white matter hyperintensities with 
age (Marnane et al., 2016). 
 
In conclusion, hypoperfusion/hypoxia, disruption of BBB and cortical pathologies 
are considered as important factors that play a major role in the development of 
WML. 
 
1.3.5 WML arise in a field effect of pathology 
Histological analysis of radiologically normal-appearing white matter (NAWM) has 
identified subtle pathological abnormalities, including an increase in MHC-II+ 
microglia, extending beyond the lesion, suggesting these lesions may arise in a field 
effect of pathology (Simpson et al., 2007b; Wardlaw et al., 2015; Wharton et al., 
2015). Whole-genome RNA microarray analysis of the radiologically normal area 
surrounding the lesion revealed 419 genes were significantly, differentially 
expressed and included genes mainly associated with immune function, cell cycle 
and ion transport (Simpson et al., 2009).  Furthermore, histological characterisation 
has revealed a significant increase in oxidative DNA damage associated with glia in 
the normal-appearing white matter from lesional cases, demonstrating pathology 
extends beyond the established lesion (Al-Mashhadi et al., 2015). Recently, a  study 
revealed radiological changes in the white matter surrounding lesions, indicating 





1.4 Vascular dementia (VaD) 
White matter is highly sensitive to vascular disruptions, including cerebrovascular 
injuries (Black et al., 2009; Iadecola, 2013). Disruption to the cerebral vasculature 
results in a reduction of brain function impacting cognitive ability, forgetfulness and 
problem-solving (Sachdev et al., 2004). Vascular dementia is the second most 
common cause of dementia, which may be caused by a stroke or small vessel disease 
(Kalaria, 2018).  
 
1.4.1 Large vessel disease  
Large vessel disease, such as atherosclerosis, is characterised by the abnormal 
deposition of lipid, plasma proteins and plaques in the walls of large arteries leading 
to a reduction in blood flow. A population-based post-mortem study conducted on 
600 cases found that the odds ratio for dementia increased significantly with 
internal carotid artery atherosclerosis (Suemoto et al., 2011).  
 
1.4.2 Small vessel disease 
Small vessel disease (SVD) is a frequent finding on both MRI and CT, which reflects 
a range of pathological features associated with the small vessels of the brain 
(Pantoni, 2010), including arterioles and capillaries (Pantoni, 2010; Wardlaw et al., 
2013). SVD may arise due to either arteriolosclerosis which is mainly associated 
with vascular risk factors such as hypertension and atherosclerosis (Vermeer et al., 
2003; Giwa et al., 2012; Prins & Scheltens, 2015) or due to the presence of cerebral 
amyloid angiopathy (CAA).  CAA is characterised by the abnormal deposition of β-




to occlusion of the vascular lumen, and eventually resulting in ischemia. CAA is an 
important factor for the progression of cognitive decline in old age population 
(Boyle et al., 2015; Case et al., 2016). 
 
Lacunar infarcts arise due to acute occlusion of small vessels and appear as focal 
hyperintensities on MRI scans.  Cerebral microbleeds are another neuroimaging 
marker of SVD, associated with the rupture of vessels and resulting in intracerebral 
haemorrhage (ICH) (Caceres & Goldstein, 2012). ICH, which is a type of 
haemorrhagic stroke, may lead to injury of both grey and white matter and is 
associated with an increase in the risk of developing dementia (Corraini et al., 2017).  
Recently, a retrospective study revealed that the progression rate of WML is higher 
in patients with a history of ICH (Chen et al., 2018), supporting other studies which 
suggest ICH may underlie the pathogenesis of WML (Román et al., 2002; Weller et 
al., 2015).    
 
1.5 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common age-related neurodegenerative 
disease and is characterised by progressive neurodegeneration and memory loss 
(Selkoe, 2001). Late stages of this disease are associated with dementia, together 
with behavioural changes and motor deficits (DeTure & Dickson, 2019).  
 
AD is neuropathologically characterised by the extracellular deposition of β-amyloid 
(Aβ) protein in the form of diffuse and neuritic plaques, and the intracellular 




(Vickers et al., 2015).  These characteristic features are associated with neuronal 
death, loss of synapses and glial activation, which eventually contribute to cognitive 
decline in a progressive fashion (DeTure & Dickson, 2019). The hippocampus and 
entorhinal cortex are the first regions in AD to be affected by these 
neuropathological changes, which later spread to involve limbic and isocortical 
regions (Braak & Braak, 1991).   
 
1.6 Microglia  
Microglia, first described by Rio-Hortega in 1919, are the resident brain macrophage 
(Rio-Hortega & P, 1919). They play a significant role in maintaining homeostasis 
within the CNS and share similar functions with tissue macrophages, including 
immune surveillance, antigen presentation, and phagocytosis of cell debris 
(Nimmerjahn et al., 2005; Teeling & Perry, 2009; Hashemiaghdam & Mroczek, 
2020). 
 
Under normal resting conditions, microglia are ramified in morphology with small 
cell bodies and multiple processes. The motile processes of microglia constantly 
extend and retract to survey their surroundings (Nimmerjahn et al., 2005). These 
cells become activated by various triggers such as trauma, ischemia and 
neurodegeneration (Luo et al., 2010). Immunoglobulins and the leakage of other 
plasma proteins into the brain parenchyma also activate microglia (Lu et al., 2001). 
Once activated, these cells can retract their processes and transform to become 




functional changes and rapid migration to the site of injury (Nimmerjahn et al., 
2005; Lynch et al., 2010).  
 
1.6.1 Microglial activation (including primed microglia) 
Several factors determine the behaviour of microglia in the CNS, which can exert 
either neuroprotective and neurotoxic effects based on the type of injury, 
pathological environment and the activated microglial phenotype (Luo et al., 2010; 
Tang & Le, 2016). 
 
Microglia have historically been suggested to adopt two distinct phenotypes based 
on the mechanism of activation (Figure 1.3): “classically” activated microglia, also 
known as pro-inflammatory (M1) and “alternatively” activated microglia, also 
known as an anti-inflammatory (M2).  
 
The classically activated M1 phenotype is induced by interferon-gamma (IFN-γ) and 
lipopolysaccharide (LPS) (Boche et al., 2013; Satoh, 2018), which can, in turn, induce 
detrimental damage to the surrounding tissue by releasing pro-inflammatory 
cytokines, including tumour necrosis factor-alpha (TNF-), interleukin-1-beta (IL-
1β) (Tang & Le, 2016), nitric oxide (NO) (Block et al., 2007) and free radicals, such 
as reactive oxygen species (ROS) (Nakagawa & Chiba, 2014). In contrast, the 
alternatively activated M2 phenotype is induced following the exposure to 
interleukin 4 (IL-4) and is associated with the release of anti-inflammatory 
cytokines and plays a role in repair processes (Yang et al., 2016). M2 microglia serve 





Figure 1.3 Activated microglial phenotypes 
Classically activated microglia (M1) adopt a mainly neurotoxic phenotype, as they release 
pro-inflammatory cytokines such as interleukin-1-beta (IL-1β), nitric oxide (NO) and 
reactive oxygen species (ROS). In contrast, alternatively activated microglia (M2) adapt a 
neuroprotective phenotype, releasing neurotrophic factors such as, glial cell-derived 
neurotrophic factor (GDNF) and IL-10, which are mainly neuroprotective and involved in 
the phagocytic mechanism of cellular debris in the brain. Adapted from (Nakagawa & Chiba, 







neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) and glial 
cell-derived neurotrophic factor (GDNF) (Jiao et al., 2018), helping in the reduction 
of both demyelination and oligodendrocyte injury (Miron et al., 2013).  
 
It should be noted that this simple classification of M1/M2 phenotypes was 
originally defined in peripheral macrophages to explain the pro- and anti-
inflammatory states of infiltrating monocyte-derived macrophages, and was mainly 
observed in animal studies (Mills et al., 2000). Microglia are considered among the 
most versatile cells in the body. They are characterised by the ability to shift into 
different activation states, including in response to ageing, trauma, infections, 
ischemia, and neurodegenerative diseases, which are not limited to the M1/M2 
classification (Ransohoff, 2016). This classification represents extreme states, and it 
is likely that both states, as well as intermediate forms, will be present in the ageing 
brain. Characterisation of the microglial activation states associated with ageing 
WM pathology may provide evidence of a critical role of these cells in WML 
formation.   
 
Transcriptomic profiling of microglia faces several challenges.  Gene expression 
studies on total tissue extracts will include a heterogeneous population of cells, 
which likely mask cell-specific changes in the transcriptome and requires 
identifying genes associated with the cell of interest. A study using animal models of 
EAE, ALS and Huntington’s, developed a protocol to separate the microglial 
population from other CNS cells and infiltrating myeloid cells using single-cell mass 
spectrometry [cytometry by time-of-flight (CyTOF)]. The microglial population 




CD11b, BST2 (CD317), MHC-II, CD39 and CD86.  Activated microglia highly 
expressed MHC-II, CD86, TREM2, CD274 and CD80. However, the inactivated group 
lack the expression of these markers and only express BST2 (CD317) (Ajami et al., 
2018),  which diminishes the expression of inflammatory genes (Polyak et al., 2013).  
These findings can be employed to study microglial heterogeneity in transcriptomic 
profiling studies, as examining co-expressed genes will aid in identifying activated 
and inactivated microglia. 
 
single-cell RNA-sequencing (snRNA-seq) profiling of microglia in human post-
mortem tissue has revealed differences in the microglial phenotype depending on 
their location. Microglia in the white matter express higher levels of MHC-II related 
HLA-DR and CD68 than the grey matter (Sankowski et al., 2019). Furthermore, the 
subventricular zone of the white matter contains a distinct microglial phenotype 
compared to other brain regions, with microglia in this region expressing high levels 
of microglial activation markers, including CD68, CD86, CD45, CX3CR1, CD11c, CD64 
and HLA-DR (Böttcher et al., 2019). Together these findings demonstrate the 
diversity of microglia between different brain regions.  
 
1.6.2 Microglia in the ageing brain  
Ageing is the greatest risk factor for the development of many neurodegenerative 
diseases, and no cell is safe from the ageing effects, including microglia (von 
Bernhardi, 2007). Innate immune activation occurs during brain ageing and is 
associated with cognitive decline. Microglia become primed during 




Primed microglia were first described in animal models associated with prion 
diseases (Combrinck et al., 2002). Primed microglia have a lower activation 
threshold, and when stimulated, they produce an exaggerated inflammatory 
response, which may contribute to neurodegeneration and cognitive impairment 
(Perry & Holmes, 2014). In  ageing mice, LPS administration leads to an exaggerated 
neuroinflammatory response, including increased cytokine expression (Godbout et 
al., 2005). Similarly, excessive pro-inflammatory IL-1B is produced following LPS 
administration , mainly derived from primed microglia (Henry et al., 2009). 
 
Ageing murine studies indicate a disturbance in the microglial functions, including 
a reduction in surveillance, phagocytosis, and a delayed response to injury (Floden 
& Combs, 2011; Hefendehl et al., 2014). Primed microglia shift toward the 
neurotoxic activation phenotype (M1) (Hu et al., 2012), resulting in increased 
production and secretion of pro-inflammatory cytokines such as IL-6, IL-1β, and 
TNF- (Cunningham et al., 2009) and an increase of ROS production alongside an 
increased phagocytic activity in the earlier stages of priming, which is reduced over 
time (Koellhoffer et al., 2017; Angelova & Brown, 2019). The release of these 
neurotoxic factors can lead to more microglial priming, forming a positive feedback 
loop (Li et al., 2018). Furthermore, ageing animal models are associated with an 
increased expression of CD68 (Godbout et al., 2005), co-stimulatory molecule CD86 
(B7) (Griffin et al., 2006) and MHC II (Henry et al., 2009).  Increased expression of 
CD68 in aged microglia is one of the hallmarks of ageing, together with an increased 
lipofuscin accumulation in mice (Safaiyan et al., 2016) and human microglia 
(Moreno-García et al., 2018). Lipofuscin, which are insoluble lipid debris, is a 




2018), leading to reduction/impairment of microglial homeostatic functions, 
including myelin clearance and phagocytosis (Kakimura et al., 2002).  
 
It should be noted that animal findings do not necessarily translate to human 
diseases. Microglia in humans are heterogeneous and may not reflect the findings of 
animal models. In addition, genetically engineered animal models do not 
recapitulate the whole profile of the disease, which may lead to misinterpretation of 
the data. Yet, some aspects of these models are helpful to understand the 
mechanisms underlying pathological diseases to be translated into humans.  For 
example, transcriptomic profiling of human and murine microglia reveals an 
overlap in immune function genes, but has identified that age-associated gene 
expression changes show little overlap between the two species (Galatro et al., 
2017). 
 
Microglia in the ageing brain display changes in their morphology, which is reflected 
by hypertrophied cell bodies and shorter, twisted and fragmented processes, these 
changes have been referred to as senescent or dystrophic microglia (Streit et al., 
2004). These microglia found to have reduced surveillance (Davies et al., 2017), 
alongside a significant reduction in processing speed, motility and cellular migration 
(Damani et al., 2011; Hefendehl et al., 2014) leading to a failure in responding 





1.6.3 The role of microglia in the formation of WML  
Microglial activation and changes in microglial morphology are a prominent feature 
of both PVL and DSCL; however, there are striking differences between both lesion 
types which suggest variation in underlying pathological mechanisms. As discussed 
above, the amoeboid morphology of CD68+ microglia in DSCL suggests that these 
microglia play a role in demyelination, phagocytosis and the removal of myelin 
breakdown debris (Simpson et al., 2007b). In contrast, microglia in the PVL have a 
mainly ramified morphology with significantly increased expression of MHC II and 
the co-stimulatory molecule CD86 (B7-2) and CD40, suggesting these lesions are 
associated with an ongoing immune activation process (Simpson et al., 2007a). 
Whether the microglia have adapted an M1 or an M2 phenotype within these lesion 
types is currently unknown. 
 
In addition to significantly increased levels of MHC II+ microglia within the PVL, the 
radiologically NAWM from lesional cases have also been shown to contain 
significantly higher levels of MHC II+ microglia than control WM from non-lesional 
cases (Simpson et al., 2007b). This finding demonstrates that the radiologically 
NAWM is histologically abnormal, but it is still unknown whether these microglia 
are contributing to lesion progression or inhibiting lesion spread. 
 
As discussed earlier, cerebral hypoperfusion together with disruption of the BBB 
plays a major role in the formation of age-associated WML (Figure 1.4), which may 





Figure 1.4 Pathway for the formation of WML 
This figure illustrates the proposed mechanisms for the development of white matter 
lesions. Small vessel disease and ageing are the main factors affecting the cellular processes 
in the brain, leading to cerebral hypoperfusion and leakage of plasma proteins into the 
white matter. These processes were suggested to activate glial cells in the white matter.  
Microglial activation may result in multiple pathological processes, including subsequent 
pro-inflammatory response, oxidative stress and cellular death resulting in degeneration of 
axons, myelin, and oligodendrocytes depletion, which eventually leading to demyelination 






characterised by the formation of ROS including hydrogen peroxide, free radicals 
and NO (Merrill et al., 1993; Park et al., 2002). An imbalance between the formation 
of ROS and their removal by antioxidants leads to the accumulation of ROS, giving 
rise to oxidative stress. Oligodendrocytes and axons are highly susceptible to 
oxidative stress (Merrill et al., 1993; Giacci et al., 2018), which can result in 
oligodendrocyte depletion, and disrupt their maturation, impacting their role in 
myelination (French et al., 2009). 
 
Secretion of pro-inflammatory cytokines by microglia may directly impact the 
integrity of the BBB, leading to the accumulation of plasma proteins into the brain  
(Rosenberg, 2009; Shigemoto-Mogami et al., 2018). This increased production and 
secretion of pro-inflammatory mediators may also activate surrounding glia, and 
impact on axonal function (Rosenberg, 2009; Winkler et al., 2014). In addition to 
increased production and expression of pro-inflammatory mediators, activated 
microglia are also responsible for the secretion of damaging molecules such as 
lysosomal proteases, including cathepsins, which are a family of protein degrading 
enzymes.  Transcriptomic profiling of DSCL indicates that cathepsins are highly 
expressed by amoeboid microglia, suggesting that these molecules play a role in 
myelin degradation and the pathogenesis of WML (Simpson et al., 2009; Liu et al., 
2019b). 
 
1.7 Hypothesis and aims 
The role of microglia in age-associated white lesion pathogenesis is currently 
unknown; therefore, this project will test the following hypotheses:  




(ii)  Microglia within PVL adapt a neurotoxic M1 phenotype which promotes 
axonal damage and results in cognitive decline in the ageing population.  
(iii) The mechanisms underlying the pathogenesis of PVL are different to 
DSCL. 
 
This research aims to: 
i. Characterise the microglial phenotype of confluent lesions, specifically 
assessing the immunoreactive profile of MHC-II and CD68, to determine if 
confluent lesions arise as a spread of PVL, DSCL or both.  
ii. Characterise the gene expression profile of age-associated PVL using 
microarray analysis to identify significant changes in biologically relevant 
functional groups and pathways using DAVID. 
iii. Perform bioinformatics analysis using EnrichR and computational microglial 
deconvolution of the bioinformatic datasets to identify microglial-specific 
transcriptomic changes. 
iv. To validate a key panel of candidate gene expression changes identified in 
the microarray analysis using an independent approach, namely NanoString 
nCounter, and to confirm the differential expression of the proteins encoded 





 CHARACTERISATION OF THE 
MICROGLIAL PHENOTYPE IN AGE-ASSOCIATED 






To date, the majority of dementia research has focussed on cortical pathology. AD is 
neuropathologically characterised by β-amyloid (Aβ) plaques and neurofibrillary 
tangles composed of hyperphosphorylated tau. The amyloid hypothesis currently 
dominates the AD field, proposing that Aβ and its oligomers are central to neuronal 
damage (Hardy & Selkoe, 2002).  This hypothesis has given rise to research to 
identify treatments that remove Aβ; however, clinical trials aimed at removing 
pathogenic Aβ have all failed to slow disease progression (Honig et al., 2018; Sun & 
Benet, 2020). In contrast, the myelin model of AD proposes that cerebral white 
matter pathology triggers an adaptive response that initiates the deposition of Aβ 
and tau (Bartzokis, 2011). In support of this model, which suggests cortical 
pathology occurs as a downstream event in AD, MRI of patients has shown that 
WMH are prominent early features of both late-onset (Brickman, 2013) and 
hereditary AD (Lee et al., 2016). Moreover, WML are an independent risk factor for 
dementia (Matthews et al., 2009), and form secondary to vascular pathology, 
including SVD, as discussed in detail in Chapter 1.  
 
WML are broadly classified based on their neuroanatomical location into PVL and 
DSCL. However, it should be noted that extensive WML encompassing both 
periventricular and deep subcortical regions are classified as confluent lesions 
(Barkhof & Scheltens, 2006). These WML are further subdivided into punctate, early 
confluent and confluent lesions based on their detection by MRI (Fazekas et al., 
1988; Schmidt et al., 1992). Confluent lesions are clinically relevant and are 




dementia (Srikanth et al., 2010; Callisaya et al., 2015). White matter tracts 
throughout the brain connect cortical and subcortical regions into functional units 
that play a role in cognition and emotion; therefore cognitive ability is as reliant on 
brain connectivity as it is on neuronal activity (Filley & Fields, 2016).  
 
While a number of studies have focussed on MRI assessment of WML in ageing and 
dementia patients (Wahlund et al., 1996; Fernando et al., 2004; Kim et al., 2008), 
research has also been performed to histologically characterise these lesions in 
ageing population-representative neuropathology cohorts, such as CFAS. CFAS is a 
prospective longitudinal study of an ageing population-representative cohort. The 
study began in 1989 when over 18,000 people aged 65 and older were selected from 
GP registers and invited to participate in the study. The study participants were 
located in six different centres across the UK, representing north and south, urban 
and rural areas (Brayne et al., 2006). The participants underwent regular cognitive 
testing and completed questionnaires regarding their lifestyle, medication and 
general health, enabling longitudinal data to be collected.  A subgroup of around 550 
participants donated their brain to the CFAS neuropathology study which has 
enabled assessment of the molecular and cellular pathologies of brain ageing, frailty 
and dementia to be evaluated (Wharton et al., 2011).   
 
Microglia exist in a quiescent state with a ramified morphology in the healthy brain, 
constantly surveying their environment to maintain homeostasis.  In response to an 
insult or infection, microglia become activated and can change their morphology to 
adopt a larger, amoeboid morphology.  Microglial activation is a complex and 




intracellular markers, secrete different factors and perform different functions 
depending on their activation phenotype. M1 microglia express the distinctive 
markers CD74, CD40, CD86, CCR7 (Peferoen et al., 2015), whereas M2 microglia are 
associated with the expression of mannose receptor and CCL22 (Peferoen et al., 
2015; Liu et al., 2018). These microglial states are predominantly defined by 
cytokine expression patterns as evidenced in animal and human studies (Boche et 
al., 2013). Microglia with an M1 phenotype are regarded as pro-inflammatory, while 
those with an M2 phenotype are regarded as an anti-inflammatory.  However, it 
should be noted that (as discussed in Chapter 1) these states were originally defined 
in peripheral macrophages, and the extent to which this applies to microglia is less 
certain.  These states are 2 extremes and it is generally accepted that the phenotype 
of activated microglia exists along a spectrum between these two poles (Boche et al., 
2013). 
 
Current microglial markers include Iba-1, CD68 and MHC II. Ionized calcium-binding 
adaptor molecule (Iba-1) is a member of calcium-binding proteins which interacts 
with actin molecules and is mainly located in the cytoplasm of microglia (Ohsawa et 
al., 2004). This marker is widely used as a microglial pan-marker which 
immunolabels both ramified and amoeboid microglial phenotypes in WML (Walker 
& Lue, 2015; Korzhevskii & Kirik, 2016). However, a recent study by Waller et al. 
reported that not all microglia are Iba-1+, and demonstrated the presence of Iba-1- 
microglia in DSCL (Waller et al., 2019). HLA-DR class II molecules of the major 
histocompatibility complex (MHC-II) play a major role in antigen processing and 
presentation and are expressed by immune-activated microglia.  Histological 




PVL contain significantly higher levels of MHC-II+ microglia than DSCL (Simpson et 
al., 2007b).  Interestingly, the radiologically normal-appearing white matter from 
lesional cases contains significantly higher levels of these immune activated 
microglia than control white matter from non-lesional cases, demonstrating that 
microglial pathology extends beyond the WML itself.  CD68 is a lysosomal-
associated membrane protein (Ramprasad et al., 1996) used to identify microglia 
with a phagocytic phenotype (Zotova et al., 2011).  In contrast to the PVL which 
contain high levels of immune activated microglia, DSCL contains significantly 
elevated levels of CD68+ microglia with an amoeboid, phagocytic phenotype.  
 
While the histological evaluation of WM pathology in the CFAS cohort has identified 
significant differences in the microglial profile of PVL compared to DSCL, to date the 




2.1.1 Hypothesis and aims: 
We hypothesise that confluent white matter lesions arise as a result of the combined 
spread of PVL and DSCL.  
 
To test this hypothesis, this chapter aims to: 
(i) Characterise the microglial immunoreactive profile of MHC II and CD68 




(ii) Quantify the percentage area immunoreactivity across the 
periventricular, middle and deep subcortical regions, to determine if 







2.2 Materials and methods  
2.2.1 MRI guided sampling of confluent lesions  
Post-mortem brain tissue was obtained from the CFAS, following multi-centre 
research ethics committee (REC) approval (REC Reference number 15/SW/0246). 
Cases were identified by two independent, experienced radiologists who examined 
the MRI of formalin fixed coronal slices from three distinct anatomical levels of each 
brain (Newcastle coronal brain map reference levels 10/12, 19/20 and 24/25), and 
scored WML using a modified Schelten’s rating,  as shown in Table 2-1 (Scheltens et 
al., 1993; Fernando et al., 2004). Based on these scores, and using post mortem MRI 
as a guide, 18 confluent lesions from 16 cases were sampled from the formalin fixed 
hemisphere with a mean age of 87.9 years (standard deviation (SD) 6.3 years; range 
87-101), post-mortem delay (PMD) mean of 39.6 hrs (SD 41.2; range 17-164 hrs), 






Table 2-1 A modified Scheltens rating scale for PVL and DSCL (Scheltens et al., 
1993) 
Periventricular lesions (PVL) Deep subcortical lesions (DSCL) 
0   Absent 0   No abnormality 
1   ≤5 mm 1   <4 mm; n < 6 
2   >5 mm - ≤10 mm 2   <4 mm; n ≥ 6 
3   >10 mm 3   4-10 mm; n ≤ 6 
 4   4-10 mm; n ≥ 6 
 5   >10 mm 





Table 2-2 Details of cases used in the confluent lesion study 
Case Number Age Gender PMD (Hrs) pH 
CASE 1 87 F 17 6.50 
CASE 2 101 F 5 5.97 
CASE 3 84 F 36 7.04 
CASE 4 91 F 35 5.97 
CASE 5 94 F 35 6.43 
CASE 6 91 F 36 6.50 
CASE 7 (BLOCK 1) 80 M 20 6.18 
CASE 7 (BLOCK 2)     
CASE 8 (BLOCK 1) 89 M 46 6.42 
CASE 8 (BLOCK 2)     
CASE 9 82 F N/A N/A 
CASE 10 86 F N/A N/A 
CASE 11 94 F N/A N/A 
CASE 12 90 F 72 N/A 
CASE 13 77 F 7 6.23 
CASE 14 82 M 164 N/A 
CASE 15 89 F 19 N/A 
CASE 16 90 F 24 N/A 
 






2.2.2 Characterisation of the microglial phenotype in confluent 
lesions 
2.2.2.1 Pre-treatment of FFPE sections  
FFPE sections (5μm) were prepared using a microtome, collected onto charged 
slides (Leica, UK) and dried overnight in an oven at 60oC. All steps were carried out 
at room temperature (RT) unless otherwise stated. Sections were dewaxed in xylene 
(2x5 min), rehydrated to water using a graded series of ethanol (EtOH) (100%, 95%, 
70%, for 5 minutes each). Sections were placed in 3% Hydrogen Peroxide 
(H2O2)/methanol (Fisher Chemicals, Loughborough, UK) for 20 minutes at room 
temperature (RT) to block endogenous peroxidase activity and then briefly washed 
with tap water. Antigen retrieval was required to unmask the antigen binding site 
in the FFPE tissue and was performed by microwaving the sections for 10 minutes 
at maximum power (800 watts) (model NN-E255W, Panasonic, Franklin Park, IL, 
USA) in 10mM Tri-Sodium Citrate buffer (TSC, pH6.5). The sections were cooled to 
RT by placing them in running tap water. 
 
2.2.3 Immunohistochemistry (IHC) 
IHC is a biochemical technique used to detect specific antigens in tissue sections and 
occurs via binding of a specific primary antibody to the antigen of interest. The 
signal from the primary antibody (Ab) is amplified through a species-specific 
secondary antibody and the introduction of peroxidase enzyme via an avidin 
biotinylated complex (ABC). This process enhances and amplifies the signals to be 





Following antigen retrieval, IHC was performed on the sections using the Vectastain 
Elite Mouse IgG kit (Vector Laboratories, Peterborough, UK), using solution 
preparations as outlined in Table 2-3. Sections were covered with 1.5% normal 
horse blocking solution for 30 minutes at RT; then, following removal of blocking 
solution, incubated with the primary antibody (diluted in blocking solution) for one 
hour at RT (all antibody details are shown in Table 2-4). After rinsing slides with 
Tris-buffered saline (TBS, 50mM Tris, 150mM NaCl, pH 7.6) for 5 minutes, the 
sections were incubated with 0.5% secondary biotinylated antibody for 30 minutes. 
Then, after rinsing with TBS for 5 minutes, the sections were incubated with 2% 
ABC-HRP (avidin-biotin-complex horse radish peroxidase) for 30 minutes at RT, 
which was freshly made at least 30 minutes prior to its usage (Fadul, 2016). 
 
2.2.3.1 Visualisation of ABC-HRP complex 
The sections were washed with TBS for 5 minutes at RT and then incubated with the 
peroxidase enzyme substrate 3,3′-diaminobenzidine tetrahydrochloride (DAB) 
(Vector Laboratories, Peterborough, UK). 100 μl of DAB was added to each section 
and incubated at RT for 5 minutes. The reaction was observed under the microscope 
and once developed; sections were washed with dH2O to quench the HRP enzyme 
activity. The sections were counterstained with haematoxylin (Leica Biosystems) 
for 30 seconds and blued in Scott’s tap water. Following this step, slides were 
dehydrated using a graded series of ethanol in ascending concentration: 70%, 95%, 
100%, and 100% for 1 minute each, then cleared in xylene before mounting in DPX 






Table 2-3 Preparation of Vectastain Solutions 
Reagent name Composition 
Blocking Solution  3 drops (150µl) of normal horse serum blocking solution 
in 10 ml TBS  
Secondary Biotinylated 
Antibody  
1 drop (50µl) of biotinylated anti-mouse IgG antibody in 
10 ml TBS  
Avidin-biotin-complex 
(ABC) horse radish 
peroxidase complex  
2 drops of A solution (100µl) and 2 drops (100µl) of B in 
10 ml TBS  
DAB 2 drops (100µl) of the buffer, 2 drops (100µl) of H2O2 and 
4 drops (200µl) of DAB in 5 ml of distilled water (dH2O) 






Table 2-4 Antibodies source and dilution 
Table of markers used to characterise microglial phenotype of confluent lesions.  
Antibody Dilution Isotype Source 
MHC-II 
(HLA-DR) 










2.2.4 Analysis of the microglial immunoreactive profile of 
confluent lesions  
2.2.4.1 Semi-quantitative Analysis  
The immunoreactive profiles of MHC II and CD68 within the periventricular and 
deep subcortical regions of radiologically identified confluent lesions were assessed 
semi-quantitatively by two independent observers (J.S) and (M.F). The 
immunoreactive profile of MHC II+ and CD68+ microglia were observed across the 
entire WM, starting from the ventricular region and scanning across to the 
subcortical area using bright-field microscopy. Each observer classified the staining 
based on the localisation of both, MHC-II+ and CD68+ microglial cells in the 
periventricular and deep subcortical regions: occasional immunopositive cell (+); 
moderate expression (++); high levels of expression (+++). Agreement for the scores 
was assessed using Cohen’s Kappa. If the independent observers disagreed on the 
score for cases, the stained sections were reviewed together to reach consensus on 
the rating. Representative images were captured using Nikon Eclipse 80i 
microscope (20x objective) and analysed using the NIS-Elements Imaging Software 
(Nikon UK, Kingston Upon Thames).  
 
2.2.4.2 Quantitative analysis  
Stained sections were scanned under a 20x objective lens using NanoZoomer-XR 
scanner and viewed using NDP view software version 2.3 (Hamamatsu, Photonics 
Ltd, Hertfordshire, UK). Assessment of the immunoreactive profile of CD68 and 
MHC-II was performed by starting from the area next to the ventricular region to 
capture 3 images in the periventricular region (PV), followed by capturing 3 images 




(MID) where 3 images were captured. This process was done for each case in the 
study (Figure 2.1). The area of the selected field dimensions: 2834 x 1665 pixels; 
size 0.436 mm2 (436000 µm2) using x20 magnification. The images were analysed 
using Analysis^D software (Nikon UK, Kingston Upon Thames). The total 
immunoreactive area of both CD68 and MHC-II within the captured images was 
determined per total area studied. The average % area immunoreactivity of both 




Agreement for semi-quantitative scores was assessed using Cohen’s Kappa 
(unweighted) using SPSS software version 26 (Chicago, IL, USA). Statistical 
comparisons to assess the variation of CD68 and MHC-II mean % area 
immunoreactivity across the white matter regions  (PV, MID and DSC) were carried 
out using Friedman’s analysis of variance (ANOVA) for non-parametric data using 







Figure 2.1 Approach used in quantitative analysis of WM confluent lesions 
Selection of analysis region was made by capturing three images from each of the three 
different white matter regions: periventricular [PV] (A),) mid-region [MID] (B) and deep 
subcortical [DSC] (C) at x20 magnification. Images were imported into Analysis^D software 
to quantitatively analyse the % area immunoreactivity of both CD68 and MHC-II in the three 






2.3.1 Characterising microglial pathology in confluent lesions 
The confluent lesion cohort displayed a spectrum of MHC II+ and CD68+ microglial 
morphologies and phenotypes in both the deep subcortical and periventricular 
regions. MHC-II+ microglial mainly displayed a ramified morphology with extending 
processes from the cell body. CD68+ microglia mainly showed retracted processes 
with swollen and enlarged cellular bodies, reflecting an amoeboid microglial 
phenotype as shown in Figure 2.2. 
 
2.3.2 Quantitative assessment of MHC-II and CD68 
immunoreactivity in confluent lesions 
Quantitative assessment of MHC-II and CD68 immunoreactivity was performed 
using analysis ^D software. The immunoreactive profile of CD68 and MHC-II (mean 
% area ± Standard Deviation (SD)) varied across the three regions of all confluent 
lesions. CD68+ microglia were a feature of the deep subcortical (DSC) region (0.343 
±0.303), compared to middle (MID) (0.308 ±0.200) and periventricular regions 
[0.201 ±0.162).  In contrast, MHC-II+ microglia were a feature of the periventricular 
region (0.231 ±0.221), compared to both middle (0.183 ±0.127) and deep 
subcortical regions (0.150 ±0.148), as shown in Figure 2.3.  
 
Friedman’s test demonstrated a significant variation between CD68 χ2 (N = 18, df = 
2) =12.197, p = 0.002 and MHC-II χ2 (N = 18, df = 2) =8.444, p = 0.015 across the 






Figure 2.2 Microglial phenotypes in confluent lesions 
MHC-II+ microglial mainly displayed a ramified morphology with extending processes from 
the cell body (A). While CD68+ microglia mainly showed retracted processes with swollen 
and enlarged cellular bodies, reflecting an amoeboid microglial phenotype (B). Scale bar 







Figure 2.3 Mean %area immunoreactivity of CD68 and MHC-II in PV, MID and 
DSC white matter region of confluent lesions 
Mean percentage (%) area of CD68 in the periventricular region (PV) [mean ± Standard 
Deviation (SD)= 0.201 ±0.162], MID region (0.308 ±0.200) and for deep subcortical region 
(DSC) (0.343 ±0.303). For MHC-II, the mean % area in the PV region was (0.231 ±0.221), 





2.3.3 Qualitative assessment of the immunoreactive profile of 
confluent lesions 
Qualitatively, four distinct staining patterns were observed. Immunostaining 
revealed that ramified MHC II+ microglia were present primarily in the 
periventricular region but not the deep subcortical region (Figure 2.4. A) and that 
amoeboid CD68+ microglia were primarily a feature of the deep subcortical region 
(Figure 2.4. D), this pattern was classified as Type 1, and observed in 2/18 confluent 
lesions. In Type 2 lesions, immunostaining revealed a prominent MHC II+ microglia 
with a ramified morphology present throughout the confluent lesion, at similar 
levels in both the periventricular and deep subcortical regions (Figure 2.5. A, B), this 
pattern was observed in 4/18 confluent lesions. Whereas in Type 3 lesions, 
immunostaining revealed prominent CD68+ microglia with an amoeboid 
morphology were present throughout the confluent lesion, at similar levels in both 
periventricular and deep subcortical regions (Figure 2.6 C, D), this pattern was 
observed in 2/18 confluent lesions. Immunostaining in Type 4 lesions, displayed a 
mixed pattern of staining, where all regions of the confluent lesion contained both 
CD68+ and MHC II+ microglia (Figure 2.7), this pattern was observed in 10/18 
confluent lesions. 
 
In summary, the immunoreactive profile of microglia within confluent lesions could 
be classified into four lesion types with distinct staining patterns: 
1. MHC II+ and CD68+ microglia primarily associated with the periventricular 
region and deep subcortical region, respectively (Figure 2.4). 
2. MHC II+ microglia predominantly throughout all regions (Figure 2.5). 




4. A mix of both CD68+ and MHC II+ microglia were present throughout the 






Figure 2.4 Microglial staining of confluent lesions: type 1 lesion 
MHC II+ (A and B) and CD68+ (C and D) microglia are discrete to the periventricular and 
deep subcortical region, respectively. Diagrammatic representation of the staining pattern 
(E), where MHC II+ ramified microglia are illustrated by the red star-shape, while CD68+ 
amoeboid phagocytic microglia (D) are indicated by the blue round circles (E). Scale bar 







Figure 2.5 Type 2 lesion pattern 
In type 2 confluent lesions ramified MHC II+ microglia were present in both, the 
periventricular (A) and the deep subcortical region (B), as indicated in the diagrammatic 
representation (E). MHC II+ microglia are indicated by the red star, while CD68+ microglia 







Figure 2.6 Microglial staining of confluent lesions: type 3 lesion 
In type 3 confluent lesions, amoeboid CD68+ microglial were present in both the 
periventricular (C) and deep subcortical region (D), as indicated in the diagrammatic 
representation (E). MHC II+ microglia are indicated by the red star, while CD68+ microglia 






Figure 2.7 Type 4 Confluent Lesion Pattern 
The figure illustrates a mixed pattern of staining, where all regions of the confluent lesion 
contained both CD68+ and MHC II+ microglia (E). MHC II+ ramified microglia were present 
in the deep subcortical region, indicated by red arrows (B), while CD68+ amoeboid microglia 
found in the periventricular region, indicated by black arrows (C). MHC II+ microglia are 
indicated by the red star, while CD68+ microglia are indicated by the blue circles (E). Scale 




2.3.4 Analysis of staining patterns (semi-quantitative & 
quantitative) 
The microglial staining patterns were semi-quantitatively assessed by two 
independent observers, who agreed on the staining pattern of 10/18 confluent 
lesions with a moderate agreement (κ = 0.4) (Table 2-5). Where the observers 
disagreed on the staining pattern of cases, they re-evaluated the staining pattern 
together and agreed to a consensus staining pattern. 
 
In type 1 lesions, the mean of percentage (%) area of CD68 in the PV region was 
(mean ± SD= 0.066 ±0.049), MID region (0.119 ± 0.115) and DSC region (0.096 
±0.091). The mean of MHC-II % area in the PV region was (0.089 ±0.052), MID 
region (0.094 ±0.061) and for the DSC region (0.045 ±0.035). For type 2 lesions, the 
mean of % area of CD68 in the PV region was [(mean ±SD) 0.025 ±0.007], MID region 
(0.090 ±0.099) and for the DSC region (0.102 ±0.021). The mean of MHC-II area in 
the PV region was (mean ± SD= 0.108 ±0.035), MID region (0.1435 ±0.007) and DSC 
region (0.083 ±0.085). For type 3 lesions, the mean of % area of CD68 in the PV 
region was (0.234 ±0.176), MID (0.364 ±0.224), DSC (0.402 ±0.297).  The mean of 
MHC-II % area in the PV region was (0.142 ±0.116), MID (0.101 ±0.055), and DSC 
(0.070 ±0.059).  For type 4 lesions, the mean % area of CD68 in the PV region was 
(0.281 ±0.142), MID region (0.402 ±0.141), and for the DSC region (0.468 ±0.338). 
The mean of MHC-II % area in the PV region was (0.402 ±0.261), MID (0.303 
±0.118), and DSC (0.283 ±0.152) as shown in Table 2-6.  The variation of CD68 and 
MHC-II immunoreactivity across white matter regions for different confluent lesion 
subtypes is shown in Figure 2.8, statistical analysis was not performed due to the 




Table 2-5 Inter-observer agreement of confluent lesion type  
Independent scores of 2 observers assessing the microglial pathology and lesion type in a 
cohort of confluent lesions, showing moderate agreement (Kappa (κ) = 0.4) for assignment 













Second Observer (J.S) 
 Type 1 Type 2 Type 3 Type 4 Total 
Type 1 2 1 0 0 3 
Type 2 2 1 1 0 4 
Type 3 0 0 1 2 3 
Type 4 1 0 1 6 8 





Table 2-6 AnalySIS ^D quantitative analysis of % area immunoreactivity of 
microglial staining 
This table represents the % area immunoreactivity of microglial staining for both MHC-II 
and CD68 in PV, MID and DSC regions. 
Lesion 
type 
Case CD68 MHC-II 
PV MID DSC PV MID DSC 
Type 1 Case 6 0.011 0.007 0.001 0.150 0.160 0.083 
Case 7 
Block 1 
0.097 0.113 0.110 0.057 0.080 0.043 
Case 14 0.090 0.237 0.177 0.060 0.041 0.008 
Mean 0.066 0.119 0.096 0.089 0.094 0.045 
Type 2 Case 13 0.033 0.157 0.117 0.133 0.150 0.143 
Case 15 0.017 0.023 0.087 0.083 0.137 0.023 
Mean 0.025 0.09 0.102 0.108 0.1435 0.083 
Type 3 Case 5 0.517 0.350 0.447 0.293 0.060 0.097 
Case 8 
Block 1 
0.163 0.287 0.240 0.060 0.083 0.057 
Case 9 0.210 0.770 0.367 0.057 0.123 0.012 
Case 10 0.103 0.170 0.193 0.137 0.087 0.060 
Case 11 0.050 0.173 0.193 0.030 0.050 0.023 
Case 12 0.360 0.433 0.970 0.277 0.203 0.170 
Mean 0.234 0.364 0.402 0.142 0.101 0.070 
Type 4 Case 1 0.523 0.440 0.897 0.723 0.340 0.553 
Case 2 0.120 0.220 0.230 0.437 0.380 0.173 
Case 3 0.137 0.263 0.263 0.610 0.380 0.343 
Case 4 0.300 0.303 0.173 0.333 0.393 0.397 
Case 7 
Block 2 
0.260 0.507 0.370 0.583 0.223 0.163 
Case 8 
Block 2 
0.397 0.567 0.997 0.050 0.070 0.197 
Case 16 0.227 0.517 0.343 0.077 0.337 0.157 
Mean 0.281 0.402 0.468 0.402 0.303 0.283 







Figure 2.8 Immunoreactive profile of CD68 and MHC-II across the 4 confluent lesion subtypes 
This figure illustrates the variation in the immunoreactive profile of CD68 and MHC-II across the periventricular, mid and deep subcortical regions of 







Large confluent lesions, which encompass both the periventricular and deep 
subcortical regions (Barkhof & Scheltens, 2006), are clinically relevant and are 
associated with a greater risk of developing dementia (Schmidt et al., 2002; 
Ovbiagele & Saver, 2006). Multiple radiological studies have mainly focussed on the 
growth and progression of these lesions in patient cohorts but, to date, histological 
studies have been limited.  Detailed characterisation of PVL and DSCL have shown 
that these types of WML are predominantly associated with differing microglial 
profiles: PVL contains higher levels of immune activated MHC-II+ microglia while 
DSCL contains higher levels of CD68+ microglia with a phagocytic phenotype 
(Simpson et al., 2007a, 2007b; Murray et al., 2012). Studies characterising the 
microglial profile of confluent white matter lesions are limited. The current study 
characterised the expression of CD68+ and MHC-II+ microglia of confluent lesions in 
the CFAS ageing population-representative neuropathology cohort, demonstrating 
that confluent lesions are not characterised by one predominant microglial 
phenotype, instead 4 distinct lesion types were identified.  
 
Longitudinal radiological studies of an ageing community-dwelling cohort to assess 
white matter hyperintensities have shown that early confluent and confluent lesions 
progress during ageing (Schmidt et al., 2003). Patients with lacunes are at greater 
risk of developing confluent WMH and deep WMH (Ghaznawi et al., 2019). While 
some radiological studies suggest that WML likely represent a continuum of 






Hernández et al., 2014; Kim et al., 2008; Gouw et al., 2011; Iordanishvili et al., 2019).  
In patients with a history of stroke, WML have a propensity to extend from the 
periventricular region to the deep white matter, becoming more confluent (Valdés 
Hernández et al., 2014).  In contrast, studies suggest that DSCL have a tendency to 
become more confluent by extending to the periventricular region (Hase et al., 
2018).  
 
Histological characterisation of PVL and DSCL has demonstrated that while these 
lesions share some similarities, including myelin loss and astrogliosis, their 
microglial phenotype differs (Simpson et al., 2007a, 2007b; Schmidt et al., 2011). 
Based on these differences, the current study assessed the microglial profile of 
confluent lesions to determine whether they represent distinct PVL and DSCL 
pathologies (MHC-II+ in the periventricular region and CD68+ in the deep subcortical 
region; type 1 lesion), the spread of pathology from the periventricular lesion (MHC-
II+ phenotype; type 2 lesion), the spread of pathology from the deep subcortical 
region (CD68+ phenotype; type 3 lesion), or a mix of both pathologies (MHC-II+ and 
CD68+ throughout; type 4 lesion). Our findings demonstrate that confluent lesions 
are not characterised by one distinct microglial profile, rather they contain 4 profiles 
which suggests these lesions can arise as a spread of PVL, DSCL or both.  While the 
small number of cases examined do not have enough power to perform robust 
statistical analysis of the frequency of these lesion types, this initial study suggests 
that most age-associated confluent lesions arise as a result of the spread of both PVL 
and DSCL: type 1 (5/18) and type 4 (8/18). This finding highlights that detection of 






and given that different mechanisms may underlie lesion pathogenesis, a potential 
treatment of patients may require different therapeutic strategies.  
 
Previous histological characterisation studies have demonstrated that DSCL are 
associated with cerebral hypoperfusion giving rise to a hypoxic environment 
(Fernando et al., 2006) and are characterised by the presence of increased numbers 
of CD68+ microglia with a phagocytic phenotype (Simpson et al., 2007b).  In contrast, 
PVL are associated with increased markers of BBB dysfunction and contain high 
levels of immune activated MHC II+ microglia with a ramified morphology (Simpson 
et al., 2007a; Murray et al., 2012). The current study demonstrates a range of 
confluent lesion subtypes which may reflect a spread of DSCL pathology, PVL lesion 
pathology or both, suggesting that a variety of mechanisms may be associated with 
the pathogenesis of confluent lesions. 
 
2.5 Conclusion 
In summary, the current study provides evidence that a proportion of confluent 
lesions display the microglial profile associated with PVL, containing MHC II+ 
microglia with a ramified morphology that extends into deep subcortical regions, 
suggesting confluent lesions arise as a spread of PVL. A proportion of confluent 
lesions display the microglial profile associated with DSCL, containing CD68+ 
microglia with an amoeboid morphology that extends into periventricular regions, 
suggesting confluent lesions arise as a spread of DSCL.  A proportion of confluent 






and DSCL: the periventricular region containing high levels of MHC-II+ microglia and 
the deep subcortical region containing CD68+ microglia.  And a final proportion of 
cases contain a mix of both MHC II+ and CD68+ microglia throughout periventricular 
and deep subcortical regions. 
 
Understanding how WML arise, particularly the role of microglia in the 
pathogenesis of WM pathology, may identify novel therapeutic treatments designed 
to modulate the microglial phenotype.  Currently, much more is known about the 
microglial phenotype and transcriptomic profile of DSCL than PVL; therefore, the 
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White matter lesions appear as hyperintensities on T2 weighted magnetic 
resonance images (MRI) (de Leeuw, 2001) and are classified anatomically into PVL 
and DSCL (Fazekas et al., 1987; Wharton et al., 2015). Using the radiological 
assessment of white matter hyperintensities by fluid-attenuated inversion recovery 
(FLAIR) MRI, Fazekas proposed the following rating system for periventricular 
white hyperintensities: absent (0); caps or pencil-thin lining (1); smooth halo (2); 
irregular periventricular hyperintensity extending into the deep white matter (3); 
and for deep white matter hyperintensities: absent (0); punctate (1); early confluent 
(2); and confluent (3) (Fazekas et al., 1987). This scale was subsequently modified 
by Scheltens, and was designed based on the brain regions and divided into four 
areas: periventricular white matter hyperintensities (WMH), deep subcortical 
WMH, infratentorial WMH and basal ganglia WMH (Scheltens et al., 1993), as shown 
in section 2.2.1. 
 
WML have a propensity to extend to become more confluent, as discussed in the 
previous chapter. Several mechanisms underlying lesion formation have been 
proposed, including cerebral hypoperfusion, dysfunction of the BBB and 
neurodegeneration due to overlying cortical pathologies (Huang et al., 2007; 
Wharton et al., 2015; Li et al., 2017; Moscoso et al., 2020). However, the exact 
mechanism(s) underlying the formation of WML remain unknown. 
 
Transcriptome profiling provides comprehensive information on all genome 






pathological conditions to identify the genes expressed in the selected tissue or cell 
(Casamassimi et al., 2017). This technology also helps in identifying the alterations 
of the biological and genetic variations, which may underlie human diseases 
(Casamassimi et al., 2017). Microarray and Ribonucleic acid-Sequencing (RNA-Seq) 
are the major techniques used for transcriptomic profiling (Nelson, 2001; Wang et 
al., 2009). RNA-Seq refers to the quantification and detection of RNA. Initially, RNA 
is converted into cDNA fragments to build a cDNA library. These short transcripts 
are sequenced and are then analysed to recreate reads for a specific gene (Wang et 
al., 2009; Ozsolak & Milos, 2011).  
 
Microarray analysis, and in particular the Affymetrix GeneChip Human Genome 
U133 Plus 2.0 microarray used in the current study, measures the expression levels 
of an extensive number of genes, interrogating more than 47,000 transcripts 
representing over 20,000 genes (Zwemer et al., 2014). Microarray technology can 
be used for the determination of crucial molecular pathways to elucidate the 
changes in gene expression underlying pathological conditions (Ding & Cantor, 
2004) and can cover the whole genome or be specifically designed to identify the 
expression of a selected panel of genes (Cuccaro et al., 2018). The basis of this 
technology involves a synthesis of complementary DNA from RNA by reverse 
transcription. This is followed by complementary cDNA fragmentation and labelling, 
which is then hybridised to the microarray chip for scanning (Lonergan et al., 2007). 
The amount of labelled cDNA is reflected by the presence of signal intensity spots 
bound to the microarray chip. The intensity of these signals, reflecting mRNA 






samples. Microarrays can be used to assess the transcriptomic profile of samples 
and identify differentially expressed genes.  
 
Advancement in these gene expression technologies has enabled the identification 
of changes in gene expression and biological processes associated with multiple 
pathologies, including astrocytic transcriptomic profiling in the ageing brain 
(Simpson et al., 2011) and multiple sclerosis (Waller et al., 2016), in addition to the 
identification of blood-brain barrier changes in ageing populations (Goodall et al., 
2019).  
 
Laser capture microdissection (LCM) is a robust method which enables precise 
extraction of a specific region of interest or cellular type from a tissue section under 
microscopic visualisation (Decarlo et al., 2011). This technology has been used in 
conjunction with microarray to characterise gene expression changes in human 
post-mortem tissue and animal models to identify the transcriptomic gene 
expression changes in multiple neurological diseases and provide an insight into the 
mechanisms and the pathogenesis of these diseases.  
 
Histological characterisation of deep subcortical white matter lesions in human 
post-mortem studies has shown they are associated with an increased expression of 
multiple hypoxia-related molecules, suggesting an increase in vascular insufficiency 
together with hypoperfusion are the primary underlying mechanism for the 
formation of these lesions (Fernando et al., 2006). Transcriptomic profiling of these 






these lesions with an increased expression of hypoxia-related genes together with 
the dysregulation of immune-regulatory genes, including those associated with 
antigen processing and presentation, phagocytosis and signalling pathways 
associated with pro-inflammatory cytokines (Simpson et al., 2009).  
 
3.1.1 Transcriptomic profiling of PVL 
While transcriptomic profiling of LCM-ed DSCL has been employed to determine 
their gene expression signature, to date, no comparable studies have characterised 
the transcriptome of established PVL.  Therefore, the work in this chapter will test 
the hypothesis that microglia within PVL adapt a neurotoxic M1 phenotype. 
 
Specifically, this chapter aims to  
1. Characterise the gene expression profile of age-associated PVL and identify 
significant changes in biologically relevant functional groups and pathways 
using DAVID. 
2. Perform bioinformatics analysis using EnrichR to focus on the microglial-
associated gene expression changes 
3. Perform computational microglial deconvolution of the bioinformatics 







3.2 Materials and methods 
3.2.1 Identification of PVL and control periventricular white 
matter 
MRI analysis of formalin-fixed post-mortem tissue obtained from the CFAS 
neuropathology cohort was employed to identify PVL and scored by consultant 
radiologists using a modified Schelten’s rating (refer to section 2.2.1). PVL were 
scored between 0 to 3: where 0 represents an absence of white matter 
hyperintensities; 1 represents a PVL ≤ 5mm; 2 represents smooth halo PVL between 
6-10 mm with regular margins; and 3 represents an irregular periventricular halo 
of ≥ 10mm. All PVL used in the current project were scored 3 on the Schelten’s rating 
scale (Scheltens et al., 1993).  
 
Frozen periventricular white matter was obtained from the CFAS neuropathology 
cohort (Table 3-1), following ethical approval (Appendix I). Using MRI of the 
formalin-fixed hemisphere to guide sampling of the contralateral snap-frozen 
hemisphere, all periventricular sampled blocks were initially stained with 
haematoxylin and eosin (H&E) and luxol fast blue (LFB) to assess their basic 
histology. 
 
Briefly, 10 μm sections were warmed to room temperature (RT) for 5 min, fixed in 
ice-cold acetone at 4oC for 10min, and air-dried before staining with either H&E or 
LFB. For H&E, sections were immersed in Harris haematoxylin (CellPath Ltd, Powys, 






Table 3-1 Cohort demographics 














Control 1 0 0 89 F 24 7.07 
Control 2 0 0 73 M 23 6.85 
Control 3 0 0 89 F 12 6.00 
Control 4 0 0 84 F 6 6.68 
Control 5 0 0 85 F N/A 7.02 
Control 6 0 0 71 F 8 6.46 
Control 7 0 0 89 F 6 6.82 
Control 8 0 0 95 M N/A 6.68 
Control 9 0 0 74 F 5 6.30 
Control 10 0 0 71 M 16 6.38 
Control 11 0 0 78 F 17 6.84 








 Prelesion 1 0 0 70 F 42 6.80 
Prelesion 2 0 0 84 M 10 N/A 
Prelesion 3 0 0 76 M 7 7.05 





Lesion 1 3 0 90 M N/A 5.30 
Lesion 2 3 3 95 F 24 6.29 
Lesion 3 3 3 88 F 18 6.09 
Lesion 4 3 5 89 F 7 6.48 
Lesion 5 3 0 85 F 32 6.56 
Lesion 6 3 0 90 M 32 6.36 
Lesion 7 3 3 85 M 72 6.57 
PV: Periventricular; DSC: Deep Subcortical; PVL: Periventricular Lesion; PMD: Post-Mortem 







before being rinsed in tap water. Sections were immersed in Scott’s tap water to 
blue for 2 min before further rinsing in tap water. After that, sections were 
immersed in 1% eosin (CellPath Ltd, Powys, UK) for 5 minutes before washing 
briefly in tap water and dehydrated through a graded series of alcohols (70%, 95%, 
absolute [x2]), cleared in xylene, permanently mounted in distyrene plasticizer 
xylene (DPX) (Leica Biosystems), and dried in an oven overnight. 
 
For LFB, sections were fixed in acetone as detailed above and immersed in luxol fast 
blue (0.1% of LFB – 0.5g Luxol fast blue powder (Fischer, UK) and 2.5 ml of acetic 
acid in 500 ml of 95% ethanol) pre-heated to 60oC for two hours. Sections were 
washed in 70% alcohol for 15 seconds before washing in tap water. Differentiation 
was performed by using freshly prepared 0.5% lithium carbonate (0.25g lithium 
carbonate was dissolved in 500ml of dH2O) for 30 seconds which was then 
continued in 95% alcohol. Afterwards, sections were rinsed in tap water followed 
by dehydration through a graded series of alcohols, before being cleared in xylene 
and permanently mounted in DPX. 
 
3.2.2 Immunohistochemistry (IHC) 
3.2.2.1  Immunostaining of MHC-II and PLP 
Frozen sections (10 μm) were prepared on a cryostat (Leica, UK) and collected onto 
charged glass slides. Sections were warmed to room temperature for 5 min before 
fixing them in ice-cold acetone for 10 minutes prior to IHC using the ABC-HRP 






Laboratories, UK) as substrate (refer to section 2.2.3 for full details). Antibody 
details are shown in  Table 3-2. 
 
3.2.3 Analysis of frozen PVL samples 
Immunostaining enabled the histological characterisation of the periventricular 
region of interest identified by the MRI scans, thereby confirming whether a PVL 
was present or absent. The histologically stained frozen sections from each sampled 
case were assessed by an experienced clinical neuropathologist (SBW) blind to any 
data or MRI score using a light microscope to locate the periventricular region which 
was then classified as either lesional or non-lesional. H&E and LFB stained samples 
were analysed to locate the periventricular region within the tissue sections and for 
myelin attenuation, respectively. Immunostaining for PLP was used in addition to 
LFB to assess myelin integrity. In addition, MHC II used to visualise and assess the 
presence of immune activated microglia within the periventricular white matter. 
While four cases were radiologically classified as control (rated 0 in the PV and DSC 
regions on MRI scans), these samples were histologically characterised by intact 
myelin (LFB staining) but contained high levels of immune activated microglia 







Table 3-2 Antibody source and dilutions 
Antibody  Dilution  Isotype  Source  
MHC II  
(HLA-DR)  
1:20 Mouse, IgG  Dako, UK  
PLP 1:800 Mouse, IgG Bio-Rad, UK 








3.2.4 RNA extraction 
3.2.4.1 Trizol RNA isolation prior to LCM  
RNA analysis pre-LCM was performed in all cases. Five frozen sections (20μm) were 
prepared using a cryostat (CM3050S, Leica Microsystems, Milton Keynes, UK) and 
placed into a sterile 1.5 ml Eppendorf tube. Sections were lysed in 1000 μl of Trizol 
(Life Technologies Inc, UK) and homogenised using a handheld homogeniser (Argos 
Technologies, London, UK). 200 μl of chloroform (Fisher Scientific, UK) was added 
and vigorously vortexed for 5 seconds before incubation for 3 minutes at RT. The 
samples were centrifuged (Sigma centrifuges, UK) at 12000g for 15 minutes at 4°C. 
The upper aqueous phase was transferred into a new sterile 1.5 ml Eppendorf tube 
before the addition of 500 μl of isopropanol (Fisher Scientific, Loughborough, UK) 
and incubated at RT for 10 minutes. The sample was centrifuged at 12000g for 10 
minutes at 4°C. The supernatant was discarded before the RNA pellet was re-
suspended in 1000 μl of 75% EtOH and vortexed for 5 seconds before further 
centrifugation at 7500g for 5 minutes at 4°C. The supernatant was removed, and 
pellet air-dried for 10 minutes at RT. The pellet was re-suspended in 15 μl RNase-
free water and incubated for 10 minutes at 55°C. The sample was stored at -80oC 
until required. 
 
3.2.4.2 Assessing the quality and integrity of RNA 
Extracted RNA was assessed for quantity using the Nanodrop 1000 
Spectrophotometer (Labtech International, Uckfield, UK). Both the RNA integrity 






Bioanalyser (Agilent, UK). The RIN number is a range from 1 to 10 where a RIN of 
10 indicates fully intact RNA, and a RIN of 1 indicates severely degraded RNA. 
 
3.2.4.3 Laser capture microdissection (LCM) of periventricular white 
matter 
Five periventricular white matter frozen sections (10μm) were freshly prepared 
and collected onto uncharged sterile glass slides (Leica, UK). Sections were warmed 
to RT, fixed in ice-cold acetone (Fisher Scientific, UK) for 3 minutes, and stained with 
Toluidine blue for 30 seconds. Sections were rinsed in diethylpyrocarbonate (DEPC) 
water and dehydrated using a graded series of ethanol (70%, 95%, and 100%) for 
~30s each. Sections were cleared in xylene for 3 min before being placed in an air-
flow hood for at least one hour prior to LCM. The periventricular areas were 
identified on histologically stained sections (obtained in section 3.2.3) and mapped 
onto the Toluidine Blue stained slides to guide LCM.  
 
The periventricular region was isolated using a PixCell II laser-capture 
microdissection system (LCM) (Arcturus BioScience, Mountain View, CA, USA) and 
CapSure Macro Caps (Arcturus Engineering, Mountain View, CA, USA) (Figure 3.1). 
A 30 μm laser spot size was used to capture the periventricular area, using a pulse 
power of 65-90 mW. Following isolation of periventricular region with several laser 
pulses, the film was carefully removed from the cap using sterile forceps and placed 
in a sterile 0.2 ml Eppendorf tube, covered with 50 μl of extraction buffer and stored 







Figure 3.1 Laser Capture Microdissection  
The mechanism of laser capture microdissection in isolating a region of interest from a 
tissue section. (A) The laser beam is targeted to the periventricular region. (B) The region 
of interest is micro-dissected from the tissue. (C) The film from the cap containing the 






3.2.5 RNA extraction of LCM-ed material 
RNA isolation was performed using the Arcturus Pico Pure RNA isolation kit (Life 
Technologies, (Arcturus, Applied Biosystems, USA). The film containing the LCM-ed 
tissue in 50 μl of extraction buffer was incubated at 42°C for 30 minutes in a thermal 
cycler. In the meantime, a column was prepared by adding 250 μl of conditioning 
buffer and incubated at RT for 5 minutes before being centrifuged at 13300g for 1 
minute. The sample was mixed with 50 μl of 70% EtOH by pipetting and carefully 
added to the pre-conditioned column before centrifugation at 100g for 2 minutes, 
followed by 1 minute at 13300g. 100 μl of wash buffer 1 was added into the column 
and centrifuged at 8000g for 1 minute. 100 μl Wash buffer 2 was added and 
centrifuged at 8000g for 1 minute. This step was repeated with the centrifugation 
speed increased to 13300g for 1 minute. The column was transferred to a sterile 1.5 
ml Eppendorf, and 11 μl of elution buffer was added to the membrane of the column 
and incubated at RT for 1 minute. The tube was centrifuged at 1000g and then 
13300g for 1 minute each to elute the RNA. Extracted RNA samples were stored at -
80 °C until required. 
 
3.2.5.1 Assessing the quality and integrity of RNA 
Extracted RNA was assessed for quantity using the Nanodrop 1000 
Spectrophotometer (Labtech International, Uckfield, UK), and quality using the 







3.2.6 Affymetrix GeneChip cDNA Microarray Hybridization  
3.2.6.1 Poly-A RNA control preparation 
Extracted RNA from the periventricular white matter samples were processed and 
amplified with the 3’ IVT Pico Reagent kit (ThermoFisher Scientific, MA, USA), to 
prepare low input RNA samples for gene expression profiling. In summary, 50ng of 
total RNA per periventricular sample was mixed with 5µl of poly-A RNA control. This 
step was performed to monitor the process and contains probe sets from B. subtilis 
that are absent in eukaryotic samples. These ‘spike-in’ controls were set at different 
concentrations to enable monitoring of the labelling process efficiency. 
 
3.2.6.2 First-strand cDNA synthesis  
In order to make cDNA, RNA was converted to single-stranded cDNA (ss-cDNA) with 
a T7 promoter sequence at the 5’ end by reverse transcription. The first-strand 
master mix was prepared by adding 40 μl of First-strand buffer to 10 μl of the first-
strand enzyme in a nuclease-free tube and mixed thoroughly by gentle vortexing 
and centrifuging. Then on ice, 5 μl of the first-strand master mix was added to each 
sample and mixed thoroughly by gentle vortexing before incubation for 1 hr at 25 °C, 
followed by 1 hr at 42 °C, and finally 2 min at 4 °C in a thermal cycler.  For clean-up, 
2 μl of 3’ IVT pico clean-up reagent was added to each sample and mixed thoroughly 
before incubation for 30 min at 37 °C, 10 min at 70 °C, and 2 min at 4 °C. 
 
3.2.6.3 3’ adaptor cDNA synthesis 
3’ adaptor was added to the ss-cDNA which acted as a template for ds-cDNA 






and RNase H to break down the RNA strand and synthesise ss-cDNA with a 3’ 
adaptor. On ice, the 3’ adaptor master mix was made by adding 70 μl of 3’ adaptor 
buffer to 10 μl of 3’ adaptor enzyme in a nuclease-free tube, vortexed and 
centrifuged before adding 8 μl of the 3’ master mix to each of the first strand cDNA 
samples. Afterwards, samples were vortexed and centrifuged before incubation in a 
thermal cycler for 15 minutes at 15 °C, then 15 minutes at 35 °C, 10 minutes at 70 
°C and for 2 minutes at 4 °C. Tubes were centrifuged briefly to collect the samples at 
the bottom of the tube.  
 
3.2.6.4 Double-strand cDNA synthesis 
In this step, ss-cDNA is converted to ds-cDNA which acts as a template for in vitro 
transcription (IVT). This reaction uses Taq DNA polymerase and adaptor-specific 
primers to synthesise and pre-amplify ds-cDNA. The pre-IVT master mix was 
prepared by adding 290 μl of IVT Pico PCR buffer with 10 μl of IVT Pico PCR enzyme 
to the sample in a nuclease-free tube and mixed thoroughly by vortexing, followed 
by centrifugation. Then 30 μl of the mix was added to each 3’ adaptor cDNA samples, 
vortexed and centrifuged before incubating for 2 minutes at 4 °C, for 9 cycles of 30 
seconds at 94 °C and 5 minutes at 70 °C. Samples were centrifuged to collect ds-
cDNA at the bottom of the tube.  
  
3.2.6.5 Preparation of complementary RNA by in vitro transcription 
In vitro transcription (IVT) of the ds-cDNA template using a T7 RNA polymerase was 
performed to synthesise antisense RNA (complementary RNA, cRNA). The IVT 






thoroughly and centrifuged briefly at room temperature. 30 μl of the mix was added 
to each sample of ds-cDNA before incubation in a thermal cycler for 14 hours at 40 
°C and kept at 4 °C. 
 
Purification was performed to remove enzymes, salt, unincorporated nucleotides 
and inorganic phosphates. In a well of a round bottom plate, 80 μl of each cRNA 
sample was mixed with 140 μl of magnetic purification beads and gently pipetted 
up and down 10 times before being incubated for 10-minutes. The plate was moved 
to a magnetic stand to capture the purification beads for 5 minutes. The supernatant 
was carefully removed without disturbing the purification beads. Washing of the 
purification beads was carried out using 200 μl of freshly prepared 80% ethanol and 
repeated three times to enhance purification of cRNA, before air-drying. Next, cRNA 
was eluted by adding 27 μl of pre-heated nuclease free-water (65 °C) and incubated 
for 1 minute before pipetting up and down 10 times. The plate was moved to a 
magnetic stand for approximately 5 minutes and the supernatant, which contains 
the eluted cRNA, was transferred to a nuclease-free tube. The quantity of cRNA was 
assessed on the Nanodrop™ 1000 Spectrophotometer (ThermoFisher Scientific, MA, 
USA). 
 
3.2.6.6 Second cycle single-stranded cDNA synthesis 
Purified cRNA was reverse transcribed to synthesise sense-strand cDNA using 2nd-
cycle primers. On ice, 16 μl of cRNA was added to 4 μl of 2nd cycle primers which 
were mixed before incubating for 5 minutes at 70 °C, followed by 5 minutes at 25 °C 






ss-cDNA buffer and 4 μl of 2nd cycle ss-cDNA enzyme. Both components were mixed 
thoroughly before centrifuging and incubated for 10 minutes at 25 °C for 90 
minutes, followed by 70 °C for 10 minutes and 2 minutes at 4 °C. 
 
3.2.6.7 Hydrolysis of RNA using RNase H 
In this step, RNase H hydrolyses the cRNA template to be removed from the ss-cDNA. 
On ice, 4 μl of RNase H was added to each 2nd-cycle ss-cDNA sample and mixed 
thoroughly by vortexing and briefly centrifuged to collect the reaction at the bottom 
of the tube. The samples were incubated for 25 minutes at 37 °C, followed by 5 
minutes at 95 °C and finally for 2 minutes at 4 °C. Following this, 11 μl of nuclease-
free water was added to each sample for a final reaction volume of 55 μl. 
 
3.2.6.8 Purification of ds-cDNA 
Following hydrolysis, 2nd cycle ss-cDNA is purified to remove salts, enzymes and 
unincorporated dNTPs. In a well of a round bottom plate, 100 μl of purification 
beads were added to bind to ss-cDNA. The plate was moved to a magnetic stand to 
capture the purification beads for 5 minutes. The supernatant was removed 
carefully without disturbing the purification beads. Washing of the purification 
beads was carried out using 200 μl of 80% ethanol and repeated three times to 
enhance purification of ss-cDNA before air-drying. Next, ss-cDNA was eluted by 
adding 27 μl of pre-heated nuclease free-water (65 °C) and incubated for 1 minute 
before pipetting up and down 10 times. The plate was moved to a magnetic stand 
for approximately 5 minutes and the supernatant, which contains the eluted cRNA, 







3.2.6.9  ds-cDNA fragmentation and labelling 
Purified ds-cDNA was fragmented using uracil-DNA glycosylase (UDG) and 
apurinic/apyrimidinic endonuclease 1 (APE1) enzymes. The fragmented cDNA was 
labelled by terminal deoxynucleotidyl transferase (TdT) using DNA labelling 
reagent provided with the kit, which was covalently linked to biotin. In this 
procedure, 5.5 μg of ds-cDNA was added to 0.2ml RNase free tube, and RNase free 
dH2O was added to make a final volume of 46µl. Fragmentation and Labelling 
Master Mix was prepared in a nuclease-free tube by adding 12µl of the 3’ IVT Pico 
Fragmentation and Labelling Buffer with 2µl of the 3’ IVT Pico Fragmentation and 
Labelling Enzyme per reaction and mixed thoroughly before adding the master mix 
to each (46µl) purified ds-cDNA sample and incubated for 1 hour at 37 °C, for 2 
minutes at 93 °C and finally 2 minutes at 4 °C. The Agilent 2100 Bioanalyzer (Agilent, 








Figure 3.2 Assessment of fragmented ds-cDNA 
The Agilent 2100 Bioanalyser was used to assess fragmentation of ds-cDNA. The 
fragmentation band lies with the size of 40 and 70 nucleotides, with a slight peak shift to 










3.2.6.10 Array Hybridisation  
In this procedure, fragmented and labelled ss-cDNA was hybridised to GeneChip® 
Human Genome U133 Plus 2 Arrays (ThermoFisher Scientific, MA, USA) using a 
GeneChip® Hybridisation wash and stain kit. Initially, the hybridisation master mix 
was prepared in a nuclease-free tube by combining pre-heated 20x hybridisation 
controls (BioB, BioC, BioD, Cre heated at 65 °C) with control Oligo B2, DMSO, 2x 
hybridisation mix and nuclease-free water (160 μl).  The contents of the tubes were 
mixed thoroughly by gentle vortexing and centrifuged before adding 60 μl of ds-
cDNA samples. The mix was incubated for 5 minutes at 99 °C, followed by 5 minutes 
at 45 °C, and centrifuged briefly. Samples were injected and hybridised to 
GeneChip® probe array cartridges and incubated in a hybridisation oven for 16 
hours at 45 °C and 60 rpm. Next, the hybridisation cocktail mix was removed, and 
the arrays washed with wash buffer A and left to equilibrate at room temperature 
before staining with Affymetrix GeneChip® Command Console Fluidics Control 
(ThermoFisher Scientific, MA, USA). Scanning of the arrays was performed using a 
GeneChip® Scanner 3000, and the Affymetrix Expression Console generated the 
raw signal intensity values (CEL files). 
 
3.2.7 Analysis of transcriptomic data 
3.2.7.1 Analysis using transcriptome analysis console (TAC) 
Microarray data were analysed using the Transcriptome Analysis Console (TAC) 
software version 4.1.1 (Affymetrix®, UK). TAC was also used to compare the gene 
expression profile of the 3 groups (control, “pre-lesion” and lesion). Genes were 






change ≥ +/-1.2 and p≤0.05. Qlucore Omics Explorer (version 3.0) software 
(Qlucore, Lund, Sweden) was used to visualise the distribution of the samples using 
Principal Component Analysis (PCA). 
 
3.2.7.2 Analysis using DAVID 
Transcriptomic datasets were analysed using the Database for Annotation 
Visualisation and Integrated Discovery (DAVID) version 6.8 (Huang et al., 2009) 
which recognises the main changes in the gene expression associated with specific 
pathways and functional groups. Each functional cluster provided an enrichment 
score, where the higher the enrichment score, the more significant the finding.  
DAVID was employed to filter the annotated genes using the highest stringency 
setting to obtain high specificity and to minimise the rate of false-positive results.  
 
3.2.7.3 Analysis using EnrichR 
To elucidate microglial functions, we focussed on the top 1000 differentially 
expressed genes from each comparison group (lesion versus control, “pre-lesion” 
versus control and “pre-lesion” versus lesion). Genes were analysed using EnrichR, 
which aids clustering of the genes based on their similar functions (Chen et al., 
2013), mainly focussing on the top 10 enrichment score obtained from the top 1000 
based on the following groups; KEGG, Panther and Gene Ontology (GO) biological 
process, which provides a detailed interpretation of functions and pathways for a 







3.2.8 Computational deconvolution analysis of the data 
Computational deconvolution of transcriptomic data was used to interrogate 
microglial functions within the periventricular white matter region (Avila Cobos et 
al., 2018). Specific cell-type markers for activated and inactivated microglia were 
used based on single-cell mass cytometry of the Experimental Allergic 
Encephalomyelitis (EAE) mouse model (Ajami et al., 2018).  Here, a similar 
technique was used to identify (A) inactivated and (B) activated microglia to 
characterise microglial phenotypes in the non-lesional control, “pre-lesion” and 
lesional white matter groups. BST2 (CD317) was selected to assess the inactivated 
microglia, while CD39 (ENTPD1), HLA-DRA, CD86, CD80, TIMD4, ITGAX, TREM2, 
CCR5, MRC1 and CD274 were selected as activated microglial-representative genes 
as shown in Table 3-3.  
 
GeneMania web interface was used to build an interaction network of the co-
expressed genes to construct and generate a network of genes of interest. These data 
were mainly collected from the Gene Expression Omnibus (GEO) (Warde-Farley et 
al., 2010; Barrett et al., 2013).  In GeneMania, a co-expression network category with 
default weighting methods was selected (20 maximum resultant genes and 10 
maximum resultant attributes) to reduce undesirable data and to identify relevant 
pathways and co-localisation of gene networks which were then analysed using a 







Table 3-3 Microglial genes: Group A (inactivated) and Group B (activated) 
 Gene symbol Gene name 
Group A CD317 (BST2) Bone marrow stromal cell antigen 2 
Group B CD39 (ENTPD1) Ectonucleoside Triphosphate Diphosphohydrolase 1 
HLA-DRA Major Histocompatibility Complex, Class II, DR Alpha 
CD86 Cluster of differentiation 86 
CD80 Cluster of differentiation 80 
CD274 Cluster of differentiation 274 
TIMD4 T Cell Immunoglobulin and Mucin Domain Containing 4 
CD11C (ITGAX) Integrin Subunit Alpha X 
TREM2 Triggering Receptor Expressed on Myeloid Cells 2 
CCR5 C-C chemokine receptor type 5 







focused on microglial subtypes associated with human CNS cell-types using an 
independent dataset (http://www.brainrnaseq.org/)  (Zhang et al., 2016). 
 
Candidate genes were interrogated in the raw microarray data to detect the 
expression of each gene in non-lesional control, “pre-lesion” and PVL. However, 
some genes were referenced by multiple probesets, so we aimed to combine 
probesets into a single value to be compared between the three categories. To 
achieve this, the mean of all probesets referenced by a single gene was calculated. 
Next, the standard deviation (SD) of each probeset mean value was calculated, as 
shown in Figure 3.3. However, for genes with two probesets, the lowest variability 
between both probesets, and the probeset with lower value of mean expression was 
selected. Once values generated for each gene in all three categories (Control, “Pre-
lesion” and Lesion), the data were normalised to the non-lesional control category. 
 
Candidate genes were analysed using DAVID to identify the changes in pathways 
and functional groups. Similarly, confirmation for the involvement of candidate 
genes in microglia was performed using EnrichR, mainly focussing on wikipathways 
and Jensen Tissue expression data, which uses four human transcriptomic datasets 








Figure 3.3 Multiple probesets calculation 
Probesets were combined into a single value to be compared between the three categories 
for the genes referenced by multiple probesets. For genes with 2 probesets (A), the variance 
between both probesets was calculated and the lower value of mean expression was 
selected for comparison. However, in the case of 3 or more probesets referenced by a single 
gene (B), the mean for all probesets was calculated (1), followed by the calculation of SD 
(2). Next, the sum of both values was calculated (3). In order to identify the highest value of 
these probesets, the calculated SD was subtracted (2) from the mean calculated in (1). The 










3.3.1 Histological characterisation of control WM, “pre-lesional” & 
PVL 
3.3.1.1 Histological assessment of sampled periventricular WM   
MRI of the formalin-fixed brain hemisphere was used to guide sampling of the 
contralateral frozen periventricular region, and histological characterisation 
performed to confirm the classification of the tissue as non-lesional control or PVL. 
In total, 28 frozen tissue blocks were sampled from 23 cases for histological 
characterisation and were classified into two major groups: non-lesional control 
and PVL. Non-lesional control cases showed an intact ependymal lining (Figure 3.4. 
A) with regular staining of myelin throughout the periventricular region (Figure 3.4. 
B). In contrast, PVL cases were characterised by the presence of pale H&E staining 
(Figure 3.4. D) and a reduction in LFB staining in the periventricular region, 
indicating myelin attenuation (Figure 3.4. E). In addition, variable histopathological 
changes of ependymal lining were noted: 5 PVL cases showed fully intact ependymal 
lining, whereas 4 cases revealed a partially denuded ependyma.  
 
3.3.1.2 Demyelination in the periventricular region of the ageing brain 
In addition to LFB staining, myelin attenuation was also confirmed by 
immunohistochemistry using a specific antibody against myelin proteolipid protein. 
All PLP-immunostained non-lesional control cases showed preserved myelin 
throughout the periventricular region (Figure 3.4. C). In contrast, demyelination, as 








Figure 3.4 Histological characterisation of periventricular white matter 
Luxol fast blue (LFB, A) and H&E staining (B) of radiologically normal-appearing white 
matter demonstrated a regular pattern of myelin staining across the periventricular region. 
In contrast, LFB (D) and H&E staining (E) of radiologically identified lesional cases 
displayed a band of periventricular demyelination. Proteolipid protein of non-lesional 
control samples showed a regular pattern of myelin staining across the periventricular 
region (C) In contrast, PVL samples showed severe demyelination (F). Scale bar represents 







Immunohistochemistry for PLP identified variation in the extent of demyelination 
within PVL ranging from a discrete band of demyelination beneath the ependymal 
layer to a larger extended region of periventricular demyelination (Figure 3.4. F). 
 
3.3.1.3 MHC II 
Activated microglia within the periventricular region were visualised using 
antibodies to MHC-II, which immunolabelled the microglial cell body and proximal 
processes. A range of microglial morphologies was observed in both lesional and 
non-lesional groups (Figure 3.5). These cells are sensitive to changes in the 
surrounding environment and react to disturbances in the homeostatic state by 
changing their phenotype (Nimmerjahn et al., 2005; Chagas et al., 2020). Microglia 
in non-lesional controls mainly displayed a ramified morphology with long 
processes extending from the cell body (Figure 3.5. A). However, the presence of 
microglial cells with an amoeboid morphology was also noted, where their 
processes were retracted, and the cell body enlarged.  16 cases of MRI-rated non-
lesional control WM contained low levels of MHC II immunoreactive microglia 
throughout the PV region; however, 4 cases of MRI-rated non-lesional control WM 
contained high levels of MHC II expression.  While the MRI and histological 
characterisation of this group indicated that there was no demyelination (Figure 3.6. 
C), the immunoreactive profile of MHC II suggested immune activation of microglia 
(Figure 3.5. B). Therefore, the control group was subsequently subdivided into non-
lesional control (MRI rated control; low levels of MHC II immunoreactivity) and 







Figure 3.5 Patterns of MHC-II immunoreactivity detected in the periventricular 
region 
A range of different microglial immune-profiles and morphologies were observed in the 
periventricular white matter samples. MHC II immunostaining of radiologically normal-
appearing white matter identified low levels of ramified MHC-II+ microglia (A). However, 
“pre-lesion” (B) and PVL (C) samples were associated with high levels of MHC-II+ microglia. 











Figure 3.6 Histological characterisation of pre-lesional samples 
Luxol fast blue (LFB, A) and H&E staining (B) of “pre-lesional” samples revealed similarity 
to the radiologically normal-appearing white matter, displaying a regular pattern of myelin 
staining across the periventricular region. Proteolipid protein of “pre-lesional” control 
samples showed a regular pattern of myelin staining across the periventricular region (C). 








contained high levels of MHC II immunoreactive microglia, as shown in Figure 3.5.C.  
 
Histological characterisation of “pre-lesional” samples revealed a similar pattern of 
staining for myelin compared to radiologically normal-appearing white matter, 
displaying preserved myelin throughout the periventricular region (Figure 3.6 A, C) 
with an intact ependymal lining (Figure 3.6 B). 
 
3.3.2 Characterisation and isolation of periventricular white 
matter for gene expression analysis  
3.3.2.1 RNA integrity from frozen post-mortem periventricular samples 
Twenty-three cases were identified from the CFAS cohort to study the 
transcriptomic profile of the periventricular region. These samples were classified 
into lesional (7 cases) and non-lesional control groups (16 cases of which 12 were 
classified as non-lesional controls & 4 were classified as “pre-lesional” controls). 
RNA was extracted from all the samples, before and after LCM to assess the impact 
of the LCM procedure on the quality of the RNA obtained from the periventricular 
region. The RNA quality of the samples pre- and post-LCM is indicated in Table 3-4. 
Pre-LCM, the samples had an average RIN value of 2.764 (range 1.2 - 6.4) in controls, 
3.1 (2.6 – 3.7) in “pre-lesion” and 3.68 (2.4 – 6) in PVL. A representative 
electropherogram of the pre-LCM profile is shown in Figure 3.7. 
After assessing the pre-LCM RIN value, the entire periventricular region was 
isolated from the frozen post-mortem samples using LCM, and the RNA quantity and 







Figure 3.7 RNA integrity of Pre-LCMed RNA profile 
Example of electropherogram profiles obtained from two different frozen post-mortem 
tissue prior to LCM with low (2.3) and (B) high (5.6) RIN values. Both peaks illustrated in 







Table 3-4 Initial concentrations of RNA in frozen post-mortem samples 
Prior to LCM, RNA was extracted from the frozen post-mortem brain samples using TRIzol 
and the RNA quality assessed by Agilent 2100 Bioanalyser. Both the RNA quantity and 
quality were assessed post-LCM.  Cases selected for downstream transcriptomic profiling 
are highlighted in green. 
 




Control Control 1 1.6 N/A 12.564 
Control 2 5.6 N/A 5.723 
Control 3 2.4 N/A 6.465 
Control 4 2.3 2.9 15.923 
Control 5 6.4 N/A 10.063 
Control 6 1.8 2.3 4.504 
Control 7 2.3 2.9 5.688 
Control 8 N/A N/A 6.096 
Control 9 2.1 2.8 1.98 
Control 10 2.4 2.1 1.366 
Control 11 2.3 2 1.835 




(1.2 – 6.4) 
2.471 
(2 – 2.9) 
6.062 
(0.537 – 15.923) 
Lesion Lesion 1 N/A N/A 11.283 
Lesion 2 4.5 2.5 4.019 
Lesion 3 3 N/A 9.273 
Lesion 4 6 2.5 3.139 
Lesion 5 3.1 N/A 4.754 
Lesion 6 2.4 2.3 1.252 




(2.4 – 6) 
2.433 
(2.3 – 2.5) 
5.895 
(1.252 – 11.283) 
Pre-lesion Prelesion 1 3.3 3 3.569 
Prelesion 2 3.7 1.4 15 
Prelesion 3 2.8 N/A 5.157 




(2.6 – 3.7) 
2.2 
(1.4 – 3) 
7.64 







periventricular region (range 0.54 – 15.9 ng/µl). Post-LCM, the RIN decreased in 
almost all cases to an average of 2.47 (2 – 2.9) in controls, 2.2 (1.4 – 3) in “pre-lesion” 
and 2.43 (2.3 – 2.5) in PVL. In 11 cases, no RIN was detectable (Table 3-4). However, 
while the RIN is a good indicator of RNA integrity, the RNA profile should also be 
considered, and in all cases (even those where a RIN was not available) the RNA 
profile indicated that the RNA extracted from the cases was indeed comparable and 
of suitable quality for downstream transcriptomic profiling.  A representative 
electropherogram post-LCM profile is shown in Figure 3.8. 
 
3.3.2.2 RNA preparation for microarray analysis 
The gene expression profile of 7 non-lesional controls, 4 “pre-lesional” cases and 7 
PVL was assessed (Table 3-4). Approximately 50ng of RNA per sample was used, 
and the yield of cRNA was measured with a NanoDrop 1000 after the purification of 
ss-cDNA, as shown in Table 3-5. Next, 16 µl of cRNA was reverse transcribed for the 
synthesis of ss-cDNA, and the yield measured using spectrophotometry, as shown in 
Table 3-6. 
 
3.3.3 Microarray quality control measures 
3.3.3.1 Labelling controls 
Poly-A RNA spikes were used for labelling controls. These Spikes which derived 
from Bacillus Subtilis (Dap, Thr, Phe, Lys) are added to the RNA samples at different 
concentrations in the following order: Lys, Phe, Thr and Dap (1:100,000, 1:50,000, 








Figure 3.8 Post-LCM RNA 
Representation of the electropherogram profile from LCM-ed periventricular white matter. 







Table 3-5 Concentration of cRNA after ss-cDNA synthesis 
Condition Case cRNA concentration (ng/µl) 
Control Control 1 3776 
Control 2 3820 
Control 3 3812 
Control 4 3073 
Control 5 3801 
Control 6 3357 
Control 7 3864 
Lesion Lesion 1 3926 
Lesion 2 3447 
Lesion 3 3875 
Lesion 4 3921 
Lesion 5 3938 
Lesion 6 4007 
Lesion 7 3725 
Pre-lesion Prelesion 1 3934 
Prelesion 2 3776 
Prelesion 3 3874 
Prelesion 4 3733 
 







Table 3-6 Concentration of ss-cDNA obtained after the second amplification 
cycle 
Condition Case ss-cDNA concentration (ng/µl) 
Control Control 1 414 
Control 2 408 
Control 3 370 
Control 4 380 
Control 5 389 
Control 6 392 
Control 7 400 
Lesion Lesion 1 375 
Lesion 2 353 
Lesion 3 387 
Lesion 4 408 
Lesion 5 373 
Lesion 6 390 
Lesion 7 378 
Pre-lesion Prelesion 1 457 
Prelesion 2 392 
Prelesion 3 384 
Prelesion 4 350 
 









patterns in the labelling efficiency for the Poly-A RNA controls. However, almost all 
of the samples showed an increasing pattern across our samples (Figure 3.9). 
 
3.3.3.2 Hybridisation and signal quality 
In this assessment, the eukaryotic hybridisation controls were added into the 
hybridisation mix, which composed of biotin-labelled cRNA transcripts from E.Coli 
(BioB, bioC, bioD) and the P1 bacteriophage (Cre) in a concentration of 1.5 pM, 5 pM, 
25 pM and 100 pM, respectively. Analysed microarray signals for all hybridisation 
revealed an appropriate increasing of signal intensities in all samples from BioB to 
Cre, suggesting a good hybridisation efficiency across all samples, as shown in Figure 
3.10. 
 
3.3.3.3 Signal intensities across the arrays 
Affymetrix Expression Console Software enables the assessment of signal 
intensities generated from arrays which can be plotted as a histogram. In our data, 
the signals from the arrays were comparable across all the samples, with some 
discrepancies between some samples, as shown in Figure 3.11.  
Relative Log Expression (RLE) is a calculation method generated by MicroArray 
Suite (MAS) 5.0 software and is used for the comparison of signal intensity detected 
for each probeset in the arrays against the median signal value across all arrays. 
These data are represented as a plot to assess the spread of data across the samples. 










Figure 3.9 Poly-A RNA spike-in controls 
Signal intensities plot depicting the mean of signal intensities of Poly-A controls 







Figure 3.10 Eukaryotic hybridisation controls for control, pre-lesion and 
periventricular white matter lesion 
This graph illustrated the mean signal intensity of hybridisation controls (BioB, BioC, BioD, 









Figure 3.11 Signal intensities histogram for the periventricular arrays 
Signal histogram illustrating the signal intensities of the probesets in the selected 18 
samples. While 14 signals from the arrays were the same across all the samples, four 











Figure 3.12 Relative log expression (RLE) box plots for the periventricular 
white matter arrays 
Box plot representation of the median gene expression in all 18 arrays. The Y-axis 









3.3.4 Microarray analysis  
3.3.4.1 Transcriptomic analysis and comparison of the gene expression 
Transcriptomic analysis of periventricular white matter was conducted using 
Human Genome U133 Plus 2.0 Arrays, which contain at least one probe for each 
gene and recognize more than 39,000 genes. Genes were considered significantly 
differentially expressed if they had a minimum fold change (FC) of ≥ 1.2 and a p-
value ≤ 0.05. 2,256 genes were differentially expressed in PVL compared to non-
lesional control (1,378 upregulated and 878 down-regulated) (Figure 3.13A); 2,398 
genes significantly differentially expressed in “pre-lesional” control versus non-
lesional control (1,527 upregulated and 871 down-regulated) (Figure 3.13B) and 
2,649 genes were significantly differentially expressed in “pre-lesional” control 
compared to PVL (1,390 upregulated and 1,259 down-regulated) (Figure 3.13C). 
The microarray datasets are freely available at the Gene Expression Omnibus (GEO) 
public database (accession code GSE157363). 
 
Qlucore Omics Explorer (version 3.0) software (Qlucore, Lund, Sweden) was used 
to identify the distribution of the samples and differences in the transcriptome of 
the periventricular cases. The principal component analysis plot confirmed that 
there were no sample outliers, and a distinct separation between the groups was 












Figure 3.13 Volcano plot of differential gene expression 
(A) Volcano plot representing the differentially expressed genes in PVL compared to non-
lesional controls. A total of 2,256 genes were identified with 1,378 genes upregulated (red), 
whilst 878 genes were down-regulated (green). (B) In “pre-lesion” compared to non-
lesional control, a total of 2,398 genes were identified with 1527 upregulated and 871 genes 
down-regulated. (C) In “pre-lesion” compared to PVL, a total of 2,649 genes were 
differentially expressed, with 1390 upregulated and 1259 down-regulated genes. The 
volcano plot was plotted using log2 (fold change) and the negative log10 p-value in the x and 
y-axes respectively. Each gene locus is represented by a dot (•). A fold change of ≤ 1.2 and a 
p-value ≤ 0.05 were set to identify the differentially expressed genes. Upregulated genes are 







Figure 3.14 PCA Plot 
The principal component analysis (PCA) plot of control (blue), “pre-lesion” (yellow) and 
PVL (pink) demonstrating a clear separation of differentially expressed genes between the 








3.3.4.2 Transcriptomic analysis of PVL reveals dysregulation of the 
immune response 
Initially, the full list of probeset IDs of the significantly, differentially expressed 
genes was analysed by TAC software and imported into DAVID to identify altered 
functional groups and pathways. In addition, the list of up-and down-regulated 
genes was imported independently into DAVID for separate analysis. Using the 
highest stringency setting for functional clustering, the transcriptomic profile of the 
PVL was compared to the non-lesional control group (LvC). Functional annotation 
grouping analysis identified dysregulation of genes that were primarily associated 
with MHC class II receptor activity and antigen processing and presentation 
(enrichment score: 3.26), together with collagen IV (enrichment score: 1.52). Kyoto 
encyclopedia of genes and genomes (KEGG) pathway analysis in DAVID identified 
53 significantly dysregulated pathways (see Appendix II for the full list of 
dysregulated pathways), including immune response-associated pathways (Table 
3-7). In PVL, significant upregulation of multiple genes associated with 
phosphatidylinositol 3-kinase PI3K/AKT signalling were detected, including v-akt 
murine thymoma viral oncogene homolog 3 (AKT3) (probeset 219393_S_AT, FC= 
1.33, p= 0.002), and retinoid X receptor alpha (RXRA) (probeset 202449_S_AT, FC= 
1.34, p= 0.0035) and upregulation of genes associated with mitogen-activated 
protein kinase (MAPK) signalling, including mitogen-activated protein kinase 10 
(MAPK10) (probeset 214376_AT, FC= 1.38, p= 0.0278) as shown in Table 3-8. In 
addition, significant upregulation of heat shock proteins was identified, including 







Table 3-7 KEGG pathway analysis and functional annotations of ageing 
periventricular white matter transcriptomic datasets (lesion vs. control) 
Dysregulation of genes associated with immune response-associated pathways were 








MHC-II 8 1.06E-04 0.1518 
Antigen processing and presentation 8 1.56E-04 0.2904 
Collagen IV 4 0.0065 11.3855 
Pathway Name Pathway 
Source 




KEGG 20 9.17E-06 0.0121 
hsa04145: Phagosome KEGG 24 0.0028 3.6410 
hsa04672: Intestinal 
immune network for IgA 
production 
KEGG 11 0.0045 5.7265 
hsa04662: B cell receptor 
signaling pathway 
KEGG 12 0.0256 29.0463 
DEG: Differentially expressed genes; FDR: False discovery rate; KEGG: Kyoto Encyclopedia 










Table 3-8 DAVID functional and pathway enrichment analysis of up-regulated 
genes (lesion vs control) 
Compared 
Group 






Metabolic processes (NADP 
Oxidoreductase) 
4 0.0035 5.4026 
Aldo keto reductase 4 0.0117 11.7111 
Pathway Name Pathway 
Source 
DEG P-Value FDR Value 
AMPK Signalling pathway KEGG 16 6.40E-04 8.30E-01 
MAPK signalling pathway KEGG 22 8.20E-03 1.00E+01 
Neurotrophin signalling 
pathway 
KEGG 13 1.10E-02 1.30E+01 
HIF-1 Signalling pathway KEGG 11 1.50E-02 1.80E+01 
cAMP signalling pathway KEGG 15 8.50E-02 6.80E+01 
PI3K-Akt signaling pathway KEGG 26 0.020976 24.0868 
DEG: Differentially expressed genes; FDR: False discovery rate; KEGG: Kyoto Encyclopedia 







211968_s_at, FC= 2.02, p= 0.0075) and heat shock protein family A (Hsp70) member 
1 like (HSPA1L) (probeset 210189_at, FC= 1.48, p= 0.0015). 
 
In contrast, significant down-regulation of the genes associated with antigen 
processing and presentation were detected in PVL versus non-lesional control white 
matter (Table 3-9), including HLA-DRA (probeset 210982_s_at, FC= -1.71, p= 
0.0038) and CD74 HLA class II histocompatibility antigen gamma chain (CD74) 
(probeset 1567627_at, FC= -2.67, p= 0.0068). Significant down-regulation of genes 
associated with the phagosome were also detected, including Fc fragment of 
immunoglobulin gamma Fc receptor 1A (FCGR1A) (probeset 216951_at, FC= -2.12, 
p= 0.0164) (Table 3-9). See Appendix III for the full list of up-and down-regulated 
genes.  
 
Functional grouping analysis of the significantly differentially expressed genes in 
“pre-lesional” compared to non-lesional control white matter (PvC), identified 
dysregulation of glutamate receptor activity (enrichment score: 2.73), MHC II 
(enrichment score: 2.61), and GABA (enrichment score: 2.60). KEGG pathway 
analysis identified 79 dysregulated pathways (see Appendix II for the full list of 
dysregulated pathways), including immune-associated pathways and signalling 
pathways (including calcium, cAMP and MAPK) and synaptic pathways (including 
GABAergic, glutamatergic, dopaminergic and cholinergic synapses) (Table 3-10). 
 
In “pre-lesional” versus non-lesional control white matter samples, analysis of the 






Table 3-9 DAVID functional and pathway enrichment analysis of down-
regulated genes (lesion vs. control) 
Significant down-regulation of genes associated with the antigen presentation and 
phagosome were identified in PVL compared to control using DAVID analysis. 
Compared 
group 





MHC-II receptor activity 9 2.86E-09 4.36E-06 
Antigen processing and presentation 8 2.64E-07 4.65E-04 
Cyclooxygenase pathway 4 0.0025 4.4053 
Collagen type IV 4 4.14E-04 0.5825 
Toll/interleukin-1 receptor (TIR) 5 0.0056 8.5508 
Pathway Name Pathway 
Source 
DEG P-Value FDR Value 
Staphylococcus aureus 
infection 
KEGG 14 3.40E-08 4.40E-05 
Antigen processing and 
presentation 
KEGG 14 2.30E-06 3.00E-03 
Phagosome KEGG 19 5.70E-06 7.40E-03 
Focal Adhesion KEGG 16 6.80E-03 8.50E+00 








Table 3-10 KEGG pathway analysis and functional annotations of ageing 
periventricular white matter transcriptomic datasets (pre-lesion vs. control) 
Compared 
group 




GABA-A receptor activity 8 3.78E-04 0.6161 
Glutamate receptor, L-
glutamate/glycine-binding 
7 0.0016 2.7003 
MHC classes I/II-like antigen 
recognition protein 
11 0.0017 2.8750 
Pathway Name Pathway 
Source 
DEG P-Value FDR Value 
hsa04020: Calcium 
signaling pathway 
KEGG 42 3.38E-09 4.44E-06 
hsa04728: Dopaminergic 
synapse 
KEGG 34 5.29E-09 6.96E-06 
hsa04724: Glutamatergic 
synapse 
KEGG 30 6.28E-08 8.26E-05 
hsa04725: Cholinergic 
synapse 
KEGG 29 1.29E-07 1.70E-04 
hsa04727: GABAergic 
synapse 




KEGG 20 1.58E-05 0.021 
hsa04024: cAMP 
signaling pathway 
KEGG 34 1.54E-04 0.203 
hsa04010: MAPK 
signaling pathway 
KEGG 40 2.23E-04 0.292 
hsa04145: Phagosome KEGG 25 0.002 2.750 
hsa04660: T cell receptor 
signaling pathway 
KEGG 17 0.011 13.578 
DEG: Differentially expressed genes; FDR: False discovery rate; KEGG: Kyoto Encyclopedia 







synaptic signalling, including gamma-aminobutyric acid (GABA) A receptor, alpha 5 
(GABRA5) (probeset 206456_at, FC= 7.1, p= 0.0002; probeset 215531_S_AT, FC= 
3.89, p= 0.001; probeset 217280_X_AT, FC= 1.6, p= 0.0095) and gamma-
aminobutyric acid (GABA) A receptor alpha 4 (GABRA4) (probeset 233437_AT, FC= 
1.91, p= 0.0027) and upregulation of calcium signalling, including calcium voltage-
gated channel subunit alpha 1E (CACNA1E) (probeset 236013_at, FC= 4.46, p= 
0.001; probeset 244256_at, FC= 4.11, p= 0.001; probeset 240650_at, FC= 1.31, p= 
0.016; probeset 208432_s_at, FC= 1.62, p= 0.012). Also, an upregulation of genes 
associated with heat shock proteins was identified, including heat shock protein 90 
alpha family class A member 1 (HSP90AA1) (probeset 214328_s_at, FC= 1.34, p= 
0.0028) and heat shock protein family A (Hsp70) member 8 (HSPA8) (probeset 
208687_x_at, FC= 1.28, p= 0.0424). Interrogation of the datasets also identified 
significant upregulation of glutamatergic synaptic signalling, including glutamate 
receptor, metabotropic 5 (GRM5) (probeset 1565389_S_AT, FC= 5.37, p= 0.0017; 
probeset 214217_AT, FC= 1.78, p= 0.0004) as shown in Table 3-11. Multiple genes 
associated with phagosome and antigen processing and presentation were 
significantly down-regulated (Table 3-12), including major histocompatibility 
complex, class II, DP alpha 1 (HLA-DPA1) (probeset 213537_at, FC= -2.72, p= 0.0004; 
probeset 211991_S_AT, FC= -1.93, p= 0.0228; probeset 211990_AT, FC= -3.77, p= 
0.0324) and HLA-DQB1 (probeset 211654_x_at, FC= -1.76, p= 0.0046). See Appendix 








Table 3-11 DAVID functional and pathway enrichment analysis of up-regulated 
genes (pre-lesion vs. control) 
Multiple signalling pathways were upregulated in “pre-lesion” compared to control 











GABA receptor activity 8 7.55E-06 0.0108 
Glutamate receptor activity 7 8.88E-05 0.1443 
Neurotransmitter-gated ion channels 9 8.57E-04 1.3848 
Pathway Name Pathway 
Source 




KEGG 32 4.50E-18 1.00E-15 
Calcium signalling pathway KEGG 36 1.50E-13 1.10E-11 
Glutamatergic synapse KEGG 28 8.70E-13 4.80E-11 
Dopaminergic synapse KEGG 29 2.60E-12 1.20E-10 
GABAergic synapse KEGG 23 1.84E-11 2.35E-08 
cAMP signalling pathway KEGG 28 3.30E-07 5.60E-06 
MAPK signalling pathway KEGG 31 1.60E-06 2.30E-05 
Alzheimer's Disease KEGG 14 4.70E-02 1.70E-01 









Table 3-12 DAVID functional and pathway enrichment analysis of down-
regulated genes (“pre-lesion” vs. control) 
Down-regulation of antigen processing and presentation and phagosome were identified in 
“pre-lesional” cases compared to controls. 
Compared 
group 




MHC-II receptor activity 11 1.14E-06 0.0018 
Metallothionein 5 7.85E-04 1.2488 
Pathway Name Pathway 
Source 
DEG P-Value FDR Value 
Staphylococcus aureus 
infection 
KEGG 18 1.40E-11 1.80E-08 
Phagosome KEGG 22 4.60E-07 6.00E-04 
Antigen processing and 
presentation 
KEGG 15 1.50E-06 1.90E-03 
DEG: Differentially expressed genes; FDR: False discovery rate; KEGG: Kyoto Encyclopedia of Genes 






The significant differentially expressed genes in “pre-lesional” compared to PVL 
cases (PvL) were analysed, where functional annotation analysis identified an 
enrichment of genes associated with GABA receptor activity (enrichment score: 
2.71), neurotransmitter gated ion channels (enrichment score: 1.8), adenylate 
cyclase activity (enrichment score: 2.4), and metallothionein (enrichment score: 
2.36). KEGG pathway analysis in DAVID identified 38 significantly dysregulated 
pathways (see Appendix II for the full list of dysregulated pathways), including 
signalling pathways (including, cAMP, cGMP, MAPK and calcium) and synaptic 
pathways (glutamatergic, GABAergic and dopaminergic synapses) (Table 3-13). 
Multiple genes encoding the calcium signalling pathway were significantly 
upregulated in the pre-lesional periventricular white matter (Table 3-14), including 
calcium/calmodulin-dependent protein kinase II alpha (CAMK2A) (probeset 
213108_at, FC= 1.67, p= 0.043; probeset 207613_s_at, FC= 7.06, p= 0.008) and 
upregulation of multiple genes associated with glutamatergic signalling pathways, 
including glutamate receptor, ionotropic, N-methyl D-aspartate 1 (GRIN1) (probeset 
205915_X_AT, FC= 1.45, p= 0.011; probeset 211125_X_AT, FC= 1.65, p= 0.0409; 
probeset 210781_X_AT, FC= 1.82, p= 0.0182), glutamate receptor, ionotropic, AMPA 
2 (GRIA2) (probeset 241172_at, FC= 1.55, p= 0.015). In contrast, down-regulation of 
genes associated with WNT signalling pathways were identified in the pre-lesional 
white matter (Table 3-15), including casein kinase 1, alpha 1 (CSNK1A1) (probeset 
1556006_S_AT, FC= -1.64, p= 0.023; probeset 208867_S_AT, FC= -1.24, p= 0.045; 
probeset 208866_AT, FC= -1.21, p= 0.0218). See Appendix III for the full list of up-







Table 3-13 KEGG pathway analysis and functional annotations of ageing 
periventricular white matter transcriptomic datasets (“pre-lesion” vs. lesion) 
Compared 
group 




GABA-A receptor activity 8 6.99E-04 1.148 
Adenylate cyclase activity 7 0.004 6.637 
Metallothionein domain 6 0.004 7.460 
Neurotransmitter-gated ion-channel 10 0.017 26.53 
Pathway Name Pathway 
Source 
DEG P-Value FDR Value 
hsa04020: Calcium 
signaling pathway 




KEGG 27 3.86E-07 5.09E-04 
hsa04724: 
Glutamatergic synapse 
KEGG 29 3.97E-07 5.24E-04 
hsa04921: Oxytocin 
signaling pathway 
KEGG 34 5.84E-07 7.71E-04 
hsa04727: GABAergic 
synapse 
KEGG 21 3.58E-05 0.0472 
hsa04024: cAMP 
signaling pathway 
KEGG 33 5.36E-04 0.705 
hsa04022: cGMP-PKG 
signaling pathway 
KEGG 28 5.96E-04 0.783 
hsa04010: MAPK 
signaling pathway 
KEGG 34 0.01433 17.353 
hsa04728: 
Dopaminergic synapse 
KEGG 22 0.0038 4.997 









Table 3-14 DAVID functional and pathway enrichment analysis of up-regulated 
genes (“pre-lesion” vs. lesion) 
Multiple signalling pathways were upregulated in pre-lesion compared to PVL samples, 
including calcium and glutamatergic synaptic signalling. 
Compared 
group 






GABA receptor activity 8 3.20E-06 4.50E-03 
Neurotransmitter-gated ion channel 10 5.70E-05 9.30E-02 
Glutamate activity 6 4.90E-04 7.80E-01 
Pathway Name Pathway 
Source 
DEG P-Value FDR Value 
Retrograde endocannabinoid 
signalling 
KEGG 25 1.60E-12 2.05E-09 
Calcium Signalling Pathway KEGG 32 6.70E-12 8.58E-09 
Glutamatergic synapse KEGG 25 2.59E-11 3.31E-08 
cAMP signalling pathway KEGG 26 5.49E-07 7.02E-04 
Alzheimer's Disease KEGG 14 0.0223 25.1583 












Table 3-15 DAVID functional and pathway enrichment analysis of down-
regulated genes (pre-lesion vs. lesion) 
Compared 
group 






Metallothionein 6 2.81E-04 0.4642 
Cadmium ion 5 4.09E-04 0.5780 
Mitochondrial carrier 7 0.0332 42.9437 
Transforming growth factor beta 3 0.0204 27.8330 
Pathway Name Pathway 
Source 
DEG P-Value FDR Value 
WNT signalling pathway KEGG 15 0.005 6.3480 
Focal Adhesion KEGG 17 0.031 34.2352 
Metabolic pathways KEGG 71 0.034 36.1588 








3.3.5 EnrichR analysis result: 
The top 1000 differentially expressed genes were imported into EnrichR to identify 
their relationship with KEGG pathways, biological processes, Panther pathways and 
the human gene atlas. Out of these 1000, the top 10 significant involved pathways 
and cell types such as antigen processing and presentation (KEGG pathway, p = 
6.77E-06), inflammation (Panther, p = 1.20E-04), MHC II (Cellular Component p = 
1.24E-04) and CD14 monocytes (Gene Atlas, p= 0. 4.22E-04. The top 10 pathway and 
functional groups identified by EnrichR are shown in Table 3-16. 
 
3.3.6 Activated vs inactivated microglia 
BST2 was appointed to identify the co-expressed genes associated with inactivated 
microglia (group A), while for activated microglia (group B), multiple genes were 
selected (TREM2, HLA-DRA, ENTPD1, CD80, CD86, CCR5, CD274, ITGAX, TIMD4, and 
MRC1). In both groups, 17 genes were co-expressed with the genes selected (Table 
3-17). These genes showed a different pattern between the three groups: PVL, “pre-
lesion” and non-lesional control in the microarray datasets (Figure 3.15). Analysis 
of the co-expressed genes revealed similarity of activated and inactivated microglia 
levels within PVL compared to the control group, with the exception of CD80, which 
showed a reduced expression. Similarly, “pre-lesional” cases showed inconsistency 
in the directional change of the expression of a number of genes associated with 
activated and inactivated microglia. Co- expressed genes associated with activated 
microglia (group B) were imported into DAVID to identify their enrichment score, 







Table 3-16 Top 10 pathway and functional groups identified by EnrichR  
The PVL versus control non-lesional white matter transcriptomic dataset was imported into 
EnrichR to check the relationship with KEGG pathways, biological processes, Panther 
pathways and the human gene atlas.  The top 10 pathways/functional groups identified by 
the analysis are shown below. Selected functions and pathways are highlighted in green. 
Category Term P-value Adjusted P-value 
KEGG 
Pathway 
Antigen processing and presentation 6.77E−06 0.0020 
Epstein-Barr virus 1.06E−04 0.0156 
Prostate cancer 1.49E−04 0.0145 
Leishmaniasis 4.58E−04 0.0336 
Herpes simplex infection 8.04E−04 0.0471 
Graft-versus-host disease 8.61E−04 0.0421 
Type I diabetes mellitus 0.0012 0.0483 
Estrogen signaling pathway 0.0015 0.0532 
Allograft rejection 0.0030 0.0989 
Influenza A 0.0031 0.0920 
Panther 
Pathway 
Inflammation mediated by chemokine and 
cytokine signaling pathway 
1.20E−04 0.0134 
T cell activation 0.0068 0.3801 
N-acetylglucosamine metabolism 0.0199 0.7440 
Serine glycine biosynthesis 0.0199 0.5580 
B cell activation 0.0217 0.4853 
Axon guidance mediated by semaphorins 0.0257 0.4789 
Parkinson disease 0.0359 0.5748 
Toll receptor signaling pathway 0.0391 0.5476 
Apoptosis signaling pathway 0.0426 0.5297 






Whole Blood 2.00E-04 0.0168 
CD14+_Monocytes 4.22E-04 0.0177 
Retina 0.0019 0.0545 
CD33+_Myeloid 0.0050 0.1052 
CD4+_Tcells 0.0087 0.1465 
Smooth Muscle 0.0134 0.1878 
Cerebellum Peduncles 0.0166 0.1995 
Adipocyte 0.0227 0.2385 
Uterus 0.0234 0.2188 






MHC class II protein complex 1.24E-04 0.1008 
nuclear speck 3.02E-04 0.1231 
membrane raft  4.73E-04 0.1286 
ER to Golgi transport vesicle membrane 5.67E-04 0.1157 
clathrin-coated phagocytic vesicle membrane 9.54E-04 0.1557 
LYSP100-associated nuclear domain 0.0022 0.2961 
nuclear dicing body  0.0022 0.2538 
sphere organelle 0.0022 0.2221 
nuclear body  0.0022 0.1974 






Table 3-17 Microglial deconvolution 
In inactive microglia (group A), BST2 (CD317) was used to identify the co-expressed genes, 
while for activated microglia (group B) CD39 (ENTPD1), HLA-DRA, CD86, CD80, TIMD4, 
ITGAX, TREM2, CCR5, MRC1 and CD274 were selected to build co-expression network of 
genes associated with the selected candidate microglial markers using GeneMania. 
 


























Figure 3.15 Graphical representation of gene annotations in both, activated and 
inactivated microglia in ageing periventricular white matter 
This figure illustrates the annotations of microglial genes in inactivated (group A) microglia 
and activated microglia (group B) in non-lesional controls, “pre-lesion” and periventricular 
lesional samples. BST2 gene was used to identify the co-expressed genes associated with 
inactivated microglia (A1, A2 and A3). While for the activated group, TREM2, HLA-DRA, 
ENTPD1, CD80, CD86, CCR5, CD274, ITGAX, TIMD4 and MRC1 (group B) were selected (B1, 








Immunoglobulin domain had the highest enrichment of 9.14 (14 genes, p-value: 
6.27E-12 and FDR: 6.23E-09), followed by: the involvement of transmembrane 
functions with an enrichment of 8.6 (23 genes, p-value: 3.27E-10, FDR: 3.68E-07); 
immune response with an enrichment of 5.8 (10 genes, p-value: 2.15E-09, FDR: 
2.71E-06); MHC-II (5 genes, p-value: 4.71E-09, FDR: 5.01E-06) and antigen 
processing and presentation (5 genes, p-value: 6.29E-09, FDR: 7.93E-06) which had 
an enrichment score of 5.8.  In contrast, KEGG pathway revealed the involvement of 
8 genes associated with the phagosome (p-value: 3.30E-08, FDR: 3.00E-05), and 5 
genes associated with antigen processing and presentation (p-value: 2.94E-05, FDR: 
0.02670242) (Table 3-18). CD86, ITGAX and TREM2 genes were highly enriched in 
microglia in Jensen Tissues Database (Table 3-19).  
 
Similarly, the inactivated microglia group showed that innate immunity, together 
with the type 1 interferon signalling pathway had the highest enrichment score of 
14.4, followed by interferon-gamma mediated signalling pathways with an 
enrichment score of 2.9. KEGG pathway analysis identified the involvement of these 
genes in infectious diseases such as Influenza A, Herpes Simplex Infection and 
Measles (Table 3-20). EnrichR showed a significant expression of multiple genes 








Table 3-18 DAVID analysis of activated microglial genes 
KEGG pathway analysis of activated microglial genes reveals an involvement of multiple 
genes associated with the phagosome and antigen processing and presentation. 
 
Functional group DEG P-value FDR value 
Immunoglobulin-like domain 14 6.27E-12 6.23E-09 
Transmembrane region 23 3.27E-10 3.68E-07 
Immune response 10 2.15E-09 2.71E-06 
MHC-II 5 4.71E-09 5.01E-06 
Antigen processing and presentation 5 6.29E-09 7.93E-06 
Pathway Name Pathway 
Source 
DEG P-Value FDR Value 
hsa05330: Allograft rejection KEGG 7 1.88E-10 1.71E-07 
hsa04940: Type I diabetes mellitus KEGG 7 4.21E-10 3.83E-07 
hsa04145: Phagosome KEGG 8 3.30E-08 3.00E-05 
hsa04612: Antigen processing and 
presentation 
KEGG 5 2.94E-05 0.02670 
DEG: Differentially expressed genes; FDR: False discovery rate; KEGG: Kyoto Encyclopedia 








Table 3-19 EnrichR - Activated microglia 
EnrichR showed a significant gene expression of multiple genes associated with monocytes 
and microglia (highlighted in green). 
 




Allograft Rejection WP2328 6/89 3.57E-09 1.68E-06 
Ebola Virus Pathway on Host 
WP4217 
6/129 3.35E-08 7.90E-06 
PI3K/AKT/mTOR - VitD3 
Signalling WP4141 
3/22 4.60E-06 7.24E-04 
Microglia Pathogen 
Phagocytosis Pathway WP3937 
3/40 2.90E-05 0.0034 
Macrophage markers WP4146 2/9 7.78E-05 0.0073 
TYROBP Causal Network 
WP3945 
3/61 1.03E-04 0.0081 
Jensen Tissue - 
Human 
Immune system 12/1046 1.42E-08 2.61E-05 
Microglia 3/9 2.54E-07 2.34E-04 
Peritoneal macrophage 2/8 6.06E-05 0.0372 
Alveolar macrophage 2/10 9.71E-05 0.0447 








Table 3-20 DAVID analysis of inactivated microglial genes 
Functional group DEG p-value FDR value 
Type I interferon signaling pathway 13 1.91E-26 2.10E-23 
Interferon-gamma-mediated signaling pathway 5 6.70E-07 7.33E-04 
Innate immunity 10 1.64E-13 1.67E-10 
Pathway Name Pathway 
Source 
DEG P-Value FDR Value 
hsa05164: Influenza A KEGG 7 1.90E-08 1.26E-05 
hsa05160: Hepatitis C KEGG 6 2.97E-07 1.96E-04 
hsa05162: Measles KEGG 6 2.97E-07 1.96E-04 
hsa05168: Herpes simplex infection KEGG 6 1.46E-06 9.65E-04 










Table 3-21 EnrichR - inactivated microglia 
EnrichR analysis showed a significant expression of genes associated with monocytes in 
Jensen Tissue (highlighted in green). 
 




The human immune response to 
tuberculosis WP4197 
 6/23 2.09E-14 9.87E-12 
Non-genomic actions of 1,25 
dihydroxyvitamin D3 WP4341 
  4/71 4.30E-07 1.01E-04 
Type II interferon signaling (IFNG) 
WP619 
 3/37 4.67E-06 7.34E-04 
RIG-I-like Receptor Signaling 
WP3865 
2/60 0.0013 0.154 
Jensen Tissue - 
Human 
B-lymphoblastoid cell 15/5983 2.59E-04 0.12 
Immune system 6/1046 2.17E-04 0.133 













WMLs are a feature of ageing and are associated with multiple neurological diseases 
such as vascular dementia and Alzheimer’s disease, giving rise to clinical 
manifestations including cognitive impairment (Prins et al., 2005) and depression 
(O’Brien et al., 1996). In addition, WMLs are an independent risk factor for the 
development of dementia (Fernando & Ince, 2004; Matthews et al., 2009; Kim et al., 
2015b).  
 
WMLs are classified into PVL and DSCL based on their neuroanatomical locations.  
To date, the majority of research has focussed on DSCL, with fewer studies 
conducted on PVL. Histological characterisation of DSCL has demonstrated that they 
are associated with axonal loss, demyelination, and gliosis (Gouw et al., 2011). In 
addition, it has been demonstrated through histological characterisation and 
transcriptomic profiling that hypoxia and hypoperfusion within the deep 
subcortical region are a prominent feature of DSCL, likely contributing to their 
pathogenesis (Fernando et al., 2006; Schmidt et al., 2011). 
 
PVL are present in approximately 95% of the ageing population (de Leeuw, 2001), 
and are associated with cognitive impairment (Kim et al., 2011; Bolandzadeh et al., 
2012; Griffanti et al., 2018), BBB dysfunction (Freeze et al., 2020) and significant 
levels of immune activated MHC-II+ microglia (Simpson et al., 2007b, 2010), 
suggesting a failure in the cerebrovascular integrity results in microglial activation 
and underlies their pathogenesis. The current study aimed to extend these findings 






mechanisms underlying the pathogenesis of PVL. We demonstrate that established, 
demyelinated PVL is associated with dysregulation of the immune response and are 
part of a spectrum of white matter injury, whilst increased signalling is a feature of 
“pre-lesional” periventricular white matter and may represent attempts to prevent 
lesion formation. 
 
3.4.1 Histological characterisation of radiologically control post-
mortem periventricular white matter reveals “pre-lesional” 
pathology 
In the current study, MRI of the formalin-fixed hemisphere was used to guide 
sampling of frozen brain slices from the contralateral hemisphere. This approach is 
routinely used to identify white matter lesions, where MRI hyperintensities 
histologically correlate with myelin loss (Fazekas et al., 1991; Fernando & Ince, 
2004).  While myelin changes are part of the normal ageing process (Marner et al., 
2003), extensive periventricular demyelination is associated with an increased risk 
of dementia (Barber et al., 1999; Prins et al., 2004). In the current study, 
radiologically non-lesional control samples were histologically characterised by 
preservation of myelin staining. In contrast, demyelination was a prominent feature 
of PVL, which was found to vary from sharply demarcated areas of reduced myelin 
staining to larger extended areas of demyelination in the periventricular region.  
This supports the findings of other studies which identified severe loss of myelin 







The microglial phenotype can be investigated using a variety of markers, including 
CD68, Iba-1, and MHC-II.  CD68 is a lysosomal marker for microglia which was has 
been shown to label amoeboid phagocytic microglia within DSCL, while MHC-II is 
highly associated with ramified microglia in PVL (Simpson et al., 2007a, 2007b). Iba-
1 is a cytoplasmic protein that generally considered a pan-microglial marker that 
immunolabels all of microglia in both DSCL and PVL (Korzhevskii & Kirik, 2016). 
However, a recent study revealed that not all microglial cells are Iba-1+ (Waller et 
al., 2019).  In the current study, MHC II+ microglia were detected in both lesional and 
non-lesional periventricular white matter. Based on MHC II staining, variable 
microglial morphologies were observed in the periventricular white matter. Some 
cells displayed a ramified morphology with long processes extending from the cell 
body, while others showed retracted thick processes and an enlarged cell body.  
 
High levels of MHC II expression in PVL support previous observations (Simpson et 
al., 2007b) and suggest an immune response, as microglia are known to be involved 
in antigen presentation in the CNS (Almolda et al., 2011).  While low levels of MHC 
II+ microglia are a feature of most non-lesional control white matter cases, a 
subgroup of radiologically normal periventricular white matter samples was 
identified, which were characterised by preserved myelin, but which contained high 
levels of MHC-II+ microglia and were re-classified as “pre-lesional”.  Previous studies 
have identified an increase in levels of activated microglia in radiologically normal-
appearing white matter from lesional cases, suggesting immune activation may 
precede demyelination (Simpson et al., 2007b). However, it should be 






develop PVL is unknown, and further extensive characterisation of these cases is 
required. 
 
Homeostatic imbalance and pathological insult within the CNS are one of the major 
causes of microglial activation, which is reflected by changes in microglial 
morphology and function (Sastre et al., 2011; Perry & Holmes, 2014). The high levels 
of immune activated microglia in the periventricular region of the ageing brain could 
be due to a variety of factors, including microglial priming, BBB dysfunction and/or 
back diffusion of CSF. 
 
Innate immune activation occurs during brain ageing and is associated with 
cognitive decline (Cribbs et al., 2012). Microglia become primed during 
neurodegeneration, neuroinflammation and also as part of the normal ageing 
process (Li et al., 2018). Primed microglia have a reduced threshold for activation 
and when stimulated produce an augmented exaggerated inflammatory response 
(DiBona et al., 2019), which may contribute to both cognitive impairment and 
neurodegeneration. Primed microglia express high levels of MHC-II, in addition to 
an increased inflammatory response (Frank et al., 2006; Perry & Holmes, 2014). It 
is likely that primed microglia shift to an M1 neurotoxic phenotype (Hu et al., 2012) 
which results in the increased production of pro-inflammatory cytokines, proteases 
and reactive oxygen species (Cunningham et al., 2009). Our findings revealed an 
increased expression of MHC-II+ microglia in both PVL and “pre-lesional” 
periventricular white matter, which may reflect age-associated microglial priming 






The production of pro-inflammatory mediators such as NO and TNF- by M1 
activated microglia in the ageing brain has been proposed to have a neurotoxic effect 
which impacts myelin attenuation (Merrill et al., 1993; Tarkowski et al., 2003; Jana 
& Pahan, 2013). In addition, degeneration of oligodendrocytes, the myelin-
producing cells, may occur as part of normal ageing, resulting in myelin loss 
(Kohama et al., 2012; Peters, 2002). 
 
Disruption of the BBB may result in the accumulation of plasma proteins which are 
normally excluded from the CNS, resulting in the activation of microglia. Several 
studies provide evidence to support this theory, demonstrating BBB dysfunction is 
a feature of PVL in the ageing brain (Simpson et al., 2007b; Lu et al., 2001). 
Breakdown of the ependymal lining may lead to loss of integrity and the abnormal 
back-diffusion of CSF into the periventricular area (Scheltens et al., 1995; Simpson 
et al., 2007a). A significant correlation between ependymal loss and increased 
volume of WML has been reported (Shim et al., 2015) and supports the findings of 
the current project which demonstrated denudation of ependymal lining as a 
feature of PVL. The microgliosis observed in the periventricular white matter region 
may represent a neuroprotective or detrimental effect. 
 
The role of microglia and their contribution to neurodegeneration has been 
undervalued, but recent research has focussed on these glial cells, which play a 
significant role within the CNS, including homeostasis and surveillance mechanisms 
(Koellhoffer et al., 2017).  Therefore, in the current project, we assessed the 






non-lesional periventricular white matter, with the aim of identifying microglial-
mediated mechanisms underlying lesion pathogenesis. 
 
3.4.2 Transcriptomic profiling of post-mortem tissue 
Having histologically identified PVL, “pre-lesional” and non-lesional control 
periventricular white matter cases, LCM has been employed to isolate the 
periventricular region, using a similar approach used by Blalock, which selectively 
LCM-ed CA1 hippocampal grey matter from post-mortem tissue (Blalock et al., 
2011).   
 
Gene expression changes in each of the three groups were interrogated to identify 
potential pathways and mechanisms underlying lesion pathogenesis. The RIN value 
of each case was assessed pre-and post-LCM, identifying a decrease in the RIN 
associated with the LCM protocol.  Genomic studies can be hindered by difficulties 
in obtaining high-quality RNA from post-mortem tissue due to multiple factors such 
as tissue pH, post-mortem delay, and the agonal state of the patient prior to death 
(Tomita et al., 2004; Chevyreva et al., 2008). However, the functional data obtained 
in these post-mortem human tissue studies may be more relevant than cell or animal 
disease models, which do not entirely recapitulate all aspects of the disease process. 
While the RNA extracted from the PVL was undoubtedly of low quality, it remains of 
comparable quality to our previously published array studies (Simpson et al., 2009, 
2011) and enabled changes in the gene expression profile to be detected and 






increasing our understanding of potential mechanisms associated with lesion 
evolution. 
 
3.4.3 Microarray data analysis 
Transcriptomic profiling of PVL and “pre-lesional” white matter identified 
dysregulation of functions and pathways associated with immune response, while 
“pre-lesions” were also associated with significantly increased expression of genes 
related to signalling and synaptic pathways. 
 
3.4.3.1 “Pre-lesional” periventricular white matter and PVL are 
associated with dysregulation of the immune response 
Functional annotation grouping analysis of the “pre-lesional” and PVL datasets 
identified dysregulation of genes associated with immune-response, including MHC-
II receptor activity and antigen processing and presentation. PVL and “pre-lesion” 
compared to non-lesional control were mainly associated with significant down-
regulation of HLA-DOB, HLA-DRA and CD74. This conflicts with our 
immunohistochemical finding, which showed increased detection of MHC-II in our 
cohort, and also conflicts with other studies investigating the immune response in 
ageing populations which show that with increasing age, the expression of HLA-
DR/MHC-II+ microglia increase in the white matter (Sheffield & Berman, 1998).  
Also, a microarray study conducted on post mortem tissue showed an upregulation 
of genes associated with MHC-II in DSCL (Simpson et al., 2009). Differentially 
expressed transcripts have significantly higher correlations between mRNA and 






mRNA expression changes do not always correlate with protein levels for the 
specific gene and may give conflicting results as shown with MHC-II in this project. 
This may reflect the decoupling in time of both mRNA and protein expression 
(Fournier et al., 2010; Koussounadis et al., 2015). 
 
In the current study, the histological evaluation was done using a single marker 
(MHC-II). Using a single microglial marker does not take into account the wide range 
of markers which are expressed by the diverse population of microglia, which 
require an extensive panel of markers to capture the full spectrum of microglial 
phenotypes in the white matter.  
 
3.4.3.2 Periventricular white matter contains similar levels of both 
activated and inactivated microglia 
To elucidate microglial-associated genes, we performed a computational 
deconvolution to interrogate changes in the gene expression and build a specific 
microglial signature to identify both activated and inactivated microglia within 
control, “pre-lesions” and PVL.  
 
BST2 (CD317) was selected to identify the co-expressed genes associated with 
inactivated microglia, as this gene is associated with reducing the expression of 
inflammatory associated genes and pro-inflammatory cytokines (Ajami et al., 2018).  
Microglia express the BST2 receptor immunoglobulin-like transcript 7 (ILT7), and 
binding to this receptor results in the down-regulation of pro-inflammatory immune 







The transformation of microglia from a homeostatic to reactive phenotype in 
dementia pathologies is associated with multiple genes, including Triggering 
Receptor Expressed on Myeloid cells 2 (TREM2) (Rodríguez-Gómez et al., 2020), 
HLA-DRA (Yin et al., 2017), ITGAX (CD11c) (Keren-Shaul et al., 2017), CCR5 (Li & Zhu, 
2019), CD274 (Schachtele et al., 2014), CD80 (B7-1) (Busse et al., 2015), CD86 (B7-
2) (Simpson et al., 2007b), ENTPD1 (CD39) (Baron et al., 2014), MRC1 (Friedman et 
al., 2018) and TIMD4 (Askew & Gomez-Nicola, 2018). TREM2 is highly expressed by 
microglia (Jay et al., 2017) and interacts with tyrosine kinase-binding protein 
(TYROBP) to promote microglial activation (Yeh et al., 2017; Ulland & Colonna, 
2018) and induce phagocytosis (Wang et al., 2015). Similarly, FCER1G and FCGR2A, 
which are members of immunoglobulin Fc receptor family mediate microglial 
phagocytosis (Quan et al., 2009). ITGAX is highly expressed in the white matter of 
aged mouse brains (Raj et al., 2017), and CD11c+ microglia have been shown to 
accumulate around amyloid plaques in a mouse model of AD where they initiate the 
phagocytic process (Kamphuis et al., 2016). Similarly, CD163 is expressed by 
activated microglia (Borda et al., 2008), and CD163+ microglia have been shown to 
accumulate around Aβ plaques in AD (Pey et al., 2014). 
 
To further validate the involvement of selected candidate microglial activation-
associated genes, KEGG pathway analysis was performed and confirmed a role for 
the selected genes in phagosome and antigen processing and presentation.  
Additional confirmation was performed using the EnrichR tool and the Jensen 






ITGAX, and TREM2 in microglia, while multiple genes associated with the immune 
response were also highly enriched, including CD274, MSR1, ENTPD1, CD163, 
FCER1G, FCGR2A, MRC1, HLA-DPB1, CYBB, HLA-DRA, LCP2 and CCR5. Therefore, 
these genes were selected to identify the co-expressed genes associated with 
activated microglia in the current study. Our data revealed a similar pattern of 
expression of both active and inactive microglial transcripts are present in control, 
“pre-lesions” and PVL except for CD80, which is markedly decreased in PVL.   
 
Post-mortem tissue analyses are fundamentally constrained in that they represent 
a single time point and disease stage.  Human tissue single-cell RNA sequencing can 
be used to interrogate microglial phenotypes; however, these findings then need to 
be validated at the protein level to confirm their relevance (Swanson et al., 2020). 
Multiple studies have investigated microglial changes over the course of 
neurodegeneration, showing specific differences in microglia isolated in early and 
late stages of neurodegeneration in mouse models (Mathys et al., 2017), so-called 
disease-associated microglia (DAM) (Keren-Shaul et al., 2017).  
 
Microglial heterogeneity is extensive (Mathys et al., 2017; Sankowski et al., 2019), 
and our findings demonstrate that microglia within the periventricular white matter 
in the ageing brain reflects a highly heterogeneous population and highlights the 
need to use a comprehensive and extensive panel of microglial markers to capture 
the full spectrum of microglial cell states and to assess the microglia phenotype 







3.4.3.3 “Pre-lesional” periventricular white matter and PVL are 
associated with increased expression of heat shock proteins 
While antigen processing and presentation genes are down-regulated in both PVL 
and “pre-lesions” compared to non-lesional controls, gene expression analysis 
identified significant upregulation of heat shock proteins (HSP) associated genes, 
including the HSP70-associated genes HSPA1A, HSPA4, and HSPA8, and the HSP90-
associated genes HSP90AA1 and HSP90AB1.  
 
The 70-kDa heat shock protein (Hsp70) is a member of a family of chaperone 
proteins which play a major role in preventing protein aggregation (Liberek et al., 
2008; Griffith & Holmes, 2019), and are highly inducible following brain ischemia 
(Planas et al., 1997; Kim et al., 2020). In addition, Hsp70 is involved in anti-
inflammatory processes including inhibiting neuroinflammatory pathways in 
cultured astrocytes from mice (Kim et al., 2015a); reducing the expression of 
prostaglandin-endoperoxide synthase 2, COX-2 (PTGS2) and nitric oxide (NO) in a 
mouse model by preventing nuclear factor kappa B (NFκB) activation (Kim et al., 
2015a);  anti-apoptosis (Lanneau et al., 2007); and protecting against cell death 
induced by ischemia (Giffard et al., 2004).  Post mortem analysis of heat shock 
protein expression in MS demonstrates significant upregulation of HSP70 in CNS 
lesions (Stadelmann et al., 2005) and in myelin isolated from MS lesions (Aquino et 
al., 1997; Pinar et al., 2017).  
 
HSP90, which is another member of the chaperone protein family, has been shown 






Polanski et al., 2010). In addition to these functions, HSP90 is involved in the 
regulation of signal transduction and acts to maintain signalling kinases (Li & 
Buchner, 2013), including mitogen-activated protein kinase (MAPK) (Lei et al., 
2017).   
 
These data suggest that the upregulation of HSP in both “pre-lesional” and PVL may 
reflect attempts to protect against demyelination in “pre-lesional” cases and prevent 
further demyelination in PVL.  
 
3.4.3.4 Upregulation of calcium and glutamate signalling in “pre-
lesional” white matter may reflect a neuroprotective response 
Analysis of the “pre-lesional” microarray datasets revealed the significant 
upregulation of several signalling pathways, including calcium and glutamate 
signalling, which may reflect a neuroprotective response to prevent lesion 
formation.   
 
Calcium signalling is essential to maintain homeostasis in the CNS and plays a major 
role in regulating multiple cellular processes, including cellular excitability, 
apoptosis, the release of neurotransmitters and signal transduction (Clapham, 
1995; Horigane et al., 2019).  Calcium dyshomeostasis strongly correlates with 
ageing and neurodegenerative disorders (Bezprozvanny, 2009; Gant et al., 2018).  
Dysregulation of calcium is strongly associated with the loss of white matter 
integrity following an ischaemic stroke in aged mice, which ultimately induces 






in calcium exchange, influx and buffering results in calcium imbalance, which 
ultimately leads to neuronal dysfunction and cell death (Kurnellas et al., 2007; 
Calvo-Rodriguez et al., 2020).  
 
Disruption of the BBB is a common feature of normal ageing and neurodegenerative 
diseases, and multiple studies have demonstrated an association between BBB 
dysfunction and WM pathologies (Tomimoto et al., 1996; Akiguchi et al., 1998; Li et 
al., 2017).  BBB dysfunction leads to an increase in intracellular calcium which in 
turn impacts the modification of tight junctions (Brown & Davis, 2002; Chen et al., 
2016b).  In a mouse model, activation of calmodulin/calcium-dependent protein 
kinase plays a role in the repair of the BBB after stroke, which in turn prevents pro-
inflammatory factor infiltration (Sun et al., 2019). In the current study, we 
demonstrate the significant upregulation of genes associated with 
calcium/calmodulin dependent protein kinase genes, including, CAMK4 and 
CAMK2B. CAMK4 inhibits excitotoxicity via the activation of the anti-apoptotic 
pathway PI3K/AKT3 (Bell et al., 2013). CAMK2B is a member of the 
calcium/calmodulin-dependant protein kinase family and mediates calcium 
signalling in the brain (Swulius & Waxham, 2008; Ghosh & Giese, 2015), and is 
involved in multiple signalling pathways and plays a role in oligodendrocyte 
maturation and CNS myelination (Waggener et al., 2013).  
 
Mature oligodendrocytes are responsible for axonal myelination (Sherman & 
Brophy, 2005), and express a wide range of receptors for neurotransmitters, 






myelin production in a mechanism known as adaptive myelination (Douglas Fields, 
2015; Habermacher et al., 2019).  Glutamate released from the axons binds to α-
Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, which 
mediate synaptic transmission in the CNS (Scheefhals & MacGillavry, 2018).  The 
present study identified significant upregulation of glutamatergic synapse-
associated genes in “pre-lesional” white matter, including GRIA2 and GRIA3 which 
encode the AMPA receptors, glutamate ionotropic receptor (GLUR2) and GLUR3, 
respectively, and are involved in mediating fast synaptic transmission in the CNS 
(Meng et al., 2003).  A study conducted on a post-mortem vascular dementia cohort 
revealed an upregulation of AMPA GLUR2 immunoreactivity and mRNA in 
subcortical ischemic vascular dementia (Mohamed et al., 2011).   
 
γ-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the CNS 
and is converted from glutamate. Glutamate together with GABA and ATP is 
essential for modulating the proliferation of oligodendrocyte precursor cells (OPC) 
and the survival of oligodendrocytes and axonal myelination (Gudz et al., 2006; 
Zonouzi et al., 2015). GABAA, an ionotropic receptor, is expressed by OPC (Zonouzi 
et al., 2015), once activated it enables GABA to depolarise OPC, which facilitates 
calcium entry into these cells. Thus an increase in calcium levels within OPC may 
help in the regulation of proliferation, migration and maturation of OPC which may 
eventually help in the myelination process by oligodendrocytes (Baraban et al., 
2018; Paez & Lyons, 2020).  Our data reveal a significant upregulation of GABAergic 
synaptic signalling in “pre-lesions”, associated with GABRA1, GABRA4 and GABRA5, 






activation of this receptor, which help in facilitating the myelination process by OPC 
and oligodendrocytes in “pre-lesions”. 
 
Taken together, the upregulation of calcium and glutamate signalling pathways in 
“pre-lesional” periventricular white matter may reflect a neuroprotective response 
to prevent the formation of PVL. 
 
3.5 Conclusion  
Age-associated PVL are highly associated with cognitive decline in the ageing 
population, but the mechanisms underlying their pathogenesis are unknown. The 
current study interrogated the transcriptomic profile of PVL and radiologically 
normal-appearing control periventricular white matter cases to identify novel 
mechanisms underlying their formation.  Histological characterisation of control 
white matter samples identified a group which characterised by the presence of high 
levels of MHC-II immunoreactive microglia and was classified as “pre-lesional”. 
Although histological assessment of a single marker (MHC-II) includes immune 
activated microglia in lesion pathology, transcriptomic analysis implies a 
substantial down-regulation of a number of activated microglial markers and 
suggests that established PVLs are part of a continuous process of white matter 
injury. Overall, the data presented here lead us to reject the original hypothesis that 
microglia within established PVL adapt a neurotoxic M1 phenotype.  Interestingly, 






upregulation of many signalling pathways, including calcium and glutamate, which 








 VALIDATION OF THE 










Gene expression analysis is a widely used method to identify potential mechanisms 
and changes in key pathways associated with the pathogenesis of a range of 
diseases, and may lead to the discovery of novel therapeutic targets. In the previous 
chapter, transcriptomic profiling using a microarray analysis approach was 
employed to identify relevant gene expression changes associated with PVL in the 
ageing brain. The data indicated established that PVL displays significant 
downregulation of several genes associated with an immune response, including 
genes associated with activated microglial markers and cytokines/chemokines. 
Furthermore, the gene expression profile of “pre-lesional” periventricular white 
matter was associated with the significant upregulation of several signalling 
pathways. To increase confidence in these results, additional validation experiments 
to confirm the differential expression of a panel of candidate genes were carried out. 
This chapter reports two independent validation approaches, namely NanoString 
and immunohistochemistry, to validate changes in gene expression and the proteins 
they encode, respectively. 
 
Post-mortem tissue is frequently associated with RNA degradation due to multiple 
factors, including pH and post-mortem delay (PMD), which can affect RNA integrity 
and are generally considered as one of the significant challenges associated with 
transcriptomic profiling. The NanoString nCounter system is a novel technology 
which allows interrogation of the expression of more than 800 genes using a single 
sample with fluorescently tagged mRNA molecules (Geiss et al., 2008). This assay 






“barcodes” with high sensitivity and is fully automated without the need to amplify 
mRNA (Figure 4.1). Another significant advantage of this technology is the accuracy 
of quantification of low quality and quantity mRNA within the sample.  
 
mRNA gene expression changes are not always expressed at the protein level for 
every selected gene. However, a recent experiment revealed a strong correlation 
between mRNA and protein levels in differentially expressed transcripts, which 
have far stronger associations between mRNA and protein levels than transcripts 
that are not differentially expressed (Koussounadis et al., 2015).  Therefore, 
techniques such as immunohistochemistry can be employed to assess the 
expression of the proteins encoded by candidate genes identified in transcriptomic 
studies.  In addition to enabling changes in protein expression to be assessed, this 
approach also provides additional information to be obtained by enabling the 
cellular localisation of the protein to be determined.  
 
4.1.1 Hypothesis: 
Microarray analysis of ageing periventricular white matter characterised the 
transcriptomic profile associated with “pre-lesions” and established PVL (chapter 
3).  The current chapter will extend these findings and further test the hypothesis 
that the mechanisms underlying the pathogenesis of PVL are different to DSCL, 
specifically that “pre-lesions” and PVL are associated with the significant down-








Figure 4.1 Schematic representation of NanoString nCounter protocol 
Total RNA was extracted from the periventricular region using LCM and mixed with the 
probe set provided by NanoString containing both capture and reporter probes (A). These 
probes bind specifically to their RNA targets and create the target-probe complex (B). The 
excess probes are removed after hybridisation (C), and the fluorescent colour sequences 









• To validate a key panel of candidate gene expression identified by 
microarray using NanoString nCounter. 
• To confirm the differential expression of the proteins encoded by a panel of 







4.2 Materials and methods 
4.2.1 NanoString  
Messenger RNA (mRNA) was isolated from the periventricular white matter of 
control, lesional and “pre-lesional” cases using LCM, as described in detail in section 
3.2.4.3. In the current study, 12 samples from the previous microarray study were 
analysed, and included 4 non-lesional controls, 3 “pre-lesional” and 5 PVL, as shown 
in Table 4-1.  A customised nCounter codeset human gene panel was designed, 
consisting of 29 inflammation, antigen processing and presentation-related genes. 
In addition, 3 housekeeping genes were included for normalisation (ACTB, GAPDH 
and RPLP0) (NanoString Technologies, Seattle, WA), as shown in Table 4-2.  
 
4.2.1.1 NanoString Sample Hybridisation 
A master mix was prepared by adding 70 µl of hybridisation buffer to the tube 
containing the Reporter Codeset, followed by brief centrifugation. Following this, 8 
µl of the master mix was added to 12 pre-labelled tubes of the hybridisation strip 
before adding 100 ng of sample RNA. To complete the hybridisation reaction, 2 µl of 
Capture ProbeSet was added to each tube followed by brief centrifugation, to make 
a final volume of 15 µl (Table 4-3). The tubes were placed in a PTC 200 thermal 
cycler (MJ Research, Quebec, Canada) and incubated at 65˚C for 22 hours. Following 
this incubation, the samples were placed on ice before adding 15 µl of hybridisation 
buffer to make a total of 30 µl. In accordance with the manufacturer’s instructions, 
each sample was loaded into the nCounter SPRINT cartridge by placing the tip of the 







Table 4-1 NanoString samples 
  







Sample 1 Control 1 
Sample 2 Control 3 
Sample 3 Control 4 







Sample 5 Lesion 1 
Sample 6 Lesion 2 
Sample 7 Lesion 3 
Sample 8  Lesion 5 








 Sample 10 Prelesion 1 
Sample 11 Prelesion 3 






Table 4-2 NanoString validation candidates 
This table shows the highly annotated candidate genes generated from microarray data 
analysis and EnrichR dataset focussing on genes associated with both inflammation and 






Inflammation AKT3 NM_005465.4 V-akt murine thymoma viral oncogene homolog 
3/RAC-gamma serine/threonine-protein kinase 
CCL2 NM_002982.3 C-C motif chemokine ligand 2 
CCL3 NM_002983.2 C-C motif chemokine ligand 3 
CCL4 NM_002984.2 C-C motif chemokine ligand 4 
CCR5 NM_000579.1 C-C motif chemokine receptor 5 
(gene/pseudogene) 
COL6A3 NM_004369.3 Collagen type VI alpha 3 chain 
CX3CR1 NM_001337.3 C-X3-C motif chemokine receptor 1 
IFNAR1 NM_000629.2 Interferon alpha and beta receptor subunit 1 
IKBKB NM_001556.1 Inhibitor of nuclear factor kappa B kinase subunit 
beta 
IL1A NM_000575.3 Interleukin 1 alpha 
IL1B NM_000576.2 Interleukin 1 beta 
JUN NM_002228.3 Jun proto-oncogene, AP-1 transcription factor 
subunit 







CD74 molecule, HLA class II histocompatibility 
antigen gamma chain 
HLA-
DRA 
NM_019111.3 Major histocompatibility complex, class II, DR 
alpha 
CD8A NM_001768.5 CD8a molecule, T-cell surface glycoprotein CD8 
alpha chain 
CD163 NM_004244.4 CD163 molecule, Scavenger Receptor Cysteine-





Epithelial stromal interaction protein 1 
FGL2 NM_006682.2 Fibrinogen like 2 
FPR1 NM_002029.3 Formyl peptide receptor 1 
IGSF6 NM_005849.2 Immunoglobulin superfamily member 6 
PHF21A NM_016621.3 PHD finger protein 21A 
Inactivated 
Microglia 
IRF7 NM_001572.3 Interferon regulatory factor 7 
OAS1 NM_00103240
9.1 
2'-5'-oligoadenylate synthetase 1 




FCER1G NM_004106.1 Fc fragment of IgE receptor Ig 
MSR1 NM_002445.3 Macrophage scavenger receptor 1 
SLAMF8 NM_020125.2 SLAM family member 8 
CYBB NM_000397.3 Cytochrome b-245, beta polypeptide 
Housekeeping 
Genes 












Table 4-3 nCounter sample preparation 
Component Volume (μl) 
Master Mix (Hybridisation + Reporter CodeSet) 8 
RNA 5 









plunger to the second stop, creating an air bubble and removing the pipette before 
releasing the plunger to prevent sucking the sample out.  The top of the cartridge 
was wiped, coated with a seal and placed into the nCounter SPRINT instrument for 
mRNA transcript counting (NanoString Technologies Inc., Seattle, WA).   
 
4.2.1.2 Validation of gene expression changes - NanoString 
The reporter library file (RLF), generated by NanoString, contained the unique 
custom CodeSet information and was imported to nSolver Analysis Software 
(v4.0.70) (NanoString Technologies). Raw data (RCC files) were analysed to ensure 
all samples passed the quality parameters, including imaging and binding density 
quality control (QC) metrics, positive control linearity and limit of detection.  
 
NanoString cartridge images were taken in small divided sections or lanes referred 
to as a field of view (FOV), which enabled the counting of the barcodes in 194 FOV.  
The percentage of FOV containing barcodes divided by the total number of FOV that 
the instrument attempted to scan was assessed for each sample, with greater than 
75% considered as a successful run. 
 
The binding density, a measure of the number of fluorescent spots per µm2, was 
calculated to determine the level of image saturation in each lane and, according to 
the manufacturer, should lie between 0.1 – 1.8. 
 
Positive control linearity was automatically checked using nSolver software, which 






software calculated the linear regression between the known concentration of each 
of the positive controls and their actual counts using log2-transformed values, 
where the correlation coefficient (R2) values should be greater than 0.95. 
 
Data were normalised using two methods by nSolver software. Initially, the data 
were normalised to the geometric mean of housekeeping genes in the designed 
codeset. The second normalisation method used the pre-mixed positive controls 
with the reporter probes to normalise the gene expression data.  
 
Each sample was annotated to the comparison group using the nSolver experiment 
option. Once analysed, ratio data was selected to identify both fold change (FC) and 
p-value for each gene of interest. Additional analysis was performed using the 
Advanced Analysis package on nSolver. Genes which showed an FC of ≥ +/- 2 and 
also a p-value ≤ 0.05 were considered significantly differentially expressed between 
the comparison groups. 
 
4.2.1.3 Comparison of the NanoString findings with the microarray 
datasets 
The datasets generated were compared between NanoString and Affymetrix to 
assess the correlation of gene expression and fold change directionality for the 
selected targets. As nCounter software uses a single probeset ID for selected genes 
(Chen et al., 2016c), but multiple probesets are employed in the microarray analysis, 







4.2.2 Validation of gene expression changes - 
Immunohistochemistry 
To further validate the gene expression changes identified by microarray analysis, 
the expression of the proteins encoded by a panel of candidate genes was assessed 
by IHC using ABC-HRP method (Section 2.2.3), the antibody details are shown in 
Table 4-4. The stained sections were assessed using a Nikon Eclipse 80i microscope 
and NIS-Elements Imaging Software (Nikon UK, Kingston Upon Thames). 
Quantification of specific immunoreactivity was performed in 3 different white 
matter regions of the periventricular region for each case. The images were analysed 
using Analysis^D software (Nikon UK, Kingston Upon Thames) to assess the % area 
immunoreactivity. 
 
4.2.3 Statistical analysis 
Immunohistochemical data were not normally distributed using the Shapiro-Wilk 
test and did not show equality of variances between groups; thus, analyses were 
conducted using non-parametric methods. Statistical comparisons of quantitative 
data between groups were carried out using the Kruskal-Wallis test using SPSS 
software version 26.0  (SPSS Inc., Chicago, IL, USA).  P-values were adjusted for 
multiple testing using the Bonferroni correction method and considered significant 
if p< 0.05.   









Table 4-4 Antibody source and conditions 




CD163 Monoclonal Mouse IgG 1:100 (1h RT) Bio-Rad, UK 
CD74 Polyclonal Rabbit IgG 1:200 (1h RT) Sigma, UK 
CD80/B7-1 Monoclonal Mouse IgG1 1:20 (overnight 4°C) R&D Systems, UK 
CD86/B7-2 Polyclonal goat IgG 1:20 (overnight 4°C) R&D Systems, UK 
CX3CR1 Monoclonal Mouse IgG1 1:25 (overnight 4°C) Biolegend, UK 
IL-1β Polyclonal Rabbit IgG 1:200 (1h RT) Proteintech, UK 









4.3.1 NanoString validation of microarray-identified candidate 
gene expression changes 
NanoString is a hybridisation-multiplex digital technology which uses capture 
probes and unique colour-coded barcode reporter probes to measure almost 800 
mRNA in a single reaction. This technology does not require reverse transcription 
of mRNA or amplification of cDNA.   
 
NanoString was employed to validate gene expression changes identified by 
microarray transcriptomic profiling.  A panel of highly annotated candidate gene 
expression changes from microarray data analysis and EnrichR dataset focussing on 
genes associated with both inflammation and antigen presentation was 
interrogated in PVL versus non-lesional control (LvC), “pre-lesion” versus non-
lesional control (PvC) and “pre-lesional” white matter versus PVL (PvL). All 
analysed samples passed all quality control measures: imaging 99-100% FOV; 
binding density of 0.14-0.17; and for the positive control linearity, the linear 
regression R2 of the samples was 0.99.     
 
4.3.1.1 Nanostring validation of gene expression changes in 
periventricular lesions compared to non-lesional control white 
matter. 
In PVL versus non-lesional control (LvC), NanoString analysis confirmed the 
significant differential expression of 7 genes with similar directional change 






was not significantly different between groups, they showed a similar directional 
change to the microarray findings. Only three genes showed a different, but non-
significant, directional change between both platforms Table 4-5.  
 
Upregulation of multiple genes involved in signalling pathways were detected in 
PVL compared to non-lesional controls, including the significant upregulation of JUN 
(FC= 1.98, p=0.008). In contrast, inflammation-associated genes were significantly 
downregulated in PVL, including the significant downregulation of CCL3 (FC= -
16.11, p=0.008), CCR5 (FC= -2.17, p=0.0003), CX3CR1 (FC= -1.64, p=0.01), IL-1β (FC= 
-4.72, p=0.007), and PTGS2 (FC= -2.59, p=0.007). The antigen processing and 
presentation gene CD74 was also significantly down-regulated in PVL (FC= -1.54, 
p=0.013). 
 
4.3.1.2 Nanostring validation of gene expression changes in “pre-lesions” 
compared to non-lesional control white matter 
In “pre-lesions” compared to non-lesional control periventricular white matter 
(PvC), 4 genes displayed a significant differential expression with a similar 
directional change to the microarray dataset, while 14 genes showed the same 
directional change but did not reach statistical significance.  11 genes showed a non-
significant and different directional change between both platforms, as shown in 
Table 4-6. 
 
Significant downregulation of genes associated with inflammation were identified, 
including PTGS2 (FC= -2.56, p=0.04), IL-1β (FC= -4.17, p=0.013), the chemokine 






Table 4-5 Validation of selected candidate genes expression by NanoString 
nCounter in Lesion compared to non-lesional control 
The table shows the comparison between microarray and NanoString using the fold change 
and P-value. 
Lesion compared to Control  
Microarray NanoString 
Gene FC P-Value FC P-Value 
JUN 1.33 0.008 ** 1.98 0.008 ** 
IKBKB 1.38 0.839 1.88 0.097 
AKT3 1.33 0.002 ** 1.52 0.128 
PHF21A 1.36 0.008 ** 1.5 0.121 
IFNAR1 1.79 0.004 ** 1.25 0.190 
OAS1 -1.12 0.829 1.14 0.644 
RSAD2 -1.2 0.066 1.09 0.758 
IRF7 1.04 0.674 -1.04 0.847 
MSR1 -1.95 0.023 * -1.06 0.878 
CD163 -3.27 0.315 -1.07 0.928 
IGSF6 -1.27 0.258 -1.12 0.585 
CYBB -1.62 0.013 * -1.17 0.578 
CD8A -1.28 0.016 * -1.23 0.568 
FCER1G -1.52 0.077 -1.28 0.265 
FGL2 -1.77 0.012 * -1.29 0.191 
EPSTI1 -1.31 0.839 -1.39 0.102 
SLAMF8 -1.03 0.680 -1.48 0.327 
HLA-DRA -1.71 0.004 ** -1.51 0.072 
CD74 -2.67 0.006 ** -1.54 0.013 * 
CX3CR1 -1.5 0.005 ** -1.64 0.010 * 
IL1A -1.06 0.207 -1.71 0.062 
COL6A3 -1.62 0.010 * -1.72 0.075 
CCL2 -1.7 0.051 * -1.88 0.290 
CCR5 -1.49 0.016 * -2.17 0.0003 *** 
PTGS2 -1.3 0.011 * -2.59 0.007 ** 
FPR1 -2.39 0.017 * -2.82 0.067 
IL1B -1.34 0.010 * -4.72 0.007 ** 
CCL4 -1.16 0.060 -5.14 0.098 
CCL3 -1.31 0.052 * -16.11 0.008 ** 
ACTB 1.01 0.341 -1.1 0.233 
GAPDH 1.08 0.067 1.17 0.067 
RPLP0 -1.22 0.565 -1.06 0.584 
* p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001, pink represents down-regulated transcripts, green 








Table 4-6 Validation of selected candidate genes expression by NanoString 
nCounter in “Pre-lesion” compared to non-lesional control 
The table show the comparison between microarray and NanoString using the fold change 
and P-value. 
Pre-lesion compared to Control  
Microarray NanoString 
Gene FC P-Value FC P-Value 
AKT3 1.34 0.005 ** 1.65 0.222 
IKBKB -1.01 0.619 1.63 0.359 
PHF21A -1.05 0.516 1.52 0.397 
OAS1 -1.31 0.567 1.24 0.644 
IFNAR1 -1.09 0.063 1.16 0.394 
IRF7 -1.08 0.564 1.13 0.740 
MSR1 -3.13 0.02 * 1.04 0.933 
JUN -1.45 0.599 1.03 0.895 
IGSF6 -1.38 0.233 1.02 0.953 
FGL2 -1.5 0.03 * 1 0.995 
EPSTI1 -1.88 0.030 * -1.01 0.981 
COL6A3 -2.01 0.003 ** -1.06 0.824 
FCER1G -1.59 0.336 -1.3 0.516 
CCR5 -1.47 0.082 -1.38 0.540 
CX3CR1 -1.39 0.253 -1.55 0.04 * 
CD8A 1.05 0.469 -1.62 0.459 
IL1A -1.2 0.071 -1.62 0.461 
HLA-DRA -1.54 0.022 * -1.63 0.228 
CYBB -1.28 0.048 * -1.67 0.256 
CD74 -1.57 0.018 * -1.69 0.123 
RSAD2 -1.2 0.071 -1.74 0.131 
SLAMF8 -1.57 0.044 * -2.16 0.152 
CCL4 1.07 0.959 -2.24 0.360 
CCL2 -2.12 0.010 * -2.38 0.074 
PTGS2 -1.15 0.134 -2.56 0.04 * 
CD163 -1.97 0.727 -2.8 0.372 
FPR1 -1.83 0.044 * -3.45 0.101 
IL1B -1.26 0.042 * -4.17 0.013 * 
CCL3 -1.2 0.133 -6.64 0.04 * 
ACTB 1.09 0.406 -1.18 0.327 
GAPDH -1.1 0.915 1.25 0.308 
RPLP0 -1.12 0.249 -1.16 0.541 
* p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001, pink represents down-regulated transcripts, green 








4.3.2 Validation of microarray candidate gene expression by 
immunohistochemistry 
To further validate candidate gene expression, the expression of the proteins 
encoded by four relevant genes from pathways highlighted by both microarray and 
NanoString datasets (CD74, IL-1β, CD163, CD86) were investigated by 
immunohistochemistry (Figure 4.2), and the immunoreactive area quantified, as 
shown in Table 4-7.  
 
CD74 immunoreactivity was a prominent feature of the non-lesional control 
periventricular white matter and immunolabelled microglia, which displayed a 
ramified morphology with long processes extending from the cell body Figure 4.2 
(A-C). Quantification of the expression of CD74 revealed a significant difference 
across the three groups (p=0.003), with non-lesional control periventricular white 
matter containing significantly higher levels of CD74 compared to both “pre-lesions” 
(p=0.033) and PVL (p=0.003), as shown in Figure 4.3A. 
 
IL-1β, CD163 and CD86 immunoreactivity was positively associated with the cell 
bodies and extending processes of cells morphologically resembling microglia, as 
shown in Figure 4.2.  Expression of IL-1β (p=0.7), CD163 (p=0.38) and CD86 
(p=0.63) immunoreactivity did not significantly vary across the three groups, as 









Figure 4.2 Histological validation of candidate gene expression changes 
Expression of proteins encoded by candidate genes highlighted by both microarray and 
NanoString datasets was assessed. (A-C) CD74, (D-F) IL-1β, (G-I) CD163 and (J-L) CD86 
positively immunolabelled the cell body and processes of microglial cells in all 








Table 4-7 Expression of CD74, IL-1β, CD163 and CD86 in ageing periventricular 
white matter 
The % area of immunoreactivity of each of the markers is shown, median (IQR). 
WM group Control Pre-lesional PVL 
CD74 3.47 (3.08-4.15) 1.66 (0.9-2.14) 1.3 (1.13-1.66) 
IL-1β 3.87 (1.91-4.86) 2.76 (1.91-4.07) 3.43 (2.48-4.22) 
CD163 0.93 (0.75-1.21) 0.39 (0.29-1.08) 0.95 (0.59-1.32) 
CD86 4.55 (4.52-5.66) 5.34 (3.98-6.23) 5.04 (3.35-6.03) 









Figure 4.3 Quantitation of the expression of candidates in periventricular 
white matter 
The % area immunoreactivity of the protein encoded by a panel of candidate genes was 
assessed in the three periventricular white matter groups.  (A) CD74 expression was 
significantly higher in non-lesional control periventricular white matter compared to both 
“pre-lesional” (p=0.033) and PVL (p=0.003).  The immunoreactive profile of (B) IL-1β, (C) 








4.4  Discussion:  
Characterisation of the transcriptomic profile of PVL and “pre-lesions” using 
microarrays revealed a gene expression signature associated with the significant 
down-regulation of the immune response, therefore the research presented in this 
chapter aimed to validate these findings using two independent approaches, namely 
Nanostring and immunohistochemistry.   
 
The reproducibility between Affymetrix microarray and NanoString technologies is 
high, as demonstrated by a recent study which revealed a moderate correlation, 
where 70-80% of genes between both platforms displayed similar gene expression 
changes (Delmonico et al., 2019).  NanoString technology can measure the 
expression of multiple genes in a single reaction with small amounts of starting 
material, which is particularly advantageous when analysing LCM-ed post-mortem 
tissue, where often a limited amount of highly degraded RNA is obtained.  Therefore, 
the current study employed NanoString to validate the expression of a panel of 
candidate gene expression findings identified by the previous microarray study, 
examining the expression of 29 selected candidate genes related to inflammation 
and antigen processing and presentation. 
 
For the NanoString analysis, we selected highly annotated genes generated from 
microarray data analysis and EnrichR dataset focussing on genes associated with 
both inflammation and antigen processing and presentation. The majority of 
selected genes identified by the microarray analysis showed the same directional 






PVL compared to non-lesional controls, 24% of the genes revealed a significant 
differential expression with a similar directional change between NanoString and 
microarray platforms, and 65% of the genes selected displayed a non-significant but 
similar directional change. Similarly, in “pre-lesions” compared to non-lesional 
controls, 13% of the genes revealed a significant differential expression with the 
same directional change between NanoString and microarray platforms, and 48% 
of the genes selected displayed a non-significant but similar directional change. 
Recently, a study using frozen samples revealed a moderate concordance between 
experiments conducted using both Affymetrix microarrays and NanoString (Chen et 
al., 2016c). Similarly, a recent study comparing the correlation between next 
generation sequencing and NanoString examined the expression of 750 genes, and 
found similar gene expression changes in 734 genes (Bondar et al., 2020). These 
studies demonstrate moderate concordance and high correlation between both 
platforms support our findings.  Overall, the gene expression changes identified in 
the NanoString analysis, support the findings of the microarray data analysis, as well 
as confirming the need to validate transcriptomic datasets using an independent 
approach. 
 
4.4.1 Both “pre-lesions” and PVL are associated with a significant 
decrease in the expression of chemokines and their 
receptors  
Nanostring analysis confirmed the significant downregulation of multiple 
chemokine-related genes in both “pre-lesional” and PVL versus non-lesional 






brain for any insult, which requires rapid recruitment and migration of cells to the 
lesion site or to initiate an inflammatory mechanism to help in the damage repairing 
process. Chemoattractant cytokines, or chemokines, play an important role in the 
activation and directional migration of cells along a chemotactic gradient (Sorce et 
al., 2011; Hughes & Nibbs, 2018).  Depending on their structure they are 
subclassified as CXC, CC or CX3C chemokines, and exert their effect via interacting 
with their complementary receptors to modulate cellular responses and signal 
transduction (Hughes & Nibbs, 2018). 
 
Increased chemokine expression is a feature of a number of neurological diseases, 
including AD, multiple sclerosis (MS), Parkinson’s Disease (PD), Motor Neuron 
Diseases (MND) (Azizi et al., 2014; Liu et al., 2019a; Perner et al., 2018; Cui et al., 
2020). However, in contrast to these diseases, both “pre-lesions” and established 
PVL are associated with a significant decrease in chemokine and chemokine 
receptor expression, suggesting dysregulation of the immune response and a change 
in microglial function may contribute to the pathogenesis of age-associated PVL. 
 
CCL3 and CCL4 are members of the β-family of chemokines and act as ligands for 
the C-C chemokine receptor type 5 (CCR5) (Gu et al., 2016).  Binding to CCR5 plays 
a role in the neuroinflammatory response, including microglial activation (Bokhari 
et al., 2009; Cui et al., 2020), and recruitment (Hahn et al., 2010). A significant 
increase in CCR5 expression by microglia has been demonstrated in a mouse model 
of stroke (Joy et al., 2019), and actively demyelinating lesions in both MS (Simpson 






contrast to these studies, significant downregulation of CCR5 and CCL3 were 
detected in established PVL.  
 
Fractalkine or CX3CL1 is a member of the chemokine CX3C that is primarily secreted 
by neurons. CX3CL1 binds to and activates its receptor CX3CR1, which is mainly 
expressed and produced by myeloid cells, specifically microglia (Harrison et al., 
1998; Garcia et al., 2013), and together they mediate microglia-neuron interactions 
(Arnoux & Audinat, 2015; Mecca et al., 2018). Activation of CX3CR1 plays a role in 
regulating the recruitment of microglia to the site of injury (Tang et al., 2014; Ahn 
et al., 2019), promoting and regulating glial activation (Cardona et al., 2006) and 
stimulating the secretion of pro-inflammatory cytokines (Blauth et al., 2015; Stuart 
et al., 2015).    
 
Expression of cytokines, chemokines and their receptors are altered during ageing 
(Castro-Sánchez et al., 2019).  Large-scale transcriptomic profiling of human 
prefrontal cortex, reveals a significant age-associated downregulation of CX3CR1 
(Primiani et al., 2014), and a similar significant has been demonstrated in the 
hippocampus of ageing rats (Bachstetter et al., 2011).  Furthermore, transcriptomic 
profiling of a murine model of CX3CR1-deficient microglia found that loss of CX3CR1 
impacts antigen presentation and chemokine-chemokine receptor signalling 
(Gyoneva et al., 2019). For example, CX3CR1 deficient mouse microglia demonstrate 







There is a strong relationship between CX3CR1 and the pro-inflammatory cytokine 
IL-1β.  IL-1β is a pro-inflammatory cytokine which, while playing a major role in 
tissue repair and cellular defence, is also implicated in a range of pathogenic 
processes (Hewett et al., 2012). Activation of CX3CR1 triggers the secretion of IL-1β 
by microglia (Eyo et al., 2017) via the mitogen-activated protein kinase (MAPK) 
pathway (Clark et al., 2006). The current study revealed the significant 
downregulation of CX3CR1 and IL1B in both “pre-lesions” and PVL compared to non-
lesional control periventricular white matter.  While the decreased expression of 
CX3CR1 may represent an age-associated disruption of signalling pathways (Norden 
& Godbout, 2013), it may also indicate the dysregulation or malfunction of microglia 
in both “pre-lesions” and established PVL. 
 
4.4.2 Down-regulation of antigen processing and presentation is a 
feature of established PVL 
Microarray analysis in the previous chapter indicated that the transcriptomic profile 
of PVL was associated with significant dysregulation of genes associated with 
immune function. Downregulation of major histocompatibility complex, class II, DR 
alpha (HLA-DRA), CD74 and CD163 in PVL was validated by NanoString technology, 
but it should be noted that except for CD74 these changes were non-significant.    
 
CD74 is an MHC-II chaperone that regulates antigen processing and presentation 
and is highly expressed by microglia in AD patients (Yoshiyama et al., 2000; Bryan 
et al., 2008). In addition, CD74 interacts with the pro-inflammatory cytokine, 






Meza-Romero et al., 2019). MIF is an essential activator for inflammatory processes, 
promoting the production of cytokines and chemokines (Koda et al., 2004; Zhou et 
al., 2018). Binding of MIF to CD74 induces multiple signalling pathways, including 
MAPK, which has been shown to regulate cell survival and proliferation (Bucala & 
Shachar, 2016) and promote leukocyte migration (Fan et al., 2011).  
 
Our data revealed downregulation of CD74, which may result in an inability to bind 
to MIF, leading to dysregulation of immune response and reduction of migratory 
chemotactic function. These findings are in line with previous studies which found 
blocking CD74 results in a reduction of cytokine levels (Trifone et al., 2018), and 
reduces the migratory response of monocytes to chemokines both in vivo and in 
vitro using MIF-/- and CD74-/- mice (Fan et al., 2011).   
 
4.4.3 “Pre-lesions” and PVL are associated with decreased 
expression of CD74 
Further validation of the transcriptomic findings was carried out by selecting four 
biologically relevant genes from both microarray and NanoString to identify the 
expression of proteins encoded by the selected candidate genes CD74, CD163, CD86 
and IL1B. 
 
As discussed previously, CD74 is an MHC-II chaperone that regulates antigen 
processing and presentation (Yoshiyama et al., 2000; Bryan et al., 2008), and IL-1β 
is a pro-inflammatory cytokine which plays a major role in regulating the 






differentiation 163 (CD163) is a scavenger receptor mainly expressed by 
macrophage and monocyte cells (Pey et al., 2014), and is widely regarded as a 
marker for M2 anti-inflammatory microglia (Wattananit et al., 2016; Kanazawa et 
al., 2017). CD86 (or B7-2) is expressed by antigen-presenting cells and is associated 
with M1 pro-inflammatory microglia (Erkenstam et al., 2016).  
 
The immunoreactive profile of these candidates supports other studies 
demonstrating that microglia are primarily associated with CD74 (Swanson et al., 
2020), CD163 (Holfelder et al., 2011; Tippett et al., 2011; Pey et al., 2014; Jing et al., 
2018), CD86 (de Haas et al., 2008) and IL-1β (An et al., 2011; Liu & Quan, 2018).  
mRNA and protein expression can be decoupled in time (Fournier et al., 2010; 
Koussounadis et al., 2015); however, it has been shown that differentially-expressed 
transcripts have significantly higher correlations between mRNA and protein levels 
(Koussounadis et al., 2015).  Indeed, the current study confirmed that CD74 is 




4.4.4 The mechanisms underlying the pathogenesis of PVL are 
different to DSCL 
Interestingly, the transcriptomic profile identified in the current study of age-
associated periventricular pathology is markedly different from the gene expression 
profile of age-associated deep subcortical white matter pathology.  Similar to the 
PVL profile observed in the current study, microarray analysis of DSCL 






expression of immune‐regulatory genes (Simpson et al., 2009).  However, in 
contrast to the down-regulation of immune-associated genes observed in 
established PVL, DSCL are associated with the upregulation of genes involved in 
antigen presentation (including up‐regulation of MHC class II), complement, 
lymphocyte activation, pro-inflammatory cytokine signalling and phagocytosis 
(Simpson et al., 2009).  These findings highlight the major differences between these 
WML subtypes and the need to investigate them independently.  Their opposing 
transcriptomic profile suggests that the cellular mechanisms underlying their 
pathogenesis is different and requires further investigation to fully elucidate these 




NanoString is a robust profiling technology which enables quantification of mRNA 
without the use of reverse transcription or amplification of cDNA. The current study 
employed this technology to validate the transcriptomic profile identified in the 
microarray analysis, confirming both “pre-lesions” and established PVL are 
associated with the significant down-regulation of immune-associated genes 
compared to non-lesional periventricular white matter.  We demonstrate that the 
transcriptomic signature of PVL is distinct from other white matter pathologies and 
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5.1 Confluent lesions display a range of microglial 
profiles  
Age-associated white matter lesions, including PVL, DSCL and confluent lesions, 
which encompass both the periventricular and deep subcortical WM regions, are a 
common feature of the ageing brain and are significantly associated with cognitive 
decline (Alber et al., 2019; Kloppenborg et al., 2014). Previous histological studies 
characterising the microglial profile associated with these lesions demonstrated 
that PVL are predominantly characterised by MHC-II+ microglia with an immune 
activated phenotype, while DSCL contains significantly higher levels of CD68+ 
microglia with a phagocytic phenotype (Simpson et al., 2007a, 2007b; Murray et al., 
2012; Waller et al., 2019); however, the microglial phenotype associated with 
confluent lesions is currently unknown. Therefore, the current study examined the 
MHC-II and CD68 immunostaining patterns associated with confluent lesions to 
determine if the immunoreactive profile indicates if these lesions arise as a spread 
of PVL, DSCL or both. The findings presented in this thesis partially support the 
original hypothesis that confluent lesions arise as a result of combined PVL and 
DSCL spread. Four distinct immunoreactive profiles were identified which associate 
with confluent lesions: (i) MHC II+ and CD68+ microglia primarily associated with 
the periventricular and deep subcortical regions, respectively; (ii) MHC II+ microglia 
predominantly throughout the lesion; (iii) CD68+ microglia predominantly 
throughout the lesion; (iv) a mix of both CD68+ and MHC II+ microglia present 
throughout the confluent lesion. These microglial profiles demonstrate a range of 






pathology or both, suggesting that a variety of mechanisms may be associated with 
the pathogenesis of confluent lesions.  
 
5.1.1 Study Limitations & Future Work 
Several limitations of this study should be acknowledged. The histological 
characterisation of the microglial phenotype associated with confluent lesions was 
conducted on 18 cases; however, the 4 profiles identified meant small numbers of 
cases in each of the 4 groups. Future studies are required to extend the study to 
include a greater number of cases to enable robust statistical analyses to be 
performed. While the inter-observer qualitative scoring of confluent lesions showed 
a moderate agreement, qualitative analysis is subjective to individual interpretation 
of the staining patterns observed.  By extending the number of cases examined, the 
study would have sufficient power to robustly analyse the quantitative data. 
 
Furthermore, the study examined the expression of just two microglial markers, 
namely MHC-II and CD68. A comprehensive panel of microglial markers should be 
employed to fully elucidate the phenotype of age-associated confluent lesions.  M1 
microglia express the distinctive markers CD74, CD40, CD86, CCR7 (Peferoen et al., 
2015), whereas M2 microglia are associated with the expression of mannose 
receptor and CCL22 (Peferoen et al., 2015; Liu et al., 2018).  Extending the study to 
interrogate the immunoreactive profile of these markers will enable the M1/M2 
profile of confluent lesions to be characterised in detail.  Additionally, the study 
should also be extended to assess markers of cerebral hypoxia and BBB dysfunction, 






well as investigating the relevance of these lesions to the risk of depression, stroke 
and mortality. Understanding how WML arise, particularly the role of microglia in 
the pathogenesis of WM pathology, may identify novel therapeutic treatments 
designed to modulate the microglial phenotype.   
 
5.2 Histological characterisation of radiologically 
normal periventricular white matter detects 
“Pre-lesional” cases 
Radiologically identified normal and PVL cases were sampled and underwent 
histological characterisation. In support of the literature, the current study 
demonstrated that demyelination is a prominent feature of PVL as evidenced by the 
loss of myelin basic protein (Simpson et al., 2007a; Murray et al., 2012).  Denudation 
of ependymal lining is also a feature of PVL (Simpson et al., 2007a), where the loss 
of ependymal lining, which acts as a barrier between brain parenchyma and cerebral 
spinal fluid, may lead to back diffusion of CSF into the periventricular region and 
exacerbate lesion pathogenesis (Shim et al., 2015).  Established PVL were also 
shown to be associated with increased expression of MHC-II+ microglia (Simpson et 
al., 2007b).  
 
Interestingly, four cases of the radiological control samples in the current study, 
which were rated 0 by consultant radiologists using the Schelten’s rating (Scheltens 
et al., 1993), displayed an increased immunoreactive profile for MHC-II, and were 






5.2.1 Study limitations & Future Work 
The initial study design was to compare the gene expression profile of PVL 
compared to non-lesional control periventricular WM. The histological 
characterisation of control WM identified a subgroup of cases which displayed no 
evidence of demyelination but contained high levels of MHC-II+ microglia.  These 
cases were subsequently termed “pre-lesional”, but it should be acknowledged that 
it cannot be known whether these cases would have gone on to develop PVL.  Future 
work is required to perform a comprehensive and detailed histological 
characterisation of these cases and to extend the study to include a larger number 
of “pre-lesions”, as a minimum of 12 samples per group is required for the 
identification of the significantly differentially expressed genes (Schurch et al., 
2016). 
 
5.3 Transcriptomic profiling of PVL and “pre-
lesions” identifies dysregulation of the immune 
response  
PVL, control and “pre-lesional” periventricular WM regions were isolated from post-
mortem tissue by LCM and their transcriptomic profile assessed by microarray 
analysis.  Surprisingly, despite the increased immunohistochemical detection of 
MHC-II+ microglia in both the “pre-lesions” and PVL, there was a substantial down-
regulation of both antigen processing and presentation, and immune response-
related genes.  Therefore, subsequent validation experiments were performed to 






and proteins encoded by the selected genes, respectively. A major advantage of 
Nanostring is that it does not require purification or reverse transcription of RNA 
(Geiss et al., 2008). The majority of the selected candidate genes were validated 
using this approach, confirming the dysregulation of immune response pathways in 
both “pre-lesions” and established PVL. 
 
The transcriptomic profile of the PVL was found to be distinct from DSCL. In contrast 
to the PVL gene expression profile identified in the current study, microarray 
analysis of DSCL has demonstrated that these lesions are associated with a 
significant increase of immune-regulatory genes, including upregulation of antigen 
presentation, pro-inflammatory cytokine signalling and phagocytosis (Simpson et 
al., 2009). The significant differences in the transcriptomic profile of PVL compared 
to DSCL support the original hypothesis that the mechanisms underlying the 
pathogenesis of PVL are different to DSCL and highlight the need for future studies 
to assess these WML subgroups independently. 
 
Computational deconvolution analysis in the current study enabled gene expression 
associated with microglial phenotype to be identified. Inactivated and activated 
microglia were assessed by identifying a co-expression network of genes associated 
with the selected candidate microglial markers using GeneMania (Warde-Farley et 
al., 2010). Our data indicate heterogeneity of the microglial population in the 
periventricular white matter. Furthermore, the current study reports similarity in 






samples, with the exception of CD80, leading us to reject the original hypothesis that 
microglia within PVL adapt a neurotoxic M1 phenotype.  
 
5.3.1 Study limitations & Future Work 
The current project assessed the transcriptomic profile associated with microglia in 
age-associated periventricular white matter. Gene expression studies are sensitive 
to RNA quality which can be impacted by several factors, including PMD and brain 
pH (Mexal et al., 2006; Ferreira et al., 2018). Furthermore, the LCM technique itself 
can affect RNA integrity, as demonstrated by the decline in RNA integrity number 
following LCM in our samples.  This finding supports other studies which 
demonstrate a decline in RNA integrity following LCM (Waller et al., 2012; Mazurek 
et al., 2013). However, while there are clearly limitations to using this approach, it 
should also be acknowledged that microarray analysis of post-mortem tissue is a 
valuable tool to identify novel mechanisms potentially underlying specific 
pathologies. 
 
It should also be acknowledged that the approach used in the current study isolated 
the entire periventricular region using LCM and will therefore have isolated RNA 
from a heterogeneous population of cells, including astrocytes. Astrocytes share 
several functional similarities with microglia, including contributing to the immune 
response (Fakhoury, 2018; Vainchtein & Molofsky, 2020). Future studies should be 
employed to perform single-cell transcriptomic analysis, specifically examining the 
gene expression profile of microglia within the periventricular region using an 






microglia from frozen post-mortem tissue (Waller et al., 2012; Simpson et al., 2018). 
Transcriptomic analysis using microarray or RNA-Seq would then enable microglial 
gene expression changes to be confirmed, validating their role in age-associated 
periventricular white matter pathology. Alternatively, a comprehensive panel of 
significantly differentially expressed genes should be validated at the protein level 
by immunohistochemistry to enable the association of candidate gene expression 
changes with microglia to be confirmed. 
 
5.4 Upregulation of calcium and glutamate signalling 
pathways in “pre-lesions” may be a neuroprotective 
response to prevent the pathogenesis of PVL. 
Microglia respond to a number of extracellular stimuli, leading to an increase in their 
intracellular calcium, which provides energy and induces the release of adenosine 
triphosphate (ATP). Increased levels of ATP regulate multiple signalling pathways 
which may promote physiological and protective mechanisms (Butt et al., 2014), as 
well as promoting microglial migration to sites of injuries (Sieger et al., 2012).   
 
Transcriptomic profiling of “pre-lesions” identified the significant upregulation of 
genes associated with signalling pathways, including calcium and glutamate.  
Calcium signalling is essential in maintaining homeostasis in the CNS (Zündorf & 
Reiser, 2011). A reduction in calcium signalling induces multiple physiological 
changes, including loss of white matter integrity, by inducing oligodendrocyte 






calcium signalling in “pre-lesional” periventricular white matter may reflect a 
neuroprotective effect to prevent the pathogenesis of PVL.  
 
Glutamate released from axons promotes myelination by binding to AMPA receptors 
to mediate synaptic transmissions (Scheefhals & MacGillavry, 2018). The current 
study revealed a significant upregulation of glutamatergic synaptic genes in “pre-
lesional” white matter, suggesting a potential mechanism to maintain myelin 
integrity and prevent lesion pathogenesis. 
 
5.4.1 Study Limitations & Future work  
Although recent advances in technologies enable gene expression changes in post-
mortem tissue to be identified, the profiling of this tissue (frequently with low RNA 
quality and at end-stage of disease) does not enable researchers to assess 
potentially relevant changes at all stages of disease progression. Therefore, the use 
of an appropriate animal model could be used to interrogate and confirm the gene 
expression profile at different stages of PVL formation. The C57BL/6J mouse model 
is highly vulnerable to cerebral ischemia and displays WM pathology.  Small focal 
periventricular white matter lesions have been induced in this model by injecting 
the vasoconstrictor endothelin-1, which result in gliosis and microglial activation at 
the site of injury (Ahmad et al., 2015).  Interrogation of this model at various stages 
of PVL formation would enable changes in signalling pathways to be confirmed at 
“pre-lesional” stages.  Furthermore, studies to manipulate the microglial phenotype 







5.5 Summary of the major findings 
While transcriptomic profiling of DSCL has previously been performed to identify 
the underlying mechanisms associated with the formation of these lesions (Simpson 
et al., 2009), the current study is the first in the field to employ this approach and 
identify gene expression changes which may underlie the formation of PVL. The 
research presented in this thesis suggests that established PVL are part of a 
continuous spectrum of white matter injury and that increased signalling pathways 
in “pre-lesions”, including calcium and glutamate signalling, may play a 
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Full list of dysregulated KEGG pathways  
These tables represent the dysregulated KEGG pathways identified in the 
periventricular white matter. These pathways were identified in the isolated 
periventricular white matter using DAVID analysis. 
 
KEGG pathways (PVL compared to controls) 
Pathway Name DEG P-Value FDR 
hsa05215:   Prostate cancer 23 1.81E-06 0.002 
hsa04510:   Focal adhesion 38 4.74E-06 0.006 
hsa04612:   Antigen processing and presentation 20 9.17E-06 0.012 
hsa05416:   Viral myocarditis 15 1.69E-04 0.223 
hsa05332:   Graft-versus-host disease 11 2.29E-04 0.303 
hsa05150:   Staphylococcus aureus infection 14 3.56E-04 0.469 
hsa04940:   Type I diabetes mellitus 12 4.63E-04 0.609 
hsa05200:   Pathways in cancer 51 0.001 1.730 
hsa05152:   Tuberculosis 28 0.001 1.777 
hsa05145:   Toxoplasmosis 20 0.002 2.090 
hsa05140:   Leishmaniasis 15 0.002 2.340 
hsa05212:   Pancreatic cancer 14 0.002 2.945 
hsa04151:   PI3K-Akt signaling pathway 45 0.002 3.159 
hsa05330:   Allograft rejection 10 0.003 3.431 
hsa04145:   Phagosome 24 0.003 3.641 
hsa05213:   Endometrial cancer 12 0.003 3.956 
hsa05166:   HTLV-I infection 35 0.003 4.415 
hsa05222:   Small cell lung cancer 16 0.004 5.016 
hsa04672:   Intestinal immune network for IgA 
production 






hsa05168:   Herpes simplex infection 27 0.005 5.786 
hsa04520:   Adherens junction 14 0.005 6.471 
hsa05169:   Epstein-Barr virus infection 20 0.005 6.796 
hsa04380:   Osteoclast differentiation 21 0.005 6.908 
hsa04974:   Protein digestion and absorption 16 0.005 6.957 
hsa05321:   Inflammatory bowel disease (IBD) 13 0.006 7.279 
hsa04152:   AMPK signaling pathway 20 0.006 7.413 
hsa04514:   Cell adhesion molecules (CAMs) 22 0.006 8.164 
hsa04068:   FoxO signaling pathway 21 0.007 8.828 
hsa04015:   Rap1 signaling pathway 29 0.008 9.980 
hsa05310:   Asthma 8 0.010 12.266 
hsa04611:   Platelet activation 20 0.010 13.005 
hsa04512:   ECM-receptor interaction 15 0.012 14.491 
hsa05210:   Colorectal cancer 12 0.012 14.821 
hsa05323:   Rheumatoid arthritis 15 0.013 15.852 
hsa05223:   Non-small cell lung cancer 11 0.016 18.785 
hsa04915:   Estrogen signaling pathway 16 0.016 19.054 
hsa04913:   Ovarian steroidogenesis 10 0.018 21.224 
hsa05231:   Choline metabolism in cancer 16 0.019 22.199 
hsa05211:   Renal cell carcinoma 12 0.019 22.276 
hsa05142:   Chagas disease (American 
trypanosomiasis) 
16 0.024 27.455 
hsa04662:   B cell receptor signaling pathway 
 
12 0.026 29.046 
hsa05320:   Autoimmune thyroid disease 10 0.026 29.109 
hsa05160:   Hepatitis C 19 0.026 29.294 
hsa04064:   NF-kappa B signaling pathway 14 0.026 29.750 
hsa04012:   ErbB signaling pathway 14 0.026 29.750 
hsa05322:   Systemic lupus erythematosus 19 0.028 31.003 
hsa05146:   Amoebiasis 16 0.028 31.290 
hsa05164:   Influenza A 23 0.030 33.182 






hsa04923:   Regulation of lipolysis in adipocytes 10 0.040 41.282 
hsa04010:   MAPK signaling pathway 30 0.045 45.923 
hsa00910:   Nitrogen metabolism 5 0.047 46.933 




KEGG pathway (Pre-lesion compared to control) 
Pathway Name DEG P-Value FDR 
hsa04723:  Retrograde endocannabinoid signaling 32 1.39E-10 1.83E-07 
hsa04020:  Calcium signaling pathway 42 3.38E-09 4.44E-06 
hsa04728:  Dopaminergic synapse 34 5.29E-09 6.96E-06 
hsa04713:  Circadian entrainment 28 1.41E-08 1.86E-05 
hsa04921:  Oxytocin signaling pathway 36 2.98E-08 3.92E-05 
hsa04724:  Glutamatergic synapse 30 6.28E-08 8.26E-05 
hsa05033:  Nicotine addiction 17 6.74E-08 8.86E-05 
hsa04725:  Cholinergic synapse 29 1.29E-07 1.70E-04 
hsa05031:  Amphetamine addiction 21 3.45E-07 4.54E-04 
hsa05150:  Staphylococcus aureus infection 18 1.45E-06 0.002 
hsa04720:  Long-term potentiation 20 1.63E-06 0.002 
hsa05032:  Morphine addiction 24 1.66E-06 0.002 
hsa04727:  GABAergic synapse 23 1.82E-06 0.002 
hsa05140:  Leishmaniasis 20 5.40E-06 0.007 
hsa05169:  Epstein-Barr virus infection 27 1.08E-05 0.014 
hsa05014:  Amyotrophic lateral sclerosis (ALS) 16 1.17E-05 0.015 
hsa04612:  Antigen processing and presentation 20 1.58E-05 0.021 
hsa04940:  Type I diabetes mellitus 14 3.11E-05 0.041 
hsa05332:  Graft-versus-host disease 12 5.92E-05 0.078 
hsa04261:  Adrenergic signaling in 
cardiomyocytes 






hsa04024:  cAMP signaling pathway 34 1.54E-04 0.203 
hsa04010:  MAPK signaling pathway 40 2.23E-04 0.293 
hsa05152:  Tuberculosis 31 2.26E-04 0.297 
hsa04726:  Serotonergic synapse 22 4.37E-04 0.573 
hsa04730:  Long-term depression 15 4.46E-04 0.585 
hsa05166:  HTLV-I infection 39 4.92E-04 0.645 
hsa04915:  Estrogen signaling pathway 20 6.73E-04 0.881 
hsa05310:  Asthma 10 6.78E-04 0.888 
hsa05030:  Cocaine addiction 13 7.10E-04 0.930 
hsa04911:  Insulin secretion 18 7.82E-04 1.024 
hsa05330:  Allograft rejection 11 8.58E-04 1.123 
hsa05416:  Viral myocarditis 14 8.92E-04 1.167 
hsa05168:  Herpes simplex infection 30 8.94E-04 1.170 
hsa05145:  Toxoplasmosis 21 0.001 1.312 
hsa04971:  Gastric acid secretion 16 0.001 1.534 
hsa04380:  Osteoclast differentiation 23 0.002 2.218 
hsa04014:  Ras signaling pathway 34 0.002 2.246 
hsa04672:  Intestinal immune network for IgA 
production 
12 0.002 2.278 
hsa04022:  cGMP-PKG signaling pathway 26 0.002 2.628 
hsa05162:  Measles 23 0.002 2.701 
hsa04145:  Phagosome 25 0.002 2.750 
hsa04514:  Cell adhesion molecules (CAMs) 24 0.002 2.866 
hsa04970:  Salivary secretion 17 0.002 3.167 
hsa04924:  Renin secretion 14 0.003 3.538 
hsa04925:  Aldosterone synthesis and secretion 16 0.003 4.450 
hsa05164:  Influenza A 27 0.004 4.818 
hsa04922:  Glucagon signaling pathway 18 0.004 5.573 
hsa04062:  Chemokine signaling pathway 28 0.005 6.082 
hsa05414:  Dilated cardiomyopathy 16 0.005 6.304 






hsa04360:  Axon guidance 21 0.006 7.329 
hsa04721:  Synaptic vesicle cycle 13 0.007 8.526 
hsa04012:  ErbB signaling pathway 16 0.007 8.706 
hsa04310:  Wnt signaling pathway 22 0.007 8.910 
hsa04015:  Rap1 signaling pathway 30 0.007 9.026 
hsa04540:  Gap junction 16 0.008 9.642 
hsa04080:  Neuroactive ligand-receptor 
interaction 
37 0.008 9.989 
hsa05214:  Glioma 13 0.009 10.862 
hsa04750:  Inflammatory mediator regulation of 
TRP channels 
17 0.009 11.355 
hsa04919:  Thyroid hormone signaling pathway 19 0.009 11.361 
hsa04660:  T cell receptor signaling pathway 17 0.011 13.578 
hsa05412:  Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
13 0.011 13.620 
hsa05320:  Autoimmune thyroid disease 11 0.012 14.751 
hsa05205:  Proteoglycans in cancer 28 0.012 15.119 
hsa04662:  B cell receptor signaling pathway 13 0.014 16.818 
hsa05410:  Hypertrophic cardiomyopathy (HCM) 14 0.015 18.141 
hsa04611:  Platelet activation 20 0.015 18.324 
hsa05323:  Rheumatoid arthritis 15 0.018 20.837 
hsa05146:  Amoebiasis 17 0.019 21.994 
hsa04916:  Melanogenesis 16 0.024 26.913 
hsa04260:  Cardiac muscle contraction 13 0.026 29.038 
hsa05200:  Pathways in cancer 46 0.029 31.684 
hsa04914:  Progesterone-mediated oocyte 
maturation 
14 0.035 37.006 
hsa04068:  FoxO signaling pathway 19 0.038 40.197 
hsa04144:  Endocytosis 30 0.040 41.719 
hsa05321:  Inflammatory bowel disease (IBD) 11 0.046 46.018 






hsa04923:  Regulation of lipolysis in adipocytes 10 0.048 47.959 




KEGG Pathway (Pre-lesion compared to PVL) 
Pathway Name DEG P-Value FDR 
hsa04020: Calcium signaling pathway 46 4.71E-11 6.22E-08 
hsa04723: Retrograde endocannabinoid signaling 27 3.86E-07 5.09E-04 
hsa04724: Glutamatergic synapse 29 3.97E-07 5.24E-04 
hsa04713: Circadian entrainment 26 4.11E-07 5.42E-04 
hsa04921: Oxytocin signaling pathway 34 5.84E-07 7.71E-04 
hsa05033: Nicotine addiction 16 6.56E-07 8.66E-04 
hsa05032: Morphine addiction 23 9.23E-06 0.012 
hsa04727: GABAergic synapse 21 3.58E-05 0.047 
hsa05031: Amphetamine addiction 18 4.00E-05 0.053 
hsa05014: Amyotrophic lateral sclerosis (ALS) 15 7.12E-05 0.094 
hsa04720: Long-term potentiation 17 1.47E-04 0.194 
hsa05412: Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
17 1.78E-04 0.234 
hsa04725: Cholinergic synapse 23 2.30E-04 0.303 
hsa05414: Dilated cardiomyopathy 19 3.09E-04 0.407 
hsa04080: Neuroactive ligand-receptor 
interaction 
43 3.22E-04 0.425 
hsa04310: Wnt signaling pathway 26 3.83E-04 0.504 
hsa04970: Salivary secretion 19 4.19E-04 0.552 
hsa04024: cAMP signaling pathway 33 5.36E-04 0.705 
hsa04022: cGMP-PKG signaling pathway 28 5.96E-04 0.783 
hsa04390: Hippo signaling pathway 26 0.001 1.957 






hsa05410: Hypertrophic cardiomyopathy  (HCM) 16 0.003 3.896 
hsa00230: Purine metabolism 28 0.003 3.993 
hsa04360: Axon guidance 22 0.004 4.552 
hsa04728: Dopaminergic synapse 22 0.004 4.997 
hsa04974: Protein digestion and absorption 17 0.004 5.143 
hsa04971: Gastric acid secretion 15 0.004 5.396 
hsa04911: Insulin secretion 16 0.007 8.797 
hsa04978: Mineral absorption 10 0.013 16.116 
hsa04010: MAPK signaling pathway 34 0.014 17.354 
hsa04972: Pancreatic secretion 16 0.016 18.816 
hsa04512: ECM-receptor interaction 15 0.020 22.930 
hsa05010: Alzheimer's disease 24 0.022 25.827 
hsa04925: Aldosterone synthesis and secretion 14 0.024 27.827 
hsa05030: Cocaine addiction 10 0.026 29.240 
hsa04114: Oocyte meiosis 17 0.034 36.634 
hsa04730: Long-term depression 11 0.036 38.326 










Differentially expressed pathways identified by KEGG using DAVID analysis 
These tables represent the differentially expressed genes identified in the isolated 
periventricular white matter, using KEGG pathway analysis, focussing on pathways 
of interest. These genes were classified as up-and down-regulated. 
 
PI3K/AKT pathway (PVL compared to Control) 
ProbeSet ID Gene 
name 
Gene Detail FC P-
Value 
211550_AT EGFR epidermal growth factor receptor 1.43 0.0004 
225293_AT COL27A1 collagen, type XXVII, alpha 1 1.66 0.0005 
205291_AT IL2RB interleukin 2 receptor, beta -1.62 0.0008 
225288_AT COL27A1 collagen, type XXVII, alpha 1 1.48 0.001 
219393_S_AT AKT3 v-akt murine thymoma viral 
oncogene homolog 3 
1.33 0.002 
225669_AT IFNAR1 interferon (alpha, beta and omega) 
receptor 1 
1.79 0.0035 
202449_S_AT RXRA retinoid X receptor alpha 1.34 0.0035 
208225_AT FGFR2 fibroblast growth factor receptor 2 -1.51 0.0052 
201984_S_AT EGFR epidermal growth factor receptor 1.55 0.0057 





heat shock protein 90kDa alpha 
(cytosolic), class A member 1 
2.02 0.0075 
1557354_AT SOS1 SOS Ras/Rac guanine nucleotide 
exchange factor 1 
1.42 0.0079 
202404_S_AT COL1A2 collagen, type I, alpha 2 -1.66 0.0085 
210211_S_AT HSP90AA
1 
heat shock protein 90kDa alpha 




heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
1.47 0.0102 
201438_AT COL6A3 collagen, type VI, alpha 3 -1.62 0.0103 
209799_AT PRKAA1 protein kinase, AMP-activated, 









heat shock protein 90kDa alpha 
(cytosolic), class A member 1 
1.42 0.011 
209341_S_AT IKBKB inhibitor of kappa light polypeptide 





heat shock protein 90kDa alpha 
(cytosolic), class A member 1 
1.27 0.0114 
211804_S_AT CDK2 cyclin-dependent kinase 2 -1.32 0.0134 
208240_S_AT FGF1 fibroblast growth factor 1 (acidic) 1.33 0.0152 
236034_AT ANGPT2 angiopoietin 2 1.25 0.0178 
201108_S_AT THBS1 thrombospondin 1 -2.01 0.0178 
205923_AT HLA-
DQB1 
major histocompatibility complex, 
class II, DQ beta 1 
-1.47 0.0197 
216896_AT COL4A3 collagen, type IV, alpha 3 
(Goodpasture antigen) 
-1.21 0.02 
201125_S_AT ITGB5 integrin beta 5 1.37 0.0212 
223943_S_AT 0 0 -1.45 0.0216 
216893_S_AT COL4A3 collagen, type IV, alpha 3 
(Goodpasture antigen) 
-1.48 0.0218 
224965_AT GNG2 guanine nucleotide binding protein 
(G protein), gamma 2 
-1.47 0.0219 
201109_S_AT THBS1 thrombospondin 1 -1.32 0.0223 
203638_S_AT FGFR2 fibroblast growth factor receptor 2 -1.3 0.0224 
209561_AT THBS3 thrombospondin 3 1.33 0.024 
212688_AT PIK3CB phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic 
subunit beta 
1.25 0.0243 
206254_AT EGF epidermal growth factor 1.64 0.025 
209364_AT BAD BCL2-associated agonist of cell 
death 
1.22 0.0261 
202883_S_AT PPP2R1B protein phosphatase 2, regulatory 
subunit A, beta 
1.24 0.0278 
232555_AT CREB5 cAMP responsive element binding 
protein 5 
-1.36 0.0284 
213523_AT CCNE1 cyclin E1 1.3 0.0286 
211980_AT COL4A1 collagen, type IV, alpha 1 -1.72 0.0289 
208228_S_AT FGFR2 fibroblast growth factor receptor 2 -1.24 0.0289 
211161_S_AT COL3A1 collagen, type III, alpha 1 -1.51 0.0304 








heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
1.21 0.0328 
225066_AT PPP2R2D protein phosphatase 2, regulatory 
subunit B, delta 
1.4 0.0331 
205572_AT ANGPT2 angiopoietin 2 1.33 0.0367 
219304_S_AT PDGFD platelet derived growth factor D -1.22 0.0379 
207709_AT PRKAA2 protein kinase, AMP-activated, 
alpha 2 catalytic subunit 
-1.22 0.0392 
214036_AT EFNA5 ephrin-A5 1.29 0.0393 
203639_S_AT FGFR2 fibroblast growth factor receptor 2 -1.45 0.04 
204627_S_AT ITGB3 integrin beta 3 -1.53 0.0406 
203685_AT BCL2 B-cell CLL/lymphoma 2 1.29 0.0419 
223573_S_AT PPP2R2C protein phosphatase 2, regulatory 
subunit B, gamma 
1.41 0.0435 
222073_AT COL4A3 collagen, type IV, alpha 3 
(Goodpasture antigen) 
-1.92 0.0439 
241565_AT COL4A4 collagen, type IV, alpha 4 -1.27 0.044 
1565484_X_A
T 
EGFR epidermal growth factor receptor 1.29 0.0443 
201505_AT LAMB1 laminin, beta 1 -1.22 0.0444 
211401_S_AT FGFR2 fibroblast growth factor receptor 2 -1.41 0.0449 
204524_AT PDPK1 3-phosphoinositide dependent 
protein kinase 1 
1.59 0.0451 










MAPK Pathway (PVL compared to Control) 
ProbeSet ID Gene 
name 
Gene Detail FC P-
Value 
225185_AT MRAS muscle RAS oncogene homolog 1.75 0.0002 
210189_AT HSPA1L heat shock 70kDa protein 1-like 1.48 0.0015 
219393_S_AT AKT3 v-akt murine thymoma viral 
oncogene homolog 3 
1.33 0.002 
208225_AT FGFR2 fibroblast growth factor receptor 2 -1.51 0.0052 






1557354_AT SOS1 SOS Ras/Rac guanine nucleotide 
exchange factor 1 
1.42 0.0079 
201465_S_AT JUN jun proto-oncogene 1.33 0.0082 
201763_S_AT DAXX death-domain associated protein 1.22 0.0082 
228109_AT RASGRF
2 
Ras protein-specific guanine 
nucleotide-releasing factor 2 
-1.56 0.0088 
39402_AT IL1B interleukin 1 beta -1.34 0.0102 
205067_AT IL1B interleukin 1 beta -1.35 0.0105 
209341_S_AT IKBKB inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase 
beta 
1.38 0.0112 




206538_AT MRAS muscle RAS oncogene homolog 1.46 0.0127 
201841_S_AT HSPB1 heat shock 27kDa protein 1 2.07 0.013 
222912_AT ARRB1 arrestin, beta 1 1.58 0.0144 
233694_AT HSPA1L heat shock 70kDa protein 1-like 2.26 0.0151 




heat shock 70kDa protein 1A; heat 
shock 70kDa protein 1B 
1.41 0.0162 
212180_AT CRKL v-crk avian sarcoma virus CT10 
oncogene homolog-like 
1.27 0.017 
202948_AT IL1R1 interleukin 1 receptor, type I -1.29 0.0197 
211550_AT HLA-
DQB1 
major histocompatibility complex, 
class II, DQ beta 1 
-1.47 0.0197 




heat shock 70kDa protein 1A; heat 
shock 70kDa protein 1B 
1.61 0.0226 
34726_AT CACNB3 calcium channel, voltage-





heat shock 70kDa protein 1A; heat 
shock 70kDa protein 1B 
2.23 0.0234 
208944_AT TGFBR2 transforming growth factor beta 
receptor II 
-1.52 0.0236 
208687_X_AT HSPA8 heat shock 70kDa protein 8 1.24 0.0239 
206254_AT EGF epidermal growth factor 1.64 0.025 






214376_AT MAPK10 mitogen-activated protein kinase 10 1.38 0.0278 
208876_S_AT PAK2 p21 protein (Cdc42/Rac)-activated 
kinase 2 
-1.23 0.0288 
208228_S_AT FGFR2 fibroblast growth factor receptor 2 -1.24 0.0289 
215561_S_AT IL1R1 interleukin 1 receptor, type I -1.69 0.0348 
209332_S_AT MAX MYC associated factor X 1.26 0.0363 
210482_X_AT MAP2K5 mitogen-activated protein kinase 
kinase 5 
1.2 0.0388 
203639_S_AT FGFR2 fibroblast growth factor receptor 2 -1.45 0.04 
225662_AT ZAK sterile alpha motif and leucine 




EGFR epidermal growth factor receptor 1.29 0.0443 
211401_S_AT FGFR2 fibroblast growth factor receptor 2 -1.41 0.0449 
213603_S_AT RAC2 ras-related C3 botulinum toxin 
substrate 2 (rho family, small GTP 
binding protein Rac2) 
-1.21 0.046 
227073_AT MAP3K2 mitogen-activated protein kinase 
kinase kinase 2 
-1.3 0.0478 
FC: Fold Change 
 
Antigen processing and presentation and Heat Shock Proteins (PVL compared 
to Control) 
ProbeSet ID Gene 
name 
Gene Detail FC P-
Value 
205671_s_at HLA-DOB major histocompatibility complex, 
class II, DO beta (HLA-DOB) 
-1.79 0.0009 
210189_at HSPA1L heat shock protein family A 
(Hsp70) member 1 like (HSPA1L) 
1.48 0.0015 
210982_s_at hla-dra major histocompatibility complex, 




major histocompatibility complex, 
class II, DR beta 1 (HLA-DRB1) 
-1.62 0.004 
212671_s_at hla-dqa1 major histocompatibility complex, 
class II, DQ alpha 1 (HLA-DQA1) 
-2.93 0.0055 
1567627_at CD74 CD74 molecule (CD74) -2.67 0.0068 
211968_s_at HSP90AA
1 
heat shock protein 90 alpha family 









major histocompatibility complex, 




heat shock protein 90 alpha family 




heat shock protein 90 alpha family 




heat shock protein 90 alpha family 




heat shock protein 90 alpha family 
class A member 1 (HSP90AA1) 
1.27 0.0114 
208812_x_at HLA-C major histocompatibility complex, 
class I, C (HLA-C) 
-1.4 0.0145 
233694_at HSPA1L heat shock protein family A 
(Hsp70) member 1 like (HSPA1L) 
2.26 0.0151 
214459_x_at HLA-C major histocompatibility complex, 
class I, C (HLA-C) 
-1.34 0.016 
200799_at HSPA1A heat shock protein family A 
(Hsp70) member 1A (HSPA1A) 
1.41 0.0162 
205758_at CD8A CD8a molecule (CD8A) -1.28 0.0164 
208428_at tap2 transporter 2, ATP binding cassette 




major histocompatibility complex, 
class II, DQ beta 1 (HLA-DQB1) 
-2.08 0.0187 





major histocompatibility complex, 
class II, DQ beta 1 (HLA-DQB1) 
-1.47 0.0197 
208894_at hla-dra major histocompatibility complex, 
class II, DR alpha (HLA-DRA) 
-1.6 0.0221 
202581_at HSPA1A heat shock protein family A 
(Hsp70) member 1A (HSPA1A) 
1.61 0.0226 
200800_s_at HSPA1A heat shock protein family A 
(Hsp70) member 1A (HSPA1A) 
2.23 0.0234 
208687_x_at HSPA8 heat shock protein family A 
(Hsp70) member 8 (HSPA8) 
1.24 0.0239 
213537_at HLA-DPA1 major histocompatibility complex, 




major histocompatibility complex, 
class II, DQ beta 1 (HLA-DQB1) 
-1.44 0.0253 










heat shock protein 90 alpha family 
class B member 1 (HSP90AB1) 
1.21 0.0328 
209619_at CD74 CD74 molecule (CD74) -1.4 0.0355 
218127_at NFYB nuclear transcription factor Y 




major histocompatibility complex, 
class II, DQ beta 1 (HLA-DQB1) 
-1.49 0.0454 
226878_at HLA-DOA major histocompatibility complex, 
class II, DO alpha (HLA-DOA) 
-1.24 0.0496 
FC: Fold Change 
 
 
Phagosome (PVL compared to Control) 
ProbeSet ID Gene name Gene Detail FC P-
Value 
205671_S_AT HLA-DOB major histocompatibility 
complex, class II, DO beta 
-1.79 0.0009 
210982_S_AT HLA-DRA major histocompatibility 
complex, class II, DR alpha 
-1.71 0.0038 
208306_X_AT HLA-DRB1 major histocompatibility 





complex, class II, DQ alpha 1; 
major histocompatibility 
complex, class II, DQ alpha 2 
-2.93 0.0055 




209728_AT HLA-DRB4 major histocompatibility 
complex, class II, DR beta 4 
-9.48 0.0086 
240990_AT RAB5A RAB5A, member RAS 
oncogene family 
-1.43 0.0115 
236527_AT ATP6V0E1 ATPase, H+ transporting, 
lysosomal 9kDa, V0 subunit 
e1 
1.43 0.0118 
207446_AT TLR6 toll-like receptor 6 -1.2 0.0127 
208812_X_AT HLA-C major histocompatibility 







214459_X_AT HLA-C major histocompatibility 
complex, class I, C 
-1.34 0.016 
216951_AT FCGR1A Fc fragment of IgG, high 
affinity Ia, receptor (CD64) 
-2.12 0.0164 
208428_AT TAP2 transporter 2, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
-1.39 0.0172 







complex, class II, DR beta 1; 
major histocompatibility 
complex, class II, DR beta 3; 
major histocompatibility 
complex, class II, DR beta 4; 
HLA class II 
histocompatibility antigen, 
DRB1-7 beta chain 
-2.08 0.0187 
209823_X_AT HLA-DQB1 major histocompatibility 
complex, class II, DQ beta 1 
-1.47 0.0197 
201125_S_AT ITGB5 integrin beta 5 1.37 0.0212 
208894_AT HLA-DRA major histocompatibility 
complex, class II, DR alpha 
-1.6 0.0221 
201109_S_AT THBS1 thrombospondin 1 -1.32 0.0223 
208422_AT MSR1 macrophage scavenger 
receptor 1 
-1.95 0.0225 
221504_S_AT ATP6V1H ATPase, H+ transporting, 
lysosomal 50/57kDa, V1 
subunit H 
1.24 0.0233 
209561_AT THBS3 thrombospondin 3 1.33 0.024 
1553917_AT PIKFYVE phosphoinositide kinase, 
FYVE finger containing 
1.29 0.025 
213537_AT HLA-DPA1 major histocompatibility 
complex, class II, DP alpha 1 
-1.57 0.0252 
212998_X_AT HLA-DQB1 major histocompatibility 
complex, class II, DQ beta 1 
-1.44 0.0253 
204627_S_AT ITGB3 integrin beta 3 -1.53 0.0406 
1565673_AT FCGR2A Fc fragment of IgG, low 




Fc fragment of IgG, low 
affinity IIIa, receptor 















complex, class II, DR beta 1; 
major histocompatibility 
complex, class II, DR beta 4; 
major histocompatibility 
complex, class II, DR beta 5; 
HLA class II 
histocompatibility antigen, 
DRB1-7 beta chain 
-1.49 0.0454 
226878_AT HLA-DOA major histocompatibility 
complex, class II, DO alpha 
-1.24 0.0496 










GABAergic Synapse (Pre-lesion compared to control) 
ProbeSet ID Gene name Gene Detail FC P-
value 
206456_AT GABRA5 gamma-aminobutyric acid 
(GABA) A receptor, alpha 5 
7.1 0.0002 
216895_AT GABRG3 gamma-aminobutyric acid 
(GABA) A receptor, gamma 3 
1.78 0.0006 
215531_S_AT GABRA5 gamma-aminobutyric acid 
(GABA) A receptor, alpha 5 
3.89 0.001 
1555867_AT GNG4 guanine nucleotide binding 




GABRB2 gamma-aminobutyric acid 
(GABA) A receptor, beta 2 
2.86 0.0015 
1568612_AT GABRG2 gamma-aminobutyric acid 
(GABA) A receptor, gamma 2 
2.37 0.0019 
214933_AT CACNA1A calcium channel, voltage-
dependent, P/Q type, alpha 1A 
subunit 
1.76 0.0026 
233437_AT GABRA4 gamma-aminobutyric acid 
(GABA) A receptor, alpha 4 
1.91 0.0027 
222005_S_AT GNG3 guanine nucleotide binding 
protein (G protein), gamma 3 
2.86 0.0038 
232062_AT ADCY1 adenylate cyclase 1 (brain) 1.52 0.0039 
227830_AT GABRB3 gamma-aminobutyric acid 
(GABA) A receptor, beta 3 
2.24 0.0043 
242344_AT GABRB2 gamma-aminobutyric acid 




230255_AT GABRD gamma-aminobutyric acid 
(GABA) A receptor, delta 
1.54 0.007 
227817_AT PRKCB protein kinase C, beta 2.37 0.0076 
1566513_A_A
T 
GNG4 guanine nucleotide binding 
protein (G protein), gamma 4 
1.71 0.0081 
215340_AT ADCY1 adenylate cyclase 1 (brain) 2.21 0.0082 
206849_AT GABRG2 gamma-aminobutyric acid 
(GABA) A receptor, gamma 2 
2.08 0.0082 
209685_S_AT PRKCB protein kinase C, beta 2.04 0.009 
230437_S_AT PRKCB protein kinase C, beta 1.54 0.0094 
217280_X_AT GABRA5 gamma-aminobutyric acid 







206678_AT GABRA1 gamma-aminobutyric acid 
(GABA) A receptor, alpha 1 
5.31 0.0125 
210454_S_AT KCNJ6 potassium channel, inwardly 
rectifying subfamily J, member 
6 
1.23 0.014 
229724_AT GABRB3 gamma-aminobutyric acid 
(GABA) A receptor, beta 3 
4.42 0.0152 
228795_AT PRKCB protein kinase C, beta 1.87 0.0172 
213245_AT ADCY1 adenylate cyclase 1 (brain) 2.22 0.018 
207352_S_AT GABRB2 gamma-aminobutyric acid 
(GABA) A receptor, beta 2 
1.44 0.0192 
202125_S_AT TRAK2 trafficking protein, kinesin 
binding 2 
1.62 0.0206 
204763_S_AT GNAO1 guanine nucleotide binding 
protein (G protein), alpha 
activating activity polypeptide 
O 
2.24 0.0216 
208463_AT GABRA4 gamma-aminobutyric acid 
(GABA) A receptor, alpha 4 
2.04 0.022 






guanine nucleotide binding 




203158_S_AT GLS glutaminase 1.87 0.0264 
204762_S_AT GNAO1 guanine nucleotide binding 
protein (G protein), alpha 
activating activity polypeptide 
O 
1.78 0.029 
242891_AT ADCY5 adenylate cyclase 5 1.31 0.0308 
235049_AT ADCY1 adenylate cyclase 1 (brain) 1.41 0.0323 
203159_AT GLS glutaminase 2.2 0.0333 
227824_AT PRKCB protein kinase C, beta 1.77 0.0337 
205850_S_AT GABRB3 gamma-aminobutyric acid 
(GABA) A receptor, beta 3 
1.42 0.034 
236195_X_AT PRKCG protein kinase C, gamma 1.25 0.0397 
235781_AT CACNA1B calcium channel, voltage-








205184_AT GNG4 guanine nucleotide binding 
protein (G protein), gamma 4 
1.67 0.042 
202742_S_AT PRKACB protein kinase, cAMP-
dependent, catalytic, beta 
1.33 0.0473 
216651_S_AT GAD2 glutamate decarboxylase 2 2.08 0.0476 




Calcium Signalling (Pre-lesion compared to control) 
ProbeSet ID Gene name Gene Detail FC P-
value 
231783_AT CHRM1 cholinergic receptor, muscarinic 
1 
1.84 0.0002 
214217_AT GRM5 glutamate receptor, 
metabotropic 5 
1.78 0.0004 
229029_AT CAMK4 calcium/calmodulin-dependent 
protein kinase IV 
2.74 0.0008 
241871_AT CAMK4 calcium/calmodulin-dependent 
protein kinase IV 
3.31 0.0008 





calmodulin 2 (phosphorylase 
kinase, delta); calmodulin 3 
(phosphorylase kinase, delta) 
2.11 0.001 









236013_AT CACNA1E calcium channel, voltage-
dependent, R type, alpha 1E 
subunit 
4.46 0.0012 
205915_X_AT GRIN1 glutamate receptor, ionotropic, 
N-methyl D-aspartate 1 
1.74 0.0013 
207577_AT HTR4 5-hydroxytryptamine 








210939_S_AT GRM1 glutamate receptor, 
metabotropic 1 
3.08 0.0013 
244256_AT CACNA1E calcium channel, voltage-
dependent, R type, alpha 1E 
subunit 
4.11 0.0015 
1565389_S_AT GRM5 glutamate receptor, 
metabotropic 5 
5.37 0.0017 
214044_AT RYR2 ryanodine receptor 2 (cardiac) 2.35 0.0018 
206534_AT GRIN2A glutamate receptor, ionotropic, 
N-methyl D-aspartate 2A 
1.68 0.0019 
214933_AT CACNA1A calcium channel, voltage-
dependent, P/Q type, alpha 1A 
subunit 
1.76 0.0026 
242488_AT CHRM3 cholinergic receptor, muscarinic 
3 
1.65 0.0027 
209281_S_AT ATP2B1 ATPase, Ca++ transporting, 
plasma membrane 1 
1.83 0.0031 
221631_AT CACNA1I calcium channel, voltage-
dependent, T type, alpha 1I 
subunit 
1.58 0.0034 





calmodulin 1 (phosphorylase 
kinase, delta); calmodulin 2 
(phosphorylase kinase, delta) 
1.6 0.0036 
232062_AT ADCY1 adenylate cyclase 1 (brain) 1.52 0.0039 
205450_AT PHKA1 phosphorylase kinase, alpha 1 
(muscle) 
-1.34 0.0044 




34846_AT CAMK2B calcium/calmodulin-dependent 
protein kinase II beta 
2.1 0.006 
202425_X_AT PPP3CA protein phosphatase 3, catalytic 
subunit, alpha isozyme 
1.68 0.0065 
210448_S_AT P2RX5 purinergic receptor P2X, ligand 
gated ion channel, 5 
1.48 0.0066 
212930_AT ATP2B1 ATPase, Ca++ transporting, 
plasma membrane 1 
2.9 0.0068 
207613_S_AT CAMK2A calcium/calmodulin-dependent 







210781_X_AT GRIN1 glutamate receptor, ionotropic, 
N-methyl D-aspartate 1 
1.93 0.0074 
227817_AT PRKCB protein kinase C, beta 2.37 0.0076 
215340_AT ADCY1 adenylate cyclase 1 (brain) 2.21 0.0082 
1559633_A_A
T 
CHRM3 cholinergic receptor, muscarinic 
3 
1.78 0.0084 
209685_S_AT PRKCB protein kinase C, beta 2.04 0.009 
213222_AT PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
3.9 0.0092 
230437_S_AT PRKCB protein kinase C, beta 1.54 0.0094 
213108_AT CAMK2A calcium/calmodulin-dependent 
protein kinase II alpha 
1.72 0.0099 
217140_S_AT VDAC1 voltage-dependent anion 
channel 1 
1.24 0.01 
211483_X_AT CAMK2B calcium/calmodulin-dependent 




calmodulin 1 (phosphorylase 
kinase, delta); calmodulin 2 
(phosphorylase kinase, delta) 
1.63 0.0104 
208432_S_AT CACNA1E calcium channel, voltage-
dependent, R type, alpha 1E 
subunit 
1.62 0.0122 
229876_AT PHKA1 phosphorylase kinase, alpha 1 
(muscle) 
-1.65 0.0124 
209956_S_AT CAMK2B calcium/calmodulin-dependent 
protein kinase II beta 
5.14 0.0127 
211125_X_AT GRIN1 glutamate receptor, ionotropic, 
N-methyl D-aspartate 1 
1.79 0.0135 
1566739_AT PLCE1 phospholipase C, epsilon 1 -1.54 0.0149 
207309_AT NOS1 nitric oxide synthase 1 
(neuronal) 
1.84 0.015 
240650_AT CACNA1E calcium channel, voltage-
dependent, R type, alpha 1E 
subunit 
1.31 0.0162 
228795_AT PRKCB protein kinase C, beta 1.87 0.0172 
213245_AT ADCY1 adenylate cyclase 1 (brain) 2.22 0.018 














calmodulin 2 (phosphorylase 
kinase, delta); calmodulin 3 
(phosphorylase kinase, delta) 
1.71 0.0213 







(serotonin) receptor 7, 
adenylate cyclase-coupled; 5-
hydroxytryptamine (serotonin) 




calmodulin 1 (phosphorylase 
kinase, delta); calmodulin 2 
(phosphorylase kinase, delta) 
1.25 0.0237 
32541_AT PPP3CC protein phosphatase 3, catalytic 
subunit, gamma isozyme 
-1.29 0.0258 
207557_S_AT RYR2 ryanodine receptor 2 (cardiac) 2.75 0.0265 
233498_AT ERBB4 erb-b2 receptor tyrosine kinase 
4 
1.31 0.0268 
32540_AT PPP3CC protein phosphatase 3, catalytic 
subunit, gamma isozyme 
-1.36 0.0271 
204506_AT PPP3R1 protein phosphatase 3, 
regulatory subunit B, alpha 
1.67 0.0274 
206355_AT GNAL guanine nucleotide binding 
protein (G protein), alpha 
activating activity polypeptide, 
olfactory type 
2.7 0.0286 
209439_S_AT PHKA2 phosphorylase kinase, alpha 2 
(liver) 
-1.25 0.0288 
210404_X_AT CAMK2B calcium/calmodulin-dependent 
protein kinase II beta 
2.33 0.0298 
202429_S_AT PPP3CA protein phosphatase 3, catalytic 
subunit, alpha isozyme 
2.51 0.0303 
214348_AT TACR2 tachykinin receptor 2 1.3 0.0309 
235049_AT ADCY1 adenylate cyclase 1 (brain) 1.41 0.0323 
239132_AT NOS1 nitric oxide synthase 1 
(neuronal) 
1.63 0.0332 
227824_AT PRKCB protein kinase C, beta 1.77 0.0337 
40562_AT GNA11 guanine nucleotide binding 










calmodulin 1 (phosphorylase 
kinase, delta); calmodulin 2 
(phosphorylase kinase, delta) 
1.26 0.0348 
234729_AT PHKG1 phosphorylase kinase, gamma 1 
(muscle) 
-1.25 0.0359 
213924_AT GNAL guanine nucleotide binding 
protein (G protein), alpha 
activating activity polypeptide, 
olfactory type 
1.46 0.0388 
236195_X_AT PRKCG protein kinase C, gamma 1.25 0.0397 
235781_AT CACNA1B calcium channel, voltage-
dependent, N type, alpha 1B 
subunit 
1.84 0.0403 




203131_AT PDGFRA platelet-derived growth factor 
receptor, alpha polypeptide 
1.63 0.0432 
231916_AT NOS1 nitric oxide synthase 1 
(neuronal) 
2.26 0.0436 
202742_S_AT PRKACB protein kinase, cAMP-
dependent, catalytic, beta 
1.33 0.0473 
239357_AT ATP2B2 ATPase, Ca++ transporting, 
plasma membrane 2 
2.4 0.0477 
206356_S_AT GNAL guanine nucleotide binding 
protein (G protein), alpha 
activating activity polypeptide, 
olfactory type 
1.6 0.0481 













Glutamatergic synapse (pre-lesion compared to control) 




GRM5 glutamate receptor, 
metabotropic 5 
5.37 0.0017 
227824_AT PRKCB protein kinase C, beta 1.77 0.0337 
235049_AT ADCY1 adenylate cyclase 1 (brain) 1.41 0.0323 




203159_AT GLS glutaminase 2.2 0.0333 




236195_X_AT PRKCG protein kinase C, gamma 1.25 0.0397 
205358_AT GRIA2 glutamate receptor, 
ionotropic, AMPA 2 
1.72 0.0246 
214217_AT GRM5 glutamate receptor, 
metabotropic 5 
1.78 0.0004 
213793_S_AT HOMER1 homer scaffolding protein 1 2.53 0.0037 
211925_S_AT PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
2.73 0.0009 
204763_S_AT GNAO1 guanine nucleotide binding 
protein (G protein), alpha 
activating activity polypeptide 
O 
2.24 0.0216 
204229_AT SLC17A7 solute carrier family 17 
(vesicular glutamate 
transporter), member 7 
1.34 0.0168 
1555867_AT GNG4 guanine nucleotide binding 
protein (G protein), gamma 4 
2.57 0.0014 
204184_S_AT ADRBK2 adrenergic, beta, receptor 
kinase 2 
1.33 0.0104 
213845_AT GRIK2 glutamate receptor, 
ionotropic, kainate 2 
1.32 0.0102 
204762_S_AT GNAO1 guanine nucleotide binding 
protein (G protein), alpha 








241172_AT GRIA2 glutamate receptor, 
ionotropic, AMPA 2 
1.6 0.0043 
208389_S_AT SLC1A2 solute carrier family 1 (glial 
high affinity glutamate 
transporter), member 2 
1.48 0.0423 
203158_S_AT GLS glutaminase 1.87 0.0264 
1566513_A_A
T 
GNG4 guanine nucleotide binding 
protein (G protein), gamma 4 
1.71 0.0081 
232062_AT ADCY1 adenylate cyclase 1 (brain) 1.52 0.0039 




213222_AT PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
3.9 0.0092 
206730_AT GRIA3 glutamate receptor, 
ionotropic, AMPA 3 
2.54 0.0025 
32540_AT PPP3CC protein phosphatase 3, 
catalytic subunit, gamma 
isozyme 
-1.36 0.0271 
227817_AT PRKCB protein kinase C, beta 2.37 0.0076 
215687_X_AT PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
2.39 0.0011 
213245_AT ADCY1 adenylate cyclase 1 (brain) 2.22 0.018 
205184_AT GNG4 guanine nucleotide binding 
protein (G protein), gamma 4 
1.67 0.042 
211602_S_AT TRPC1 transient receptor potential 
cation channel, subfamily C, 
member 1 
-1.63 0.0226 




209685_S_AT PRKCB protein kinase C, beta 2.04 0.009 
230437_S_AT PRKCB protein kinase C, beta 1.54 0.0094 
228795_AT PRKCB protein kinase C, beta 1.87 0.0172 
202429_S_AT PPP3CA protein phosphatase 3, 
catalytic subunit, alpha 
isozyme 
2.51 0.0303 
202742_S_AT PRKACB protein kinase, cAMP-
dependent, catalytic, beta 
1.33 0.0473 
208032_S_AT GRIA3 glutamate receptor, 











207235_S_AT GRM5 glutamate receptor, 
metabotropic 5 
1.85 0.0034 
32541_AT PPP3CC protein phosphatase 3, 
catalytic subunit, gamma 
isozyme 
-1.29 0.0258 




204506_AT PPP3R1 protein phosphatase 3, 
regulatory subunit B, alpha 
1.67 0.0274 
242891_AT ADCY5 adenylate cyclase 5 1.31 0.0308 
209793_AT GRIA1 glutamate receptor, 
ionotropic, AMPA 1 
2.46 0.0325 
215340_AT ADCY1 adenylate cyclase 1 (brain) 2.21 0.0082 






guanine nucleotide binding 




214933_AT CACNA1A calcium channel, voltage-
dependent, P/Q type, alpha 1A 
subunit 
1.76 0.0026 
210684_S_AT DLG4 discs, large homolog 4 
(Drosophila) 
2.22 0.0134 
222005_S_AT GNG3 guanine nucleotide binding 
protein (G protein), gamma 3 
2.86 0.0038 
217565_AT GRIA3 glutamate receptor, 
ionotropic, AMPA 3 
1.88 0.0153 
230144_AT GRIA3 glutamate receptor, 
ionotropic, AMPA 3 
2.47 0.003 
202425_X_AT PPP3CA protein phosphatase 3, 
catalytic subunit, alpha 
isozyme 
1.68 0.0065 








Phagosome (pre-lesion compared to control)  
ProbeSet ID Gene name Gene Detail FC P-
Value 
211990_AT HLA-DPA1 major histocompatibility 
complex, class II, DP alpha 1 
-3.77 0.0324 
1565673_AT FCGR2A Fc fragment of IgG, low affinity 
IIa, receptor (CD32) 
-3.5 0.0391 






complex, class II, DQ alpha 1; 
major histocompatibility 
complex, class II, DQ alpha 2 
-2.8 0.0183 
213537_AT HLA-DPA1 major histocompatibility 
complex, class II, DP alpha 1 
-2.72 0.0004 




216951_AT FCGR1A Fc fragment of IgG, high affinity 









Fc fragment of IgG, low affinity 
IIa, receptor (CD32); Fc 
fragment of IgG, low affinity IIc, 
receptor for (CD32) 
(gene/pseudogene) 
-1.95 0.0485 
211991_S_AT HLA-DPA1 major histocompatibility 
complex, class II, DP alpha 1 
-1.93 0.0228 
206313_AT HLA-DOA major histocompatibility 
complex, class II, DO alpha 
-1.83 0.0238 
217478_S_AT HLA-DMA major histocompatibility 
complex, class II, DM alpha 
-1.79 0.0352 
211654_X_AT HLA-DQB1 major histocompatibility 
complex, class II, DQ beta 1 
-1.76 0.0046 
208894_AT HLA-DRA major histocompatibility 
complex, class II, DR alpha 
-1.72 0.0266 
210992_X_AT FCGR2C Fc fragment of IgG, low affinity 








211395_X_AT FCGR2C Fc fragment of IgG, low affinity 
IIc, receptor for (CD32) 
(gene/pseudogene) 
-1.69 0.0092 
226878_AT HLA-DOA major histocompatibility 
complex, class II, DO alpha 
-1.64 0.0163 
205671_S_AT HLA-DOB major histocompatibility 




Fc fragment of IgG, low affinity 
IIIa, receptor (CD16a); Fc 
fragment of IgG, low affinity 
IIIb, receptor (CD16b) 
-1.61 0.0368 
210982_S_AT HLA-DRA major histocompatibility 
complex, class II, DR alpha 
-1.54 0.0229 
210889_S_AT FCGR2B Fc fragment of IgG, low affinity 
IIb, receptor (CD32) 
-1.53 0.0161 
201137_S_AT HLA-DPB1 major histocompatibility 
complex, class II, DP beta 1 
-1.47 0.0478 
208812_X_AT HLA-C major histocompatibility 
complex, class I, C 
-1.45 0.0125 
208428_AT TAP2 transporter 2, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
-1.44 0.019 
202307_S_AT TAP1 transporter 1, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
-1.44 0.0232 
236203_AT HLA-DQA1 major histocompatibility 




CLEC7A C-type lectin domain family 7, 
member A 
-1.41 0.0255 
222385_X_AT SEC61A1 Sec61 translocon alpha 1 
subunit 
-1.38 0.0067 
214459_X_AT HLA-C major histocompatibility 
complex, class I, C 
-1.36 0.0123 
212320_AT TUBB tubulin, beta class I -1.3 0.0283 
208306_X_AT HLA-DRB1 major histocompatibility 
complex, class II, DR beta 1 
-1.27 0.0345 
211799_X_AT HLA-C major histocompatibility 
complex, class I, C 
-1.23 0.029 
1569843_AT DYNC1I1 dynein, cytoplasmic 1, 







214762_AT ATP6V1G2 ATPase, H+ transporting, 
lysosomal 13kDa, V1 subunit G2 
1.45 0.0255 
239132_AT NOS1 nitric oxide synthase 1 
(neuronal) 
1.63 0.0332 
207309_AT NOS1 nitric oxide synthase 1 
(neuronal) 
1.84 0.015 
231916_AT NOS1 nitric oxide synthase 1 
(neuronal) 
2.26 0.0436 
Antigen processing and presentation and HSP (pre-lesion compared to 
control) 
ProbeSet ID Gene name Gene Detail FC P-
Value 
213537_at HLA-DPA1 major histocompatibility 
complex, class II, DP alpha 
1(HLA-DPA1) 
-2.72 0.0004 
214328_s_at HSP90AA1 heat shock protein 90 alpha 





HLA-DQB1 major histocompatibility 
complex, class II, DQ beta 1 
-1.76 0.0046 
211969_at HSP90AA1 heat shock protein 90 alpha 
family class A member 
1(HSP90AA1) 
1.47 0.0087 
214459_x_at HLA-C major histocompatibility 
complex, class I, C(HLA-C) 
-1.36 0.0123 
208812_x_at HLA-C major histocompatibility 
complex, class I, C(HLA-C) 
-1.45 0.0125 
211968_s_at HSP90AA1 heat shock protein 90 alpha 
family class A member 
1(HSP90AA1) 
1.91 0.0127 
226878_at HLA-DOA major histocompatibility 
complex, class II, DO alpha 
(HLA-DOA) 
-1.64 0.0163 
202963_AT RFX5 regulatory factor X, 5 
(influences HLA class II 
expression) 
-1.37 0.0172 






212671_s_at hla-dqa1 major histocompatibility 
complex, class II, DQ alpha 
1(HLA-DQA1) 
-2.8 0.0183 
201422_at IFI30 IFI30, lysosomal thiol reductase 
(IFI30) 
-1.66 0.0183 
208428_AT TAP2 transporter 2, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
-1.44 0.019 
210211_s_at HSP90AA1 heat shock protein 90 alpha 
family class A member 
1(HSP90AA1) 
1.73 0.019 
205671_s_at HLA-DOB major histocompatibility 
complex, class II, DO beta (HLA-
DOB) 
-1.64 0.0207 
211991_S_AT HLA-DPA1 major histocompatibility 
complex, class II, DP alpha 1 
-1.93 0.0228 
210982_s_at hla-dra major histocompatibility 
complex, class II, DR alpha 
(HLA-DRA) 
-1.54 0.0229 
202307_S_AT TAP1 transporter 1, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
-1.44 0.0232 
206313_AT HLA-DOA major histocompatibility 
complex, class II, DO alpha 
-1.83 0.0238 
200064_at HSP90AB1 heat shock protein 90 alpha 
family class B member 
1(HSP90AB1) 
1.28 0.0254 
208894_at hla-dra major histocompatibility 





HLA-C major histocompatibility 
complex, class I, C 
-1.23 0.029 
211990_AT HLA-DPA1 major histocompatibility 
complex, class II, DP alpha 1 
-3.77 0.0324 
208306_x_at HLA-DRB1 major histocompatibility 
complex, class II, DR beta 
1(HLA-DRB1) 
-1.27 0.0345 
217478_S_AT HLA-DMA major histocompatibility 
complex, class II, DM alpha 
-1.79 0.0352 
236203_AT HLA-DQA1 major histocompatibility 







208687_x_at HSPA8 heat shock protein family A 
(Hsp70) member 8(HSPA8) 
1.28 0.0424 
201137_S_AT HLA-DPB1 major histocompatibility 




HSPA8 heat shock 70kDa protein 8 1.4 0.048 
200799_at HSPA1A heat shock protein family A 
(Hsp70) member 1A(HSPA1A) 
1.22 0.0488 
208814_AT HSPA4 heat shock 70kDa protein 4 1.24 0.0491 
FC: Fold Change 
 
 
Calcium Signalling Pathways (Pre-lesion compared to PVL) 
ProbeSet ID Gene 
name 
Gene Detail FC P-Value 
217623_AT MYLK3 myosin light chain kinase 3 -3.29 0.0462 
211492_S_A
T 
ADRA1A adrenoceptor alpha 1A -2.58 0.0103 
206811_AT ADCY8 adenylate cyclase 8 (brain) -2.25 0.0022 
1566739_AT PLCE1 phospholipase C, epsilon 1 -2.15 0.0053 
205450_AT PHKA1 phosphorylase kinase, alpha 1 
(muscle) 
-1.53 0.0046 
205125_AT PLCD1 phospholipase C, delta 1 -1.48 0.0404 
216836_S_A
T 
ERBB2 erb-b2 receptor tyrosine kinase 2 -1.45 0.0009 
210930_S_A
T 
ERBB2 erb-b2 receptor tyrosine kinase 2 -1.44 0.0418 
221864_AT ORAI3 ORAI calcium release-activated 
calcium modulator 3 
-1.43 0.0057 
1557477_AT STIM1 stromal interaction molecule 1 -1.43 0.0293 
205410_S_A
T 





PHKA2 phosphorylase kinase, alpha 2 
(liver) 
-1.38 0.0076 
203723_AT ITPKB inositol-trisphosphate 3-kinase B -1.32 0.0055 
235213_AT ITPKB inositol-trisphosphate 3-kinase B -1.31 0.0353 






32541_AT PPP3CC protein phosphatase 3, catalytic 


















dependent, R type, alpha 1E 
subunit 
1.29 0.024 
214348_AT TACR2 tachykinin receptor 2 1.33 0.0148 
210637_AT TACR1 tachykinin receptor 1 1.34 0.0279 
232062_AT ADCY1 adenylate cyclase 1 (brain) 1.36 0.0126 
















GRIN1 glutamate receptor, ionotropic, N-










P2RX5 purinergic receptor P2X, ligand 







receptor 7, adenylate cyclase-
coupled; 5-hydroxytryptamine 





calmodulin 1 (phosphorylase 
kinase, delta); calmodulin 2 




GRIN1 glutamate receptor, ionotropic, N-


















ATP2B1 ATPase, Ca++ transporting, plasma 
membrane 1 
1.75 0.007 
242488_AT CHRM3 cholinergic receptor, muscarinic 3 1.76 0.002 
214217_AT GRM5 glutamate receptor, metabotropic 
5 
1.77 0.001 
206534_AT GRIN2A glutamate receptor, ionotropic, N-
methyl D-aspartate 2A 
1.77 0.0082 
239132_AT NOS1 nitric oxide synthase 1 (neuronal) 1.77 0.0351 
204506_AT PPP3R1 protein phosphatase 3, regulatory 




GRIN1 glutamate receptor, ionotropic, N-






calmodulin 2 (phosphorylase 
kinase, delta); calmodulin 3 




PRKCB protein kinase C, beta 1.85 0.0029 
202425_X_A
T 
PPP3CA protein phosphatase 3, catalytic 




PPP3CA protein phosphatase 3, catalytic 
subunit, alpha isozyme 
1.85 0.0122 
214596_AT CHRM3 cholinergic receptor, muscarinic 3 1.88 0.0056 
1561615_S_
AT 
















PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
1.99 0.0046 
214652_AT DRD1 dopamine receptor D1 1.99 0.0187 
1559633_A_
AT 
CHRM3 cholinergic receptor, muscarinic 3 2 0.004 
231783_AT CHRM1 cholinergic receptor, muscarinic 1 2.06 0.000011
7 






203131_AT PDGFRA platelet-derived growth factor 
receptor, alpha polypeptide 
2.09 0.004 
227824_AT PRKCB protein kinase C, beta 2.14 0.03 
227817_AT PRKCB protein kinase C, beta 2.18 0.0034 
207957_S_A
T 
PRKCB protein kinase C, beta 2.18 0.0045 
207577_AT HTR4 5-hydroxytryptamine (serotonin) 
receptor 4, G protein-coupled 
2.2 0.0001 
231916_AT NOS1 nitric oxide synthase 1 (neuronal) 2.2 0.0445 
211925_S_A
T 






dependent, N type, alpha 1B 
subunit 
2.29 0.0076 
207309_AT NOS1 nitric oxide synthase 1 (neuronal) 2.31 0.002 
210939_S_A
T 
GRM1 glutamate receptor, metabotropic 
1 
2.34 0.0041 
214044_AT RYR2 ryanodine receptor 2 (cardiac) 2.35 0.0027 




215340_AT ADCY1 adenylate cyclase 1 (brain) 2.42 0.0117 
209685_S_A
T 
PRKCB protein kinase C, beta 2.42 0.0164 




239357_AT ATP2B2 ATPase, Ca++ transporting, plasma 
membrane 2 
2.73 0.0382 
229029_AT CAMK4 calcium/calmodulin-dependent 











dependent, R type, alpha 1E 
subunit 
3.01 0.0001 
213245_AT ADCY1 adenylate cyclase 1 (brain) 3.18 0.003 








241871_AT CAMK4 calcium/calmodulin-dependent 
































protein kinase II alpha 
7.06 0.0085 
 
Glutamatergic synapse (pre-lesion compared to PVL) 
ProbeSet ID Gene 
name 
Gene Detail FC P-
Value 
206811_AT ADCY8 adenylate cyclase 8 (brain) -2.25 0.0022 
1555240_S_A
T 
GNG12 guanine nucleotide binding protein 




homer scaffolding protein 3 -1.29 0.0115 
32541_AT PPP3CC protein phosphatase 3, catalytic 
subunit, gamma isozyme 
-1.24 0.0464 
224964_S_AT GNG2 guanine nucleotide binding protein 




adrenergic, beta, receptor kinase 2 1.29 0.0202 
213664_AT SLC1A1 solute carrier family 1 
(neuronal/epithelial high affinity 
glutamate transporter, system Xag), 
member 1 
1.33 0.0151 
242891_AT ADCY5 adenylate cyclase 5 1.35 0.0251 
232062_AT ADCY1 adenylate cyclase 1 (brain) 1.36 0.0126 
235049_AT ADCY1 adenylate cyclase 1 (brain) 1.39 0.024 
204229_AT SLC17A
7 
solute carrier family 17 (vesicular 







205915_X_AT GRIN1 glutamate receptor, ionotropic, N-
methyl D-aspartate 1 
1.45 0.011 
213845_AT GRIK2 glutamate receptor, ionotropic, 
kainate 2 
1.48 0.0011 
223943_S_AT 0 0 1.48 0.0067 
210412_AT GRIN2B glutamate receptor, ionotropic, N-
methyl D-aspartate 2B 
1.49 0.0441 
235527_AT DLGAP1 discs, large (Drosophila) homolog-
associated protein 1 
1.53 0.049 





GRIA3 glutamate receptor, ionotropic, 
AMPA 3 
1.6 0.0166 
211125_X_AT GRIN1 glutamate receptor, ionotropic, N-
methyl D-aspartate 1 
1.65 0.0409 
217008_S_AT GRM7 glutamate receptor, metabotropic 7 1.71 0.0055 
214217_AT GRM5 glutamate receptor, metabotropic 5 1.77 0.001 
206534_AT GRIN2A glutamate receptor, ionotropic, N-
methyl D-aspartate 2A 
1.77 0.0082 
204506_AT PPP3R1 protein phosphatase 3, regulatory 
subunit B, alpha 
1.78 0.0343 
210781_X_AT GRIN1 glutamate receptor, ionotropic, N-
methyl D-aspartate 1 
1.82 0.0182 
210411_S_AT GRIN2B glutamate receptor, ionotropic, N-
methyl D-aspartate 2B 
1.83 0.003 
230437_S_AT PRKCB protein kinase C, beta 1.85 0.0029 
202425_X_AT PPP3CA protein phosphatase 3, catalytic 
subunit, alpha isozyme 
1.85 0.0122 
217565_AT GRIA3 glutamate receptor, ionotropic, 
AMPA 3 
1.87 0.0206 
1555867_AT GNG4 guanine nucleotide binding protein 
(G protein), gamma 4 
1.94 0.0174 
207235_S_AT GRM5 glutamate receptor, metabotropic 5 1.96 0.0038 
215687_X_AT PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
1.99 0.0046 
210684_S_AT DLG4 discs, large homolog 4 (Drosophila) 1.99 0.0139 
1566513_A_A
T 
GNG4 guanine nucleotide binding protein 
(G protein), gamma 4 
2 0.0284 
203158_S_AT GLS glutaminase 2.06 0.0198 






239095_AT GRIN2B glutamate receptor, ionotropic, N-
methyl D-aspartate 2B 
2.13 0.0015 
227824_AT PRKCB protein kinase C, beta 2.14 0.03 
227817_AT PRKCB protein kinase C, beta 2.18 0.0034 
207957_S_AT PRKCB protein kinase C, beta 2.18 0.0045 
211925_S_AT PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
2.24 0.0018 
210939_S_AT GRM1 glutamate receptor, metabotropic 1 2.34 0.0041 
208032_S_AT GRIA3 glutamate receptor, ionotropic, 
AMPA 3 
2.38 0.0005 
215340_AT ADCY1 adenylate cyclase 1 (brain) 2.42 0.0117 
209685_S_AT PRKCB protein kinase C, beta 2.42 0.0164 
222005_S_AT GNG3 guanine nucleotide binding protein 




homer scaffolding protein 1 2.66 0.0006 
230144_AT GRIA3 glutamate receptor, ionotropic, 
AMPA 3 
2.66 0.0044 
206730_AT GRIA3 glutamate receptor, ionotropic, 
AMPA 3 
2.94 0.0057 
213245_AT ADCY1 adenylate cyclase 1 (brain) 3.18 0.003 





GRM5 glutamate receptor, metabotropic 5 4.93 0.0091 
 
 
WNT signalling pathway (pre-lesion compared to PVL) 
ProbeSet ID Gene 
name 
Gene Detail FC P-
value 
226029_AT VANGL2 VANGL planar cell polarity protein 2 -2.09 0.0152 







casein kinase 1, alpha 1 -1.64 0.0229 








216511_S_AT TCF7L2 transcription factor 7-like 2 (T-cell 
specific, HMG-box) 
-1.54 0.0108 
225745_AT LRP6 LDL receptor related protein 6 -1.47 0.0381 
229997_AT VANGL1 VANGL planar cell polarity protein 1 -1.46 0.024 
201868_S_AT TBL1X transducin (beta)-like 1X-linked -1.45 0.0232 
201465_S_AT JUN jun proto-oncogene -1.43 0.0239 
216035_X_A
T 





TCF7L2 transcription factor 7-like 2 (T-cell 
specific, HMG-box) 
-1.39 0.0389 
201614_S_AT RUVBL1 RuvB-like AAA ATPase 1 -1.39 0.0478 
212762_S_AT TCF7L2 transcription factor 7-like 2 (T-cell 
specific, HMG-box) 
-1.38 0.0345 
229774_AT CXXC4 CXXC finger protein 4 -1.36 0.0216 




215310_AT APC adenomatous polyposis coli -1.3 0.0307 
212571_AT CHD8 chromodomain helicase DNA 
binding protein 8 
-1.3 0.0008 
213400_S_AT TBL1X transducin (beta)-like 1X-linked -1.29 0.0293 





casein kinase 1, alpha 1 -1.24 0.045 
32541_AT PPP3CC protein phosphatase 3, catalytic 
subunit, gamma isozyme 
-1.24 0.0464 





casein kinase 1, alpha 1 -1.21 0.0218 
229154_AT WNT10
A 
wingless-type MMTV integration 
site family, member 10A 
1.25 0.0476 
206459_S_AT WNT2B wingless-type MMTV integration 
site family, member 2B 
1.28 0.0495 
218318_S_AT NLK nemo-like kinase 1.34 0.0288 
206213_AT WNT10
B 
wingless-type MMTV integration 












204506_AT PPP3R1 protein phosphatase 3, regulatory 
subunit B, alpha 
1.78 0.0343 
230437_S_AT PRKCB protein kinase C, beta 1.85 0.0029 
202425_X_A
T 
PPP3CA protein phosphatase 3, catalytic 









PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
1.99 0.0046 
228795_AT PRKCB protein kinase C, beta 2.07 0.0162 
227824_AT PRKCB protein kinase C, beta 2.14 0.03 
207957_S_AT PRKCB protein kinase C, beta 2.18 0.0045 
227817_AT PRKCB protein kinase C, beta 2.18 0.0034 
211925_S_AT PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
2.24 0.0018 
209685_S_AT PRKCB protein kinase C, beta 2.42 0.0164 
204712_AT WIF1 WNT inhibitory factor 1 3.19 0.0056 






protein kinase II alpha 
7.06 0.0085 
 
 
 
 
